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 Following polytrauma and major surgery patients experience a period of 
immunosuppression, which can predispose them to the development of nosocomial 
infections. This thesis examines how polytrauma and surgery influences T-helper (Th) cell 
differentiation and antigen presentation, whilst exploring how the detrimental 
immunomodulatory effects of these insults may be reversed. 
Methods 
 Serial blood samples were drawn from two cohorts of patients at The Royal London 
Hospital; following severe polytrauma (n=112) or major abdominal surgery (n=119). mRNA 
levels of candidate cytokines and transcription factors were assayed, along with protein levels 
of key cytokines IL-10 and IL-6. Associations between these data, acquisition of nosocomial 
infection and outcome were described. As a validated surrogate of immune competence 
CD14+HLA-DR levels were quantified. In vitro models explored the reversibility of tissue 
damage induced immunosuppression and determined the role of individual circulating 
mediators in altering host immune function.  
Results 
 A consistent up-regulation in gene expression of prototypical anti-inflammatory 
pathways in conjunction with features of depressed pro-inflammatory Th cell pathways was 
detected across both cohorts. This was accompanied by early down-regulation of 
CD14+HLA-DR. Gene expression changes were quantitatively associated with the subsequent 




and was independently associated with an increased risk of nosocomial infection. Culture 
experiments determined that postoperative decreases in antigen presentation were IL-10 
dependent and reversible in the presence of Interferon-Gamma and Granulocyte Monocyte-
Colony Stimulating Factor.  
Conclusions  
 This thesis describes a significant host immune response immediately following 
significant tissue damage which is dominated by features of immune suppression. Blood 
transfusion appears to have a distinct, additive effect. These data identify a potential role for 
targeted treatment with currently licenced immune stimulants (IFN-γ and GM-CSF). In 
addition exploitation of the IL-10 signalling pathway may be of importance as a strategy to 
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 Introduction  Chapter One:
 
The Chapter contains two published works:  
‘Does major surgery induce immune suppression and increase the risk of postoperative 
infection?’ Torrance HD, Pearse RM, O’Dwyer MJ. Current Opinion in Anaesthesiology. 
(ePub 9 Mar) 2016. PMID: 26963469 
 
 ‘The perioperative immune response’ O’Dwyer MJ, Owen HC, Torrance HD. Current 
Opinion in Critical Care. 2015; 21:336-42. PMID: 26103142 
As a consequence in this Chapter aspects outlining the inflammatory response to tissue 
damage and subsequent risk of nosocomial infections have been co-authored by;  Dr Hew DT 







1.1 Trauma: A Disease Of Physical Injury 
 Trauma is the disease of physical injury (Trunkey et al., 1974). Despite heightened 
public awareness of the catastrophic implications of severe trauma following recent conflicts 
in Iraq and Afghanistan it is primarily a civilian disease. Trauma itself can take the form of a 
diverse array of incidents such as; falls from height, motor vehicle collisions (MVC), 
stabbings or gunshot wounds. The disease affects both the western and developing worlds, 
however there is often a disparity, with a predominantly blunt mechanism of injury seen most 
often in the United Kingdom (UK), (National Audit Office, 2010). It is often cited in the 
literature as the most common disease affecting those under the age of 45 worldwide 
(Polinder et al., 2012), however this paradigm is evolving as there is now a growing 
incidence of trauma affecting those over 60 (McCullough et al., 2014). In the UK there are 
thought to be 20,000 episodes of major trauma per year which are believed to be responsible 
for 5,400 deaths (National Audit Office, 2010). However, as many more people suffer from 
serious lasting injury from their trauma this mortality figure doesn’t address the impact that 
this disease has on the emotional, physical or psychological needs of these patients (Brohi et 
al., 2011; Polinder et al., 2012) or the complex rehabilitation and health requirements often 
needed by elderly trauma patients (McCullough et al., 2014).  
 The estimated annual lost economic output due to deaths and serious injury from 
major trauma is thought to be between £3.3 and 3.7 billion (National Audit Office, 2010). 
This figure is however likely to be a gross underestimate, as the widespread, long lasting 
implications of trauma have already been alluded to. This figure predominantly reflects the 
injury and its immediate treatment, however significant amounts of NHS money are spent on 
the rehabilitation of these patients. From what little data we have on the rehabilitation phase, 
those suffering from trauma are often of lower socioeconomic groups (Roberts, 2012) and 




clearly a topic that requires further research so we are able better to understand the impact of 
this disease on the UK population. 
1.2 Changes To Trauma Management 
1.2.1 The Birth Of ATLS 
 Over the last 30 years there have been progressive improvements in the provision of 
trauma care since the original opening of dedicated trauma centres in the United States in the 
1960s. Often one of the most cited was the introduction of the Advanced Trauma Life 
Support (ATLS) programme. An American orthopaedic surgeon, who along with his family 
was tragically involved in a plane crash in Nebraska, established this course. When taking his 
severely injured family members to a local hospital he was appalled to find that he was able 
to provide better care for his family in the pre-hospital environment. As a result the ATLS 
programme was born, based on the successful Advanced Cardiac Life Support (ACLS) 
programme (Carmont, 2005). This basis for the assessment and management of trauma 
patients has been adopted worldwide with the ATLS manual now available in its 9th edition 
(American College of Surgeons, 2012). Interestingly, despite the impression that ATLS 
provides the gold standard of trauma care, there is no robust evidence demonstrating that its 
implementation has reduced trauma-related morbidity and mortality in the developed world 
(Jayaraman et al., 2014; Wiles, 2015). With the rapid ongoing improvements to clinical 
practice the course or manual is not considered the cutting edge in trauma care; however it 
does provide a minimum competence, allowing a standardisation of the level of care for 
trauma patients to be applied worldwide (Wiles, 2015). 
1.2.2 Recognition Of Acute Traumatic Coagulopathy  
 Alongside the structured management system that the ATLS programme provides there 
have been numerous developments in the resuscitation and operative strategies employed. A 




following their recent experiences in the Middle East (Hettiaratchy et al., 2010). However one 
of the most important is the recognition and early treatment of coagulopathy. The first large-
scale description of Acute Traumatic Coagulopathy (ATC) can be credited to Professor Karim 
Brohi from the Royal London Hospital (RLH) who published a landmark paper in the Journal 
of Trauma (Brohi et al., 2003). This paper identified that nearly a quarter of polytrauma patients 
presenting to the Emergency Department (ED) were coagulopathic, (defined as a prothrombin 
time (PT) >18 seconds, activated partial thromboplastin time (APTT) >60 seconds, or thrombin 
time (TT) >15 seconds (1.5 times normal)), (Brohi et al., 2003). Recognition of this life 
threatening pathology with novel point of care testing devices such as Rotational 
Thromboelastometry (ROTEM) has led to changes in the resuscitation strategy of these patients 
(Davenport et al., 2011). This has led to a paradigm shift: Based largely on retrospective 
observational data there has been a movement away from the infusion of large volumes of clear 
fluids (as described in the previous ATLS guidelines (American College of Surgeons, 2012)) 
with an aim to replace any lost volume with a set ratio of blood, to blood products (Holcomb et 
al., 2015). This has led to the inclusion of massive transfusion protocols in all western major 
trauma centres (MTCs) (Khan et al., 2013; Nunez et al., 2010). In addition to this there has been 
widespread adoption in Europe of the anti-fibrinolytic drug tranexamic acid, with early 
administration (<3 hours following injury) showing reductions in mortality in trauma patients 
(Crash-trial collaborators et al., 2010). 
1.2.3 Damage Control Resuscitation & Surgery 
 Damage Control Resuscitation is again a relatively recent phenomenon. 
Haemorrhage in trauma accounts for over a third of (potentially preventable) deaths (Gruen et 
al., 2006; Sauaia et al., 1995) and damage control resuscitation is based on two strategies, 
permissive hypotension and haemostatic resuscitation. ‘Permissive’ hypotension is based on 
the premise that aggressive infusion of fluids leads to the dilution of clotting factors, an 
increase in metabolic acidosis (due to the pH and chloride content of these clear fluids) and 





exacerbate, what is termed the lethal triad of coagulopathy, acidosis and hypothermia 
(Holcomb et al., 2007). Additionally, artificially raising the blood pressure to normotensive 
pressures can lead to disruption of the first fragile clot formed, causing bleeding to recur 
(Mitra et al., 2012). This ‘permissive’ hypotension is a temporary measure, which is 
continued until there is control of the bleeding source. This obviously has to be carefully 
balanced with acceptable levels of oxygen delivery (DO2) so as not to exacerbate any 
anaerobic respiration that may be present and cause cell necrosis and irreversible organ 
damage. This is paired with haemostatic resuscitation, the principle being that patients 
resuscitated with ratios closer to whole blood i.e. 1:1 or 1:2 of PRBCs to Fresh Frozen 
Plasma (FFP) alongside good quantities of platelets and cryoprecipitate were less likely to 
experience coagulopathy of mass transfusion (Lamb et al., 2014). However there is 
controversy with these data as it is largely based on observational or retrospective data, with 
some critics citing a survival bias (Ho et al., 2012). Further recent observational data also 
questions the effectiveness of current haemostatic resuscitation, as despite its use during the 
acute bleeding phase in trauma resuscitation and damage control surgery there were no 
improvements to patient hypoperfusion or coagulopathy (Khan et al., 2014).  
 Damage control surgery is a modern turn of phrase for a strategy that has been 
practised for millennia (Schreiber, 2012). This combines ongoing resuscitation with essential 
surgery, coordinated by both the surgical and anaesthetic teams. Surgical procedures are 
limited to the minimum necessary, designed to prevent physiological exhaustion commonly 
associated with immediate definitive surgical care (Rotondo & Zonies, 1997). Patients are 
then transferred to the Critical Care department for optimisation of coagulation, temperature 
and pH, returning sometimes days later to the operating theatre for definitive surgical 




1.2.4 The Fusion Of Military & Civilian Practice 
 Recent military conflicts have driven improvements in the care of severe polytrauma 
patients, putting into practice these principles, with encouraging evidence (Hettiaratchy et al., 
2010). They have also lead to a re-introduction of tourniquets and haemostatic dressings in 
both military and civilian practice (Kelly et al., 2008) as well as the re-introduction of devices 
such as the REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) to 
temporarily stabilise the patient suffering from a complex pelvic vascular injury or torso 
injury, until definitive vascular repair or artery embolisation is available. This technique has 
the potential be used as a less invasive option to ‘clam shell’ thoracotomy (with distal aorta 
clamping) for uncontrollable haemorrhage, however it requires a greater evidence basis for 
widespread usage (Morrison et al., 2016). 
1.2.5 Improvements In Civilian Practice 
 In the UK there have been dramatic improvements in the delivery of trauma care 
following a damning report carried out by the National Confidential Enquiry into Patient 
Outcome and Death (NCEPOD), (NCEPOD, 2007). This has led to the centralisation of care 
for trauma patients with the creation of MTCs as well as improvements to the training of 
ambulance staff (McCullough et al., 2014). This was pioneered in London with all patients 
suffering major trauma being screened in the pre-hospital environment and consequently 
being transported directly to one of the four new MTCs with peripheral hospitals being 
bypassed. A recent appraisal of this organisational change demonstrated significant 
improvements in the overall quality of care and survival for patients treated at these MTCs 
(Cole et al., 2015).  
1.2.6 Survival To The Critical Care Unit 
 Trauma deaths generally follow a tri-modal distribution, with patients dying either at 
the scene, in the first 24-48 hours (due to massive haemorrhage or from unsurvivable injuries) 




to, the implementation of modern trauma practices and a better understanding of the 
pathophysiology of severe trauma are resulting in the admission of a cohort of severely 
injured patients, who previously would not have survived to hospital admission. These 
advances in trauma care have led to a change in the perception of what an unsurvivable injury 
is. During the first 24-48 hours there have been improvements in the management of massive 
haemorrhage trauma induced coagulopathy. After arriving on the Critical Care unit the most 
serious threat to their survival is the development of nosocomial infections, sepsis and multi-
organ failure (Lord et al., 2014). 
1.3 Major Abdominal Surgery: A Global Health Problem 
 Annually there are an estimated 234.2 million major surgical procedures performed 
globally (Weiser et al., 2008). These procedures are performed in diverse health care settings, 
where there may be different standards of care (Pearse et al., 2012). As a result there is a 
wide range in the incidence of complications reported in the literature. These complications 
are many; including death, infection, postoperative bleeding, deep vein thrombosis, stroke, 
cardiac injury and renal injury amongst others (Bratzler & Hunt, 2006). Due to the sheer 
number of patients undergoing operations worldwide even marginal gains to reduce 
morbidity and mortality could have dramatic population benefits. 
1.3.1 Challenges For Major Elective Surgery 
 Therefore a challenge for clinicians is to minimise the mortality risk, as well as the 
morbidity of these perioperative complications. This is primarily done via the identification 
of the high-risk patient. It has been reported that the mortality rate for major elective surgery 
in the UK is as high as 4% for non-cardiac surgery (Pearse et al., 2012). However this 
statistic doesn’t tell the complete story, as 80% of these deaths occur in a much smaller 
cohort of only 12% of the surgical population (Pearse et al., 2006). As a result research has 
been targeted towards identifying this at risk cohort by preoperative screening. This 




history and available blood tests, inputting these values into algorithms designed to define 
risk. This therefore allows clinicians to allocate appropriate levels of perioperative care, 
individualising treatment. The alternative option is via sophisticated tools designed to assess 
the individual patient’s functional capacity, commonly cardiopulmonary exercise testing 
(CPET). This testing is based upon the premise that patients who were able to perform at four 
– six metabolic equivalents (METs) on testing had a reduced perioperative risk (Smith et al., 
2009). A large international study is ongoing to evaluate definitively the benefit of 
preoperative CPET in elective major surgery (UKCRN, 2013). However, all of these 
preoperative scoring systems are designed mainly to address mortality risk as well as key 
comorbidities such as cardiovascular disease or renal dysfunction and as a result poorly 
predict the incidence of nosocomial infection following elective major abdominal surgery. 
1.3.2 Improvements To Surgical Care 
 Over the last twenty years there have been steady improvements to the care of 
elective surgical patients. These have led to the more judicious administration of fluids and 
vasoactive drugs in the perioperative period (Pearse et al., 2011), with a recent meta-analysis 
suggesting that postoperative goal-directed therapy, the use of cardiac output monitors to 
guide the administration of intravenous fluid and inotropic drugs via a haemodynamic 
therapy algorithm may result in a reduction of postoperative complications (Pearse et al., 
2014). There have been strategies to ensure the maintenance of perioperative normothermia 
(Moola & Lockwood, 2011) as well as enhanced recovery programmes (Grace et al., 2011). 
Not all of these interventions have been as successful. It has long been recognised that 
patients with a raised preoperative heart rate were at an increased risk of cardiovascular 
events (Devereaux et al., 2005). As a result randomised controlled trials have been performed 
to preoperatively beta-blockade those patients. This intervention although reducing the 
prevalence of cardiovascular events led to increases in the incidence of stroke, death, 
hypotension and bradycardia (Blessberger et al., 2014; Wijeysundera et al., 2014). However 




occurred close to ten times more frequently than myocardial ischemia or infarction (Pearse et 
al., 2014). This is clearly an under appreciated postoperative cause of morbidity and 
mortality.   
 Following this recognition of the risks associated with elective non-cardiac surgery, 
particularly in those over 65 years (Jhanji et al., 2008), there have been an increasing number 
of patients who are routinely admitted to the critical care unit postoperatively (Pearse et al., 
2011). This has led to the creation of perioperative physicians, clinicians who are 
predominantly anaesthetists, who aim to address the complex medical needs of patients 
during their surgical treatment (Grocott & Pearse, 2012). 
 Medicine has also begun to translate ideas designed to improve safety and minimise 
error from areas such as the aviation industry, with the introduction of checklists into clinical 
practice. This aims to standardise certain aspects of perioperative care across the world 
ensuring that interventions such as the presence of basic monitoring or if any blood loss is 
anticipated then adequate access and products are available (Haynes et al., 2009). This 
checklist was trialled in a diverse group of eight hospitals around the world with 
implementation of the list demonstrating a reduction in morbidity and mortality (Haynes et 
al., 2009). 
1.4 The Rationale Of This Thesis 
 As has already been summarised severe polytrauma causes both a shock state and 
tissue damage. In order to tease out the influence that shock and tissue damage has on the 
adaptive immune system two patient models have been used:  
 Major elective abdominal surgery, provides a controlled model of tissue damage, in 
the absence of shock. This model has advantages such as the availability of preoperative 
sampling (allowing each patient to act as their own control), predictable sampling timings, 




 On the other hand severe polytrauma, used for the patient model of shock and tissue 
damage, poses a number of challenges. Logistically these patients are difficult to recruit due 
to their unpredictable admission timings and it can be difficult to gain consent as they often 
lack capacity in the emergency department. Polytrauma by its nature is a heterogeneous 
disease that commonly happens to younger fit patients and as a result age appropriate normal 
healthy controls are used as comparators.  
1.5 The Inflammatory Response To Tissue Damage 
1.5.1 Introduction 
 The immune response to major tissue damage has been recently extensively 
characterised (Lord et al., 2014). Although severe traumatic injury as a model provides 
information that is highly relevant and applicable to perioperative medicine, the picture is 
clouded by confounding influences such as hypoperfusion and the subsequent reperfusion 
injury, the frequent transfusion of allogeneic blood products and neuro-inflammatory 
mediated changes secondary to an often coexisting traumatic brain injury (Lord et al., 2014). 
The key link between tissue damage and subsequent inflammation is the release of alarmins 
(Oppenheim & Yang, 2005).  
1.5.2 Alarmins  
 Alarmins, often termed Damage-Associated Molecular Pattern molecules (DAMPs), 
are a group of structurally diverse compounds released following tissue damage as cells 
undergo physiological stress or necrosis (Chan et al., 2012). DAMPs are the endogenous 
equivalent of Pathogen Associated Molecular Pattern molecules (PAMPs) which initiate an 
immune response in the setting of infection. Indeed, DAMPs such as high-mobility-group 
box (HMGB) 1 and mitochondrial DNA (mtDNA) bear significant structural homology to 
their PAMP analogues and often activate the same pattern recognition receptors (PRRs) 




severe sterile inflammation and sepsis can be difficult or impossible to distinguish. A wide 
variety of PRRs have been described including the membrane bound Toll-like receptors 
(TLRs) and the cytoplasmic NOD-like receptors (NLRs) (Chan et al., 2012; Manson et al., 
2012). Activation of PRRs induces an enzymatic cascade, which results in down-stream 
phosphorylation of transcription factors such as NF-κB, which in turn alters cytokine 
transcription. Immune cell subtypes are activated dependent on their expression of specific 
PRRs on their cell surface at the time of alarmin release (Manson et al., 2012). Alarmins not 
only activate this innate response but also provide a vital link between the innate and adaptive 
immune systems by activating antigen-presenting cells such as monocytes and dendritic cells 
(Bianchi & Manfredi, 2007).  
1.5.3 The Reductionist Approach to Analysis 
 Until quite recently, studies exploring the inflammatory response to major tissue 
damage have been mainly limited to a reductionist approach where correlations have been 
sought between clinical end points and a limited number of candidate mediators. The success 
of this approach has varied depending on the end point chosen and the assay methodology, 
with quantitative polymerase chain reaction (qPCR) quantification of messenger RNA 
(mRNA) transcripts proving more sensitive than enzyme linked immunosorbant assays 
(ELISA) quantification of protein product. Levels of interleukin 6 (IL-6) and IL-10 
consistently rise in proportion to the extent of the tissue damage and levels are associated 
with a greater incidence of subsequent nosocomial infection (Baigrie et al., 1992; Fragkou et 
al., 2014; Giannoudis et al., 2000; Mokart et al., 2005b). As arguably the most potent anti-
inflammatory cytokine it is unsurprising that high IL-10 levels are associated with later 
infection. However, although IL-6 is traditionally considered a pro-inflammatory cytokine it 
also up-regulates suppressor of cytokine signalling (SOCS)-1 expression and inhibits T helper 
cell type 1 (Th1) differentiation (Diehl & Rincon, 2002). In this manner, IL-6 could plausibly 
exert an effect that limits effective host bactericidal capacity. Similarly, the expression of 




following tissue damage and is related to nosocomial infection (Cheron et al., 2010; 
Wakefield et al., 1993). Again this is unsurprising as the maintenance of adequate Major 
Histocompatibility Complex (MHC) class ΙΙ molecules such as HLA-DR on the surface of 
antigen presenting cells is crucial to maintain immune competence. Others have proposed 
genomic signatures where higher ratios of anti-inflammatory to pro-inflammatory cytokines 
correlate with postoperative infection (White et al., 2011). What remains elusive is the 
mechanism whereby alarmin release and the subsequent enzymatic cascades lead to an 
immunosuppressed phenotype and the survival advantage, if any, of this trait.  
1.5.4 The Proposed Genomic Storm 
 Advances in technology recently permitted the simultaneous analysis of the 
leukocyte transcriptome of 20,720 genes in patients following severe blunt trauma and burn 
injury in a landmark paper (Xiao et al., 2011). Following these stimuli, which would clearly 
result in significant alarmin release, 80% of cellular pathways and functions were altered. 
Innate immunity pathways, B-cell receptor signalling and IL-10 signalling all demonstrated 
up-regulated gene expression whereas antigen presentation and T-cell activation were down-
regulated. Importantly, it was the overall magnitude of the genomic alterations which 
correlated with nosocomial infections and organ impairment as opposed to differential 
activation of specific pathways. Although this snapshot of the transcriptome was within 12 
hours of injury, in some cases patients had undergone extensive resuscitation and therefore 
this heterogeneous picture should be interpreted with caution in the context of the 
perioperative patient. This paper has however helped to re-define the previously proposed 
bimodal inflammatory response model to tissue damage, suggesting concomitant activation of 
pro-inflammatory and anti-inflammatory pathways. 
1.5.5 Mass Cytometry & Further Single-Cell Analysis Developments 
 Further application of advanced technology has seen investigators utilise mass 




these findings to postoperative recovery (Gaudilliere et al., 2014). Mass cytometry involves 
using antibodies to tag cellular components prior to nebulising the cells and then using a time 
of flight mass spectrometer for analysis. This complex technique has extensively described 
the immune response in peripheral blood following elective hip arthroplasty and has 
demonstrated a time-dependent and cell type specific activation of immune signalling 
networks.  
 Over the early postoperative period there is an expansion of Natural Killer (NK) 
cells, neutrophils and CD14+ monocytes, which is followed, within 24 hours, by contraction 
of CD4+ and CD8+ T cells. Most notable was a six-fold expansion of 
CD33+CD11b+CD14+HLA-DRlow monocytes with phenotypic similarities to myeloid derived 
suppressor cells (MDSCs). MDSCs are a heterogeneous group of immunosuppressive cells 
(Gabrilovich et al., 2007) which remain poorly defined in terms of cell surface markers and 
directly suppress T cell functions through a variety of mechanisms including the production 
of reactive oxygen species (ROS) (Schmielau & Finn, 2001) and Arginase-1 (Highfill et al., 
2010) as well as IL-10 and TGF-β release (Ostrand-Rosenberg & Sinha, 2009). In addition to 
the monocyte derived MDSCs that expand following hip arthroplasty, a distinct subset of 
CD62Ldim neutrophil-derived MDSCs appear shortly after blunt trauma and tissue injury and 
induce T cell suppression in a Mac-1 (CD11b) dependent fashion (Pillay et al., 2012; Pillay et 
al., 2013). Further characterisation of the expansion of MDSCs in the postoperative period 
may provide a vital link between alarmin release and an immunosuppressed phenotype. An 
analysis of surgery induced changes in the phosphorylation of intracellular signalling proteins 
in different immune subsets provides interesting correlations, particularly in the CD14+HLA-
DRlow monocyte clusters where immune correlates, such as STAT3 signalling, account for up 
to 60% of the variability in postoperative recovery (Gaudilliere et al., 2014). It is particularly 
relevant that in another cohort preoperative differences in monocyte STAT signalling 




1.5.6 Circulating Cellular Aspects Of The Immune Response  
1.5.6.1 Introduction 
 The majority of circulating cells of the immune system are referred to as leukocytes 
and have in the past been broadly divided into two categories, those influencing the innate or 
the adaptive arms of the immune system. The innate immune has traditionally been thought to 
provide an acute but less specific immune response, while the adaptive arm provides a more 
specific but delayed immune response that is antigen mediated (Janeway, 2012). These 
terminologies are perhaps now becoming archaic with more recent single cell analysis 
demonstrating CD4+ STAT3 and STAT5 upregulation only an hour following hip 
arthroplasty (Gaudilliere et al., 2014). 
1.5.6.2 Neutrophils 
 Neutrophils are granulocytes and in humans are the most common circulating 
leukocyte and are elevated following infection or following tissue damage. They, along with 
monocytes characterise the immediate immune response (Leliefeld et al., 2015) assisting in 
the clearance of infection and debris. Previously, they were thought to be a short-lived and 
homogenous population. However recent evidence suggests that they are able to survive in 
the circulation for an average of 5.4 days (Pillay et al., 2010), this was at least 10 times 
longer than had previously been appreciated. The same group has also reported a novel 
heterogeneity of neutrophils, with a mature form of neutrophils phenotyped as 
CD11cbright/CD62Ldim/CD11bbright/CD16bright showing immunosuppressive actions on 
circulating T cells (Pillay et al., 2012). Neutrophils are classically regarded as part of the 
innate immune system, displaying a number of receptors on their cell surface (pattern 
recognition and Fc receptors amongst others) these features allow them to respond to a wide 
variety of stimuli (Leliefeld et al., 2015). They not only secrete cytokines to signal to other 
cell types but can also destroy bacteria and fungi either by phagocytosing them or via the 
production of reactive oxygen species (ROS) or Neutrophil Extracellular Traps (NETs) 




move into the tissues from blood vessels a process known as diapedesis, in order to migrate 
into inflamed tissue. What has recently been described is the ability of neutrophils to reverse 
transmigrate, moving from the tissues across the endothelium into the bloodstream, possibly 
further potentiating an inflammatory response (Woodfin et al., 2011).  
1.5.6.3 Monocytes 
 Monocytes are another form of granulocyte and they are also able to phagocytose, 
thus assisting in the clearance of infection and debris (Gordon & Taylor, 2005).  While 
circulating, they can be characterised into three distinct subsets based on the expression of 
CD14 and CD16 (Gordon & Taylor, 2005), with the most prominent of the subsets, classical 
monocytes, phenotyped as CD14++CD16-. This subset is known to produce high levels of pro-
inflammatory cytokines following stimulation by endotoxin (Wong et al., 2011). Intermediate 
monocytes, phenotyped as CD14+CD16+, are high expressers of HLA-DR and as a 
consequence play a key role in presenting antigens to T cells. The final subset, non-classical 
monocytes, are the least common and are phenotyped as CD14dimCD16++and these cells are 
primarily involved in the response to viral infections (Alazawi et al., 2016). Monocytes 
differentiate when in the tissues to macrophages or myeloid dendritic cells (mDCs).  
 As has already been discussed earlier in this introductory Chapter there is a great deal 
of interest in the biology of MDSCs especially in the context of cancer, sepsis and tissue 
damage. At the moment, in humans, these cells are poorly phenotyped as there is a mixed and 
unclear heritage to these cells. This is summarised in an excellent review, which outlines our 
current understanding of the characteristics of the myeloid-derived and the monocyte-derived 
suppressor cells (Pillay et al., 2013).  
 Other granulocytes such as Eosinophils, Basophils and Mast cells are less common in 
the circulating blood. Eosinophils are primarily involved in the response to parasites (Kita, 
2011), while Basophils and Mast cells are involved in allergic reactions, both being potent 




1.5.6.4 Dendritic Cells 
 Dendritic cells are the circulating antigen presenting cells and as a consequence they 
act as a vital link between the innate and adaptive immune system, determining the 
magnitude and quality of the adaptive immune response (Boltjes & van Wijk, 2014). These 
cells are broadly classified into two differing types based on their heritage; conventional 
dendritic cells, previously termed myeloid dendritic cells (two differing forms phenotyped as 
CD1c+ or CD141+), are potent secretors of the pro-inflammatory cytokine IL-12 while 
plasmacytoid dendritic cells (pDCs, CD303+) secrete interferon-α (Boltjes & van Wijk, 
2014). Sterile or non-sterile inflammation is known to affect the function of dendritic cells 
causing increased rates of apoptosis as well as reductions in antigen presentation capability 
and cytokine production capacity, thus impeding the later activation of the adaptive immune 
response (Hotchkiss et al., 2013). 
1.5.6.5 Lymphocytes 
 Lymphocytes were previously thought to be exclusively adaptive immune cells, 
however a family of innate lymphoid cells (ILCs) have being recently better characterised. 
Although these cells occupy a small percentage of the total circulating lymphocyte count they 
do not exhibit any degree of antigen specificity allowing them to act rapidly and influence the 
impending adaptive immune response (Eberl et al., 2015; Klose & Artis, 2016). 
 The remainder of the lymphocyte population can be divided into T (Thymus) or B 
(Bone marrow) derived cells. T cells can further be divided in those expressing CD4 or CD8 
cell surface markers, dividing them into Helper or Cytotoxic cells. CD4+ (Helper) T cells are 
the subpopulation predominantly discussed (in greater detail later) in this thesis. Initially 
these cells were thought to be divided into Th1 or Th2 populations. With Th1 populations 
acting primarily as host immunity effectors against bacteria and protozoa, while Th2 
populations acted against parasites (Abbas et al., 1996). Further subsets of T helper cells have 
since been discovered including Th17, Th22 and follicular cells meaning this previously 




(Nakayamada et al., 2012). T cell receptor signalling has been shown to be downregulated 
both following trauma (Xiao et al., 2011) and sepsis (Boomer et al., 2012). These cells also 
exhibit signs of exhaustion via the expression of cell surface markers such as Programmed 
cell Death protein (PD-1) or Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA-4) 
following tissue damage or infection, in a similar manner to what is exhibited in cancer 
biology (Hotchkiss & Moldawer, 2014). T regulatory cells (Tregs) are also CD4+ and are 
involved in the maintenance of immune tolerance. Following sepsis, trauma or surgery these 
are thought to be increased (Cavassani et al., 2010), contributing to the anti-inflammatory 
environment by inhibiting neutrophil and monocyte function (Hotchkiss et al., 2013; Venet et 
al., 2006). CD8+ cells are commonly referred to as Cytotoxic T cells. These are typically 
involved in the response to cancer, viral infections or following transplantation; these also are 
thought to undergo apoptosis following tissue damage or infection, thus also impacting upon 
the body’s defense mechanism against intracellular infections with certain viral, protozoan, 
and bacterial pathogens (Harty et al., 2000). 
 All of these T cells can be broken down into effector, memory or naïve cells. Effector 
cells will actively respond to co-stimulation, while memory cells are specific cells that are 
retained following an infection, and as a result are able to expand at short notice. Naïve T 
cells are cells awaiting differentiation following antigen presentation (Janeway, 2012). 
 B (CD19+) cells play a dual role in the inflammatory response. They are not only able 
to present antigens to T cells but are able to produce antibodies (Vaughan et al., 2011). 
Following sepsis the rate of apoptosis is thought to increase, alongside their ability to produce 
antigen-specific antibodies (Hotchkiss et al., 2001). Following tissue damage their role is 
poorly defined, however more recently gene array data described in the genomic storm paper 





 Although platelets have been long regarded as predominantly a component of the 
coagulation system their role in shaping the immune response is only more recently being 
appreciated (Morrell et al., 2014). Platelets are able to contribute to the immune response by 
forming immunocomplexes with circulating leukocytes thereby influencing their cytokine 
secretion pattern as well as secreting their own cytokines such as IL-1β, thus contributing to 
the acute phase response (Lindemann et al., 2001). Platelets are also able to expel granules 
and microparticles further influencing the trajectory of the immune response (Morrell et al., 
2014).  
1.5.7 Conclusions 
 These data demonstrate that our understanding of the immune response to surgery 
and tissue damage is rapidly expanding in conjunction with available technology and 
provides opportunities for the identification of therapeutic targets and predictive biomarkers. 
1.6 Anaesthesia, Analgesics & The Inflammatory Response 
1.6.1 Introduction 
 Whilst the presence of significant tissue damage exerts the dominant influence on 
altered perioperative immunity, the administration of anaesthetic agents has additional and 
complex effects. In the clinical scenario it can be very difficult confidently to separate the 
immune modulating effects of anaesthesia from the response to surgery and tissue damage 
and consequently much of the available mechanistic data is generated either from in vitro 
experimental work or animal models. 
1.6.2  General Anaesthesia & Inflammation 
 Broadly speaking, the overriding effect of anaesthesia on the immune system is one 




anaesthetics induce lymphocyte apoptosis and impair neutrophil phagocytosis (Matsuoka et 
al., 2001). Secondary immunosuppressive effects are mediated through modulation of the 
neural immune-regulatory circuit and activation of cholinergic anti-inflammatory pathways 
and also as a consequence of altered adrenocortical functions (Picq et al., 2013). Opioids are 
administered frequently during anaesthesia and their inhibition of innate and adaptive 
immunity is well described (Vallejo et al., 2004). Natural killer cells, a key facet of innate 
immunity and host tumour surveillance, are suppressed by both anaesthesia and opioids 
(Markovic et al., 1993). Clearly, the choice of anaesthetic technique may have important 
clinical implications independent of the surgical procedure. The presence of an anaesthesia-
induced immunocompromised phenotype may affect outcome in different ways but in the 
perioperative setting it is the creation of a pro-tumour and pro-infection cytokine and 
inflammatory milieu that is of key concern. Cancer and infection are intimately linked as both 
flourish in an environment of T cell exhaustion and lymphocyte anergy, such as is observed 
in the perioperative period (Hotchkiss & Moldawer, 2014). It is also notable that both 
conditions themselves also induce this phenotype, which has additional implications for those 
patients with chronic infections and malignancies who undergo operative treatment.  
1.6.3 Neuraxial Anaesthesia 
 Although the hormonal stress response is not completely ablated by the use of 
regional anaesthesia, avoiding general anaesthesia is associated with a blunted response and 
lower peak levels of serum cortisol (Milosavljevic et al., 2014). Interestingly, in a large 
cohort of patients undergoing knee arthroplasty the administration of neuraxial anaesthesia 
alone when compared to general anaesthesia alone was associated with a decreased incidence 
of postoperative infections (Liu et al., 2013a). The odds of pneumonia occurrence were 0.51 
in those patients receiving neuraxial anaesthesia alone when compared to general anaesthesia 
alone in this cohort. Whilst this study was not randomised it is important that the association 




1.6.4  Conclusions 
 A strategy of limiting, but not excluding, inhalational and intravenous anaesthetics by 
combining epidural and general anaesthesia has suggested subtle advantages over general 
anaesthesia alone in terms of the duration of postoperative immunosuppression, reduction in 
absolute T lymphocyte count and the relative proportions of Th1, Th2 and Treg cell subsets 
(Chen et al., 2015; Cheng et al., 2013). However, the clinical benefit of this combined 
approach remains unclear. A meta-analysis of studies comparing a technique of combined 
epidural and general anaesthesia versus general anaesthesia alone failed to demonstrate 
convincingly a benefit in terms of cancer recurrence (Pei et al., 2014). However, in a review 
of nearly 400,000 patients undergoing hip or knee arthroplasty, whilst the benefit of neuraxial 
anaesthesia alone was replicated in terms of lesser infection risk any protective effect 
appeared markedly reduced in the cohort that received a combined general and regional 
anaesthesia technique (Memtsoudis et al., 2013). 
 In each of the above studies the absence of randomisation makes interpretation 
difficult. Consequently, these studies are prone to inherent biases making it impossible to 
draw definitive conclusions and they should be viewed as hypothesis generating. This 
viewpoint is supported by a recent consensus statement expressing concern that experimental 
evidence suggests a link between anaesthetic technique and cancer recurrence yet accepts that 
there is insufficient clinical evidence to justify any change in practice and calls for the 





1.7 Common Adjunctive Perioperative Treatments & 
Inflammation  
1.7.1 Dexamethasone & Other Commonly Administered Perioperative 
Therapeutics 
 Dexamethasone is frequently administered during anaesthesia as an effective 
prophylactic anti-emetic. Single doses have additional beneficial effects such as enhanced 
analgesia and reduced surgical site swelling. However, it is a potent glucocorticoid and even 
single doses can display effects on adrenocortical functions a number of days following 
administration (Elston et al., 2013). Although there is clear physiological rationale for 
implicating dexamethasone in enhancing the risk of postoperative infection the clinical data 
have been conflicting (Bolac et al., 2013; Corcoran et al., 2010; Percival et al., 2010). A 
recent meta-analysis of randomised controlled trials using single-dose dexamethasone found 
no association with postoperative infection (Waldron et al., 2013). These results should 
however be interpreted cautiously as the dexamethasone group also received less opioids, 
thereby introducing a potential source of bias. 
 Other ubiquitously prescribed perioperative treatments with potential 
immunomodulating properties, such as paracetamol, NSAIDs and gabapentinoids, have not 
demonstrated clear associations with important immune outcomes such as infection 
(Mathiesen et al., 2014).  
1.7.2 Allogeneic Blood Transfusion  
 The immunomodulating qualities of perioperative allogeneic blood transfusion have 
long been appreciated and have even been exploited to prevent renal allograft rejection in the 
era prior to the development of effective immunosuppressants (Opelz & Terasaki, 1978). The 
unintended clinical consequences of perioperative immune modulation by allogeneic blood, 






complications. It is not suggested that the transfused products contain pathogenic microbes; 
rather the immune response induced by the transfusion creates an environment conducive to 
the growth of pathogenic organisms. Allogeneic transfusion has also been implicated in the 
recurrence of cancer following general surgical procedures (Amato & Pescatori, 2006; Cata et 
al., 2013; Jensen et al., 1992). However, more recently similar links between transfusion and 
cancer recurrence have also been reported following surgery for prostate, hepatic, and head-
and-neck cancers (Danan et al., 2015; Schiergens et al., 2015; Soubra et al., 2014).   
 An autologous blood transfusion, used more frequently in cardiac and orthopaedic 
surgery, is potentially associated with less severe immune alterations when compared with 
allogeneic blood transfusion. Supporting this are data from over 12,000 patients undergoing 
elective hip or knee arthroplasty where patients receiving an autologous blood transfusion 
were less likely to suffer respiratory tract infections or wound infections (Friedman et al., 
2014). 
 Interestingly, blood stored for prolonged periods prior to administration may be 
particularly deleterious with in vivo models suggesting that aged red blood cells may exert 
enhanced tumour progression (Atzil et al., 2008).  However, recently, two multi-centre RCTs 
assessing the influence of the duration of storage of PRBCs prior to transfusion failed to 
demonstrate associations between ‘older’ PRBCs and the development of nosocomial 
infections in septic patients (Lacroix et al., 2015) or in patients undergoing cardiac surgery 
(Steiner et al., 2015). Despite this, in a recent meta-analysis, when looking specifically at 
trauma and cardiac surgery patient groups those receiving ‘older’ PRBCs may be more 




1.8 Epigenetics & Immune Responsiveness 
1.8.1 Introduction  
 Epigenetics is an umbrella term that describes host mechanisms of altering gene 
expression that do not require a change in the underlying DNA sequence. The enzymatic 
conversion of cytosine to 5-methylcytosine and the methylation or acetylation of chromatin 
usually causes transcriptional repression by impeding access to promoter regions whereas the 
overexpression of micro RNAs (miRs) can both inhibit transcription and target messenger 
RNA (mRNA) for degradation. Cancer research has pioneered the study of epigenetic 
modifications that promote an immunosuppressed phenotype, thereby facilitating immune 
evasion by cancerous cells, and has also been at the forefront of developing epigenetic 
modifying agents that can target these processes (Héninger et al., 2015).  
1.8.2 Epigenetics & Immunomodulation  
 In the perioperative period epigenetic studies have largely focused on acute and 
chronic pain processes, although data supportive of a key role in inflammation and 
immunosuppression have emerged (Lirk et al., 2014). For example, the use of opioids in the 
perioperative period promotes global DNA methylation in peripheral blood leukocytes 
(Doehring et al., 2013). This is consistent with the transcriptional repression of pro-
inflammatory genes, which may have longer-term implications as epigenetic alterations 
persist. Furthermore, our group have described the post-traumatic production of miRNAs 
with sequence complementarity to the mRNA transcripts of key cytokines whose expression 
levels change markedly following tissue damage (Owen et al., 2014). This may represent an 
epigenetic regulation of the response to tissue damage through the targeted degradation of 
pro-inflammatory mRNAs by miRs. In this setting miR levels also correlate with nosocomial 
pneumonia. Although the study of epigenetics in the perioperative period is in its infancy the 






 Rapid advances in our understanding of perioperative inflammatory processes, their 
causes and consequences coincide with development of multiple, clinically applicable 
immune and epigenetic modulators such as growth factors, antibodies, DNA hypomethylating 
agents, histone deacetylase inhibitors and micro RNA mimics. The prospect of manipulating 
an errant immune response to major surgery is no longer aspirational. Personalised medicine 
has become a reality for many patients suffering from a variety of immune related disorders 
such as myelodysplasia, rheumatoid arthritis and inflammatory bowel disease. These patients 
now routinely benefit from therapies which target specific facets of a pathological immune 
response and the challenge for perioperative medicine is to distinguish between protective 
and pathogenic immune responses in the perioperative period and to identify modifiable 
immune pathways which when altered can impact on important clinical endpoints. 
 Uniquely, the elective nature of the majority of surgical procedures introduces the 
possibility of developing a pre-emptive, preventative, immunotherapy strategy that may 
ultimately prove advantageous. The potential for pre-emptive or early therapies for those 
undergoing scheduled procedures vastly increases the prospects of success for any 
intervention for the perioperative patient. To achieve this ultimate aim basic scientists must 
continue to define pathological inflammatory pathways and collaborate with translational 
scientists identifying interventions suitable for clinical use. Clinical trialists must also be 







1.10 Aims Of This Thesis 
• To document changes in the expression of genes that describe T Helper cell 
inflammatory pathways in polytrauma and major abdominal surgery. 
• To describe associations between patterns of T-Helper cell related gene expression and 
key clinical outcomes. 
• To define the influence of allogeneic blood transfusion on these pathways as well as 
the impact that transfusion has on the acquisition of nosocomial infection. 
• To identify soluble mediators that circulate following tissue damage that impart a 











2.1 Activation of Coagulation & Inflammation in Trauma 2 
(ACIT2)   
 The ACIT2 study commenced recruiting at the Royal London Hospital in January 
2008 having received ethical approval from the East London and City Regional Ethics 
committee 1 on 13th November 2007 (07/Q0603/29). Initially it was developed as a stand-
alone observational study aiming better to characterise the initial coagulopathy findings of 
Professor Karim Brohi. This was later extended to encompass inflammatory changes, 
increasing the volume of blood that was ethically permitted to be drawn, allowing the 
collection of greater volumes of plasma for ELISA analysis as well as the storage of 
PAXgene® tubes for the analysis of whole blood total RNA. To collect these data there is a 
dedicated rota of fellows on-call from 08:00 – 20:00 (later extended to 22:00) who screen all 
trauma team activations (Supplementary Table 1) for eligible candidates. All those patients 
screened are recorded for ethical purposes.  
2.1.1 Inclusion & Exclusion Criteria 
 All trauma patients presenting to the Royal London Hospital are eligible for 
recruitment to ACIT2. However, pragmatically, latterly those less severely injured patients 
who are likely to be discharged < 24 hours are not recruited. The exclusion criteria are: 
• Age <16 years 
• Transfer from another hospital  
• Arrival > 120 minutes from injury  
• More than 2000ml crystalloid pre-hospital  
• More than 5% total body surface area (TBSA) burns  




• Known bleeding abnormality (including anticoagulant medication)  
• Refused consent  
• Vulnerable patients (in custody or in prison)  
For the purposes of this thesis those diagnosed with infection with the human 
immunodeficiency virus, or with neutropenia as a result of chemotherapy or receiving long-
term treatment with corticosteroids were also excluded. Only patients admitted initially to the 
Adult Critical Care Unit following resuscitation and/or damage control surgery were included 
in the analysis.  
2.1.2 Consent  
 On admission, it is frequently impossible and often unethical to attempt to obtain 
informed consent from the patient or their next of kin. To address this, emergency research 
permits the use of a professional legally appointed representative in accordance with the 
Mental Capacity Act 2005 (Great Britain. Department for Constitutional Affairs., 2007). The 
professional legally appointed representative (LAR) is the trauma team leader (usually a 
consultant or senior registrar in the Emergency Department, who has undergone good clinical 
practice (GCP) training), who has been briefed on the study protocol and therefore is able to 
provide independent assent. Following professional LAR consent the research team are then 
able draw 30mL of blood on admission and at the two following sampling points (24 and 72 
hours), if the patient is still lacking capacity. Every effort is made following admission to 
seek patient consent or LAR assent from relatives as soon as possible. If consent is then 





2.1.3 Blood Collection  
 As previously described blood sampling takes place at 3 time points, on admission to 
the Emergency Department, at 24 and 72 hours. As the majority of blood is used for 
coagulation studies only the relevant sampling tubes used for this thesis will be discussed. 
• 2 x 4.5 mL citrated vacutainers for plasma collection (0.109M + buffered sodium citrate 
3.2%, Becton Dickinson, Plymouth, UK).  
• 1 x 2.5 mL RNA PAXgene® for genetic analysis (PreAnalytix, Germany).  
• A paired standard panel of blood tests for routine laboratory processing including; Full 
blood count, coagulation screen, fibrinogen and D-dimer.  
• A blood gas (BG) is also drawn as part of standard care at admission and at 24h or 72h 
if patients have a central or arterial line in-situ. 
2.1.4 Processing & Storage of Samples 
2.1.4.1 Citrated plasma (ACIT) 
 The citrated vacutainer tubes were centrifuged at 3400 RPM for 10 minutes, with the 
brake on, in a Clinispin Horizon 853VES Laboratory Centrifuge (Woodley Equipment 
Company Ltd, UK). The resulting sample then separated into three layers; citrated plasma, 
buffy coat and erythrocytes. The top two thirds of the plasma from each tube was aliquoted 
into a clean 5 mL Falcon tube (Becton Dickinson, UK) using a Pasteur pipette and 
centrifuged for a second time at 3400 RPM. The double-spun, platelet-poor plasma was then 
transferred, using a Pasteur pipette, in 500 µL aliquots, to 3 x 0.6 mL Cliklok microcentrifuge 
tubes (MCT) (Simport, UK). The lower third of the plasma from each tube was transferred, in 
500 µL aliquots, to a 0.6 mL Cliklok microcentrifuge tube (Simport, UK) for storage as 
single spun plasma. The buffy coat was then aliquoted using a Pasteur pipette, attempting to 




The remainder of the sample was then discarded. All samples were labelled and stored in 
catalogued cryoboxes at -80°C immediately following processing. 
2.1.4.2 PAXgene® 
 PAXgene® tubes were inverted 10 times and stood upright on the lab bench for a 
minimum period of two hours. Following this they were stored upright at -20°C for a 
minimum of 24 hours before being transferred to the -80°C freezer for long-term storage. 
2.1.4.3 Blood Gas  
 Blood gas analysis was performed using a near patient testing device, ABL 500 Flex 
(Diamond Diagnostics, USA) within the ED department or the Adult Critical Care Unit. All 
of these machines are calibrated every four hours. 
2.1.5 Data collection 
 Extensive data was collected characterising the; injury severity (Injury Severity Score 
(ISS) & Abbreviated Injury Score (AIS)), shock state (blood gas and haemodynamic 
variables) as well as the prevalence of nosocomial infection (Horan et al., 2008) and organ 
dysfunction (measured by the Sequential Organ Failure Assessment (SOFA) score (Vincent 
et al., 1996)) for those patients in the adult critical care unit (ACCU) and for all patients 
recruited into this study. The trauma research fellows collected these data prospectively on a 
day-to-day basis.  
2.1.5.1 Scoring Systems 
2.1.5.2 ISS 
 The Injury Severity Score (ISS) was the first score developed to grade the severity of 
injuries and their relationship with mortality (Baker et al., 1974). The score is calculated 
retrospectively following the identification of all injuries to the patient. Each anatomical 
region is graded between 0 and 5 to obtain an abbreviated injury score (AIS). The three 




Scores ≥16 are regarded as major trauma, whilst those ≥25 are severe trauma. This scoring 
system is further outlined in Supplementary Table 2. 
2.1.5.3 The Sequential Organ Failure Assessment (SOFA) Score 
 Internationally in trauma research there is no widely agreed consensus as to the best 
way to score and diagnose organ dysfunction. A number of scoring systems have been 
devised to describe the severity of organ failure consistently between patients but selection 
remains centre specific. The SOFA, Marshall Score and Denver Score are three of the most 
widely used tools. The parameters used in this scoring system are further outlined in 
Supplementary Table 3. 
 In this thesis the development of organ dysfunction was assessed daily using the 
Sequential Organ Failure Assessment (SOFA) score (Vincent et al., 1996). Single-organ 
dysfunction was defined as a SOFA score of ≥3 in one organ system during any 24-hour 
period for the duration of the patient’s ICU stay. Multiple-organ dysfunction was defined as a 
SOFA score of ≥3 in ≥2 organ systems during any 24-hour period (Moreno et al., 1999). 
Acute Adult respiratory distress syndrome (ARDS) was deemed to be present when the 
respiratory component of the SOFA score was ≥3 for 2 consecutive 24 hour periods, the 
limitations of this are discussed in the conclusion of this thesis. 
 
2.2 Vascular Events In Noncardiac Surgery Patients Cohort 
Evaluation (VISION) 
 The VISION trial, a multicentre international observational study, commenced 
recruiting at the Royal London Hospital in March 2011 having received ethical approval from 
the North Wales Research Ethics Committee (Reference: 10/WNo03/25). The cohort of 





VISION study aimed to describe the relationship between the peak fourth-generation troponin 
T measurement over the first 3 days following elective non-cardiac surgical patients (over the 
age of 45) and 30-day mortality (Vascular Events In Noncardiac Surgery Patients Cohort 
Evaluation Study et al., 2012). Sampling took place, preoperatively, and at 24, 48 and 72 
hours postoperatively. Patients gave consent, and bloods were drawn by the critical care 
research team. Patients were free to withdraw their consent at any point or refuse blood 
sampling.  
2.2.1 Inclusion & Exclusion Criteria 
 All patients aged 45 or over undergoing scheduled surgery at the Royal London 
Hospital involving the gastrointestinal tract, requiring a general anaesthetic and at least an 
overnight hospital stay were eligible for recruitment to VISION. The exclusion criteria were: 
• Age <45 
• Refusal of consent 
• Emergency surgery  
• Surgery, which also involved access to the thoracic cavity 
2.2.2 Consent  
 Every patient on a weekday elective operating list was screened. Eligible patients 
were approached for written informed consent by a member of the research team. All team 
members had undergone good clinical practice (GCP) training. Entry into the study did not 




2.2.3 Blood Collection  
 As previously described blood sampling takes place at 4 time points, preoperatively, 
and at 6-12, 24, 48 and 72 hours postoperatively. In addition to serum, which was drawn for 
the analysis of troponin levels, a number of other vials were collected. 
• 1 x 4.5 mL citrated vacutainers for plasma collection (0.109M + buffered sodium citrate 
3.2%, Becton Dickinson, Plymouth, UK)  
• 1x 5.0 mL SSTTM II advance vacutainer (Becton Dickinson, Plymouth, UK) 
• 1 x 2.5 mL RNA PAXgene® for genetic analysis (PreAnalytix, Germany)  
2.2.4 Processing & Storage of Samples 
2.2.4.1 Citrated plasma  
 The citrated vacutainer tubes were centrifuged at 3000 RPM for 10 minutes, with the 
brake on, in a Sigma 2-16PK centrifuge (Sigma, UK). The resulting plasma was then 
aliquoted into 2.0 mL Corning® cryogenic vials (Corning Incorporated, NY, USA). All 
samples were labelled and stored in catalogued cryoboxes at -80°C immediately following 
processing.  
2.2.4.2 Serum  
 The SSTTM II vacutainer tubes were centrifuged at 3000 RPM for 10 minutes, with 
the brake on, in a Sigma 2-16PK centrifuge (Sigma, UK). The resulting serum was then 
aliquoted into 2.0 mL Corning® cryogenic vials (Corning Incorporated, NY, USA). All 





2.2.4.3 PAXgene®  
 PAXgene® tubes were inverted 10 times and stood upright on the lab bench for a 
minimum period of two hours. Following this they were stored upright at -20°C for a 
minimum of 24 hours before being transferred into the -80°C freezer for long-term storage. 
2.2.5 Data collection 
 Patients were examined daily by the clinical team for the presence of infection. 
Definitions of infection were agreed prospectively by the investigators and were based on the 
Center for Disease Control and Prevention (CDC) definitions (Horan et al., 2008) and graded 
using the Clavien-Dindo classification (Supplementary Table 4).  
 
2.3 Experimental Methodology 
2.3.1 Total RNA Isolation from PAXgene® tubes 
2.3.1.1 PAXgene® 
PAXgene® tubes are a widely used consumable for the collection of total RNA from 
whole blood. Due to their ease of use they are ideally suited to large national or international 
studies allowing a standardised total RNA collection method to be employed. 
 Prior to starting the extraction, protocol wash buffer 2 (BR4), which is supplied as a 
concentrate, is made up with ethanol (96–100%, purity grade) as indicated on the bottle to 
obtain the working solution (BR4). 
 In addition to this the DNase I stock solution is prepared when the kit is first opened. 
The solid DNase I (1500 Kunitz units) is dissolved in 550 µL of the DNase resuspension 
buffer (DRB) provided with the kit. This is then aliquoted into 130 µL volumes (to prevent 




 The PAXgene® tubes were removed from the -80°C freezer in batches of twelve the 
evening prior to processing to allow them to thaw adequately, whilst standing on the 
laboratory bench. In the morning the twelve tubes were centrifuged for 10 minutes at 3,000 x 
g (RCF) using a swing-out rotor (4K15 Bench-top Centrifuge, Sigma, UK). The supernatant 
was carefully decanted, so as not to disturb the pellet and 4 mL of RNase-free water (RNFW) 
was added to the pellet. The tube was closed using a fresh Hemogard stopper.  
 The pellet was then re-suspended with a vortex (SA7 Vortex Mixer, Stuart, UK) and 
centrifuged for 10 minutes using the same settings. Again the entire supernatant was carefully 
removed, as incomplete removal in this step can inhibit lysis in the following steps and 
therefore the binding of RNA to the membranes of the columns.  
 Following this, 350 mL of re-suspension buffer (BR1) was then added to the pellet 
and this was vortexed until the pellet was visibly suspended. The solution was aliquoted into 
a 1.5 mL microcentrifuge tube (MCT) and 300 µL of binding buffer (BR2) and 40 µL 
proteinase K (PK) were added. This was vortexed for 5 seconds, and incubated for 10 
minutes at 55°C (having been pre-heated) using a shaker–incubator at 1000 rpm (Eppendorf, 
UK).  
 After this incubation, the temperature of the shaker–incubator was altered to 65°C for 
a later step and all pipettes were treated with RNAse to prevent contamination of the samples. 
A total of 700 µL of the lysate from the MCT was pipetted directly into a PAXgene® 
Shredder spin column which was placed in a 2 mL processing tube (PT), and centrifuge for 3 
minutes at 14,000 x g (1-15 Mini-centrifuge, Sigma, UK). 
 The supernatant of the flow-through fraction is transferred into a fresh 1.5 mL MCT 
without disturbing the pellet in the processing tube. 350 µL of ethanol (96–100%, purity 
grade p.a.) was added to this MCT and then mixed by vortexing. The MCT was centrifuged 





length of the centrifuging did not exceed 1–2 seconds, to prevent pelleting of the nucleic 
acids, thus potentially reducing yields of total RNA.  
 A 700 µL aliquot of the sample was then pipetted into the PAXgene® RNA spin 
column, placed in a 2 mL PT. This was then centrifuged for 1 minute at 12,000 x g. The Spin 
column was then placed in a new 2 mL PT and the flow through was discarded. The 
remainder of the sample was pipetted into the PAXgene® RNA spin column, and re-
centrifuged for 1 minute using the same settings. As before the PT containing flow through 
was discarded and the PAXgene® RNA spin column was placed in a fresh PT. 350 µL of 
wash buffer 1 (BR3) was then added to the PAXgene® RNA spin columns and centrifuged 
for 1 minute at 12,000 x g. The PTs containing the flow through were discarded and the spin 
columns were re-housed in fresh 2 mL PTs. 
 A 10 µL volume of DNase I (RNFD) solution, pre-made up and stored at -20°C in 
batches of 13 aliquots, as previously described, was gently thawed on ice and combined with 
70 µL of DNA digestion buffer (RDD). For the processing of batches, 12 samples (plus 1 for 
pipetting error), consisting of a master mix of 130 µL of RNFD and 910 mL of RDD, was 
added a 1.5 mL MCT. This was gently mixed by flicking the tube. The RNFD solution is 
particularly sensitive to physical denaturation so vortexing was not carried out. 80 µL of the 
master mix was aliquoted, directly onto each of the PAXgene® RNA spin column 
membranes. These were then rested on the benchtop at room temperature for 15 minutes.  
 Following the 15 minute incubation 350 µL of wash buffer 1 (BR3) was aliquoted 
into each of the PAXgene® RNA spin columns. They were re-centrifuged for 1 minute at 
12,000 x g. As before, the PTs containing the flow through were discarded and the spin 








 The PAXgene® RNA spin columns were further washed with 500 µL of wash buffer 
2 (BR4) and centrifuged for 1 minute at 12,000 x g. As before, the PTs containing the flow 
through were discarded and the spin columns were re-housed in fresh 2 mL PTs. This step 
was repeated a further time, with the centrifuge time extended to 3 minutes, at the same 
speed. 
 To ensure that all remaining wash buffer had been eliminated from the PAXgene® 
RNA spin columns the spin columns were placed in fresh PTs and centrifuged for 1 minute at 
12,000 x g. 
 The PT containing the flow-through was discarded and the PAXgene® RNA spin 
column was placed in a carefully labelled 1.5 mL MCTs for the final elution. A volume of 40 
µL of elution buffer (BR5) was pipetted directly onto the PAXgene® RNA spin column 
(PRC) membrane (in order to achieve maximum elution efficiency). This fusion of the MCT 
containing the PAXgene® RNA spin column was centrifuged for 1 minute at 12,000 x g 
(RCF) to elute the RNA. This step was then repeated using the same MCT for each 
PAXgene® RNA spin column to maximise the total RNA elution. 
 The eluate was incubated for 5 minutes at 65°C (to denature the RNA) using the 
shaker–incubator (without shaking). After incubation, the MCTs are placed on ice prior to 







2.3.2 Quality Control Analysis of RNA  
2.3.2.1 NanoDropTM 2000c  
 The NanoDropTM (Thermo Fisher Scientific, USA) uses spectrophotometry, to 
measure the absorbance of UV visible light transmitted through the sample of interest. It 
utilises surface tension to hold and measure micro-volumes of samples between two optical 
pedestals. From this information the machine is able to derive an accurate concentration (in 
ng/µL) of the sample, as well as specific wavelength absorptions (230, 260 and 280 nm). 
These values can then be combined as ratios to give an approximation of the purity of the 
sample isolated. 
 As this machine is commonly used for the analysis of DNA as well as RNA, to 
prevent contamination from previous samples it was carefully cleaned prior to use with an 
alcohol swab. Prior to any analysis the machine requires that it be calibrated. Routinely the 
machine was ‘blanked’ by pipetting 1 µL of nucleotide free water (NFW) onto the optical 
pedestal. These pedestals were then wiped with tissue paper and a further 1 µL of NFW was 
added onto the optical pedestal. The machine then was then run as if to analyse this as an 
RNA sample, if the resulting concentration was not 0 ng/µL, with a straight-line graphic 
displayed on the monitor, then the machine was re-blanked.  
 Following this, the recently isolated RNA samples, stored on ice, were run on the 
NanoDropTM with the concentrations, 230, 260 and 280 ng/µL (Figure 2.1) recorded on 
Microsoft Excel spread sheet (Microsoft Inc., USA). The samples were immediately stored in 









Figure 2.1 - Nanodrop plot & Data 
Nanodrop plot (A), 260/280 ratio & concentrations obtained from total RNA isolated from the 




2.3.2.2 Agilent's 2100 Bioanalyzer 
 
 Further quality control was carried out. Although the NanoDropTM gives an accurate 
yield of RNA that has been isolated, using the 260/280 and 230/260 ratios give more of an 
approximation of the purity of the sample. As a result a more robust measurement of RNA 
quality is required. 
 The bioanalyzer generates an RNA integrity number (RIN) (Schroeder et al., 2006), a 
value out of 10, which is used to score the quality of isolated samples. A threshold value of 7 
has been advocated by some labs to prevent inaccuracies being generated during the qPCR 
phase.  
 The system uses a 16 well chip with micro-channels engineered into the glass which 
then connects the differing wells. During the chip preparation these micro-channels are filled 
with a polymer and fluorescent dye allowing a circuit to be formed. The chip reader uses 16-
pin electrodes, which allow the differing electrodes to read specific wells. As RNA are 
charged molecules, they are electrophoretically driven by this voltage gradient. In a manner 
similar to gel electrophoresis, in the presence of a sieving polymer matrix, the molecules are 
separated by size with smaller fragments moving the furthest. Due to the fluorescent dye 
mixed with the polymer these RNA strands are detected by laser. This then generates gel-like 
images (bands) as well as electropherograms (peaks). 
 Prior to starting this protocol, batches of total RNA samples were removed from the -
80°C freezer and allowed to thaw gently on ice. The ladder, provided with the kit was heat 
denatured at 70°C for 2 minutes and there after stored on ice. The Nano kit (Agilent 
Technologies, USA) was removed from the refrigerator and allowed to acclimatise at room 
temperature for 30 minutes. Following this the gel mixture was filtered. 550 µL was aliquoted 
into a spin filter and centrifuged at 1,500 x g (1-15 Mini-centrifuge, Sigma, UK). The filter 
was removed from the top of the MCT. Following this the filtered gel could be stored at 4°C 





 65 µL of filtered gel was aliquoted into a fresh MCT along with 1 µL of pre-vortexed 
RNA dye concentrate. The MCT was agitated on the vortex (MS3 Chip vortexer, IKA, UK) 
to ensure complete mixing and then centrifuged 13,000 x g (1-15 Mini-centrifuge, Sigma, 
UK) for 10 minutes at room temperature. This gel-dye mix was used within 12 hours of 
preparation. 
 To load the RNA chip a new chip was placed on the chip priming station and 9 µL of 
the freshly mixed gel-dye mix was pipetted into the wells marked G. The syringe attached to 
the chip priming station was positioned at 1 mL and the chip priming station was then closed. 
The plunger on the syringe was then pushed down until a click was heard. The plunger was 
then held in this position for exactly 30 seconds and then the clip was released, allowing a 
minimum of 5 seconds before the plunger was then returned to the 1 mL position.  
 Following this 9 µL of the freshly centrifuged gel-dye mix was also added to the 
wells marked G. 5 µL of the RNA marker was then added to all 12 of the sample wells in 
addition to the ladder well. After this was completed 1 µL of sample was added to each of the 
sample wells and 1 µL of the denatured ladder was finally added to the ladder well. The chip 
was then agitated on a specifically designed vortexer (Agilent Technologies, USA) for 1 
minute at 2400 rpm and then run on the bioanalyzer immediately following this. Prior to 
running, the electrodes on the bioanalyzer were carefully cleaned with a chip filled with 
RNAsezap® (Life Technologies, USA) to remove residual RNA which could contaminate the 
chip, and then washed with a chip containing NFW. 
 The bioanalyzer system takes approximately 30 minutes to analyse the chip, giving 
both gel-like images (bands) as well as electropherograms (peaks) and the RIN figure for 






Figure 2.2 - The Bioanalyzer system 
The Bioanalyzer system demonstrating gel-like images (bands), (A) as well as electropherograms 
(peaks), (B). The bands (A) are sharp and clear with the 28s band displaying approximately twice the 
intensity of the 18s band indicating that the RNA has not been degraded. The electropherograms (B) 
display high quality total RNA with the 18s and 28s fragments clearly visible at 40 seconds and 47 




2.3.3 Reverse Transcription Of RNA To Complementary DNA (cDNA) 
 In order for the RNA to be analysed by Taqman Qualitative Real-Time Polymerase 
Chain Reaction it needs to be reverse transcribed to complementary DNA. For all 
experiments SuperScript® VILOTM (Life Technologies, USA) was chosen based on the 
efficacy and reproducibility of this product as described in the literature. 
 In order to standardise the concentration of the mRNA that was isolated the 
NanoDrop TM concentration was used to identify the volume of mRNA required to give a total 
of 300ng of mRNA. If this volume was less than 16 µL then the remainder was made up with 
NFW in a 96 well plate (Starlab, UK). This gave a total volume of 16 µL at a concentration of 
18.75 ng/µL. The SuperScript® VILOTM master mix was removed from the -20°C freezer and 
rested on ice. A volume of 4 µL of the SuperScript® VILOTM (Life Technologies, USA) 
master mix was then aliquoted to each of the wells. The plates were then firmly sealed with 
an adhesive plate seal (Life Technologies, USA), briefly vortexed and then centrifuged (4K15 
Bench-top Centrifuge, Sigma, UK) for 10 seconds to ensure adequate mixing of the 
standardised dilution of the mRNA and the master mix. For each of the plates in addition to 
the patient samples a positive (lab mRNA sample with a RIN ≥9.5) and a negative control 
(NFW) was added. 
 Each of the plates was incubated in the MJ Tetrad 2 DNA Engine cycler (Bio-Rad, 
UK) using a standardised automated programme of a 25°C incubation for 25 minutes, 
followed by a 42°C incubation for 60 minutes, with the reaction terminated by incubation at 
85°C for 5 minutes. Following the completion of this protocol the cDNA plates were then 
rested on ice and the contents of each well was carefully transferred into a new 96 (deep) well 
plate (Starlab, UK) and made up to a working volume of 300 µL with the addition of 280 µL 
of NFW added to each well to give a final concentration of cDNA of 1 ng/µL. The deep well 




2.3.4 Standardisation Of Taqman Quantitative Real-Time Polymerase Chain 
Reaction (qRT-PCR) 
 Quantitative real-time polymerase chain reaction (qRT-PCR) is of great importance 
in biological research, providing accurate and sensitive expression profiling of candidate 
genes, offering insight into complex molecular pathways (Zamorano et al., 1996). For this 
research technique to be reproducible a standardisable technique for calculating gene 
expression is required (Freeman et al., 1999). Currently there are two main methods in the 
literature that are used to analyse the raw data from qRT-RCR; absolute and relative 
quantification (Livak & Schmittgen, 2001). 
 Absolute quantification describes the input copy numbers of the gene of interest. This 
is calculated by relating the PCR signal to a standard curve. This is performed when it is 
necessary to describe the absolute transcript copy number. It allows one to describe the effect 
of an intervention leading to (e.g.) an increase in the expression of a candidate gene from 
(e.g.) 500 copies per cell to 1500 copies (Livak & Schmittgen, 2001). Due to these 
experiments not requiring absolute copy numbers, relative quantification was used. 
 Relative quantification describes a complex relationship, requiring equations and 
assumptions. It relates the change in expression of the candidate gene in relation to one or 
more reference genes. In the qRT-PCR experiments performed as part of this thesis, this 
methodology was used, utilising the 2-ΔΔCt equation. This relies on a number of factors for this 
equation to be applied correctly (Livak & Schmittgen, 2001).  
 The first of these is the assumption that the amplification efficiencies for the 
candidate and references genes are approximately equal. This is detected by plotting a graph 
of a series of cDNA dilutions (plotted on a logarithmic scale) against the ΔCt obtained for all 
of the candidate genes and reference (housekeeping) genes. This then allows one to calculate 




then the ΔΔCt methodology may be used, as this signifies that the efficiencies of the 
candidate and reference genes are similar (Livak & Schmittgen, 2001; Winer et al., 1999). 
 The Second key factor is the selection of appropriate reference (housekeeping) genes 
for the experiment. Commonly these are drawn from ubiquitously expressed genes such as 
GAPDH, ATP5B or EIFA42 as well as many others. In the case of the trauma experiments, 
mRNA from patients with diagnosed ICU infections, no ICU infections and normal healthy 
controls were selected in order to provide an accurate representation of the expression levels 
of all the samples obtained to select the most stable combination of the six reference genes 
that were analysed in Figure 2.3. The average expression stability (M) is defined as the 
average pairwise variation between a candidate gene and all other control genes 
(Vandesompele et al., 2002). The values of the reference genes are then calculated using a 
VBA applet geNorm (geNorm, 2002; Vandesompele et al., 2002), illustrated in Figure 2.4. 
As a result ATP synthase subunit beta (ATP5B) and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) were selected in combination for the qRT-PCR experiments. This 
was assessed in a similar manner for the perioperative experiments with β2 microglobulin 
(B2M) and ubiquitin C (UBC) selected. 
 
Figure 2.3 - Average expression stability values of the housekeeping genes assessed 





Figure 2.4 - Determining the optimal number of control genes for normalisation 
This graph illustrates the optimal number of reference genes that are required for the series of 
experiments conducted. 
 Figure 2.4 goes onto illustrate that there is no significant change in the normalisation 
factor with the addition of further reference genes to the experiment. This confirmed that the 
ATP5B and GAPDH were adequate as reference genes. This is a trade off between practical 
considerations (using multiple reference genes) and the accuracy of the data (Vandesompele 
et al., 2002). 
 The third assumption is that the amount of starting material for each of the samples is 
equal and the quality of the mRNA extracted is adequate (Huggett et al., 2005). 
Concentration was measured using a spectrophotometer (NanoDrop 2000c, as previously 
described), giving a concentration value (in ng/µL). The quality of the mRNA extracted was 
qualified via a nano chip on the bioanalyzer 2100, giving an RNA integrity number (RIN), as 
previously described. This then allowed the creation of a standardised concentration (1 
ng/µL) of the mRNA for reverse transcription to an equivalent cDNA concentration (using 
SuperScript® VILOTM Master mx). As previously described, known positive controls, mRNA 
with a lab validated expression level and negative controls (NFW), were also included on 




 Other precautions were also taken; mRNA during the extraction process was treated 
with a DNase to prevent non-specific binding of contaminant DNA during the qRT-PCR 
process. Off the shelf assays were chosen that had been previously validated for accurate 
binding by publications in peer-reviewed journals. RORγT was the exception to this. This 
was a custom assay, chosen to span the final two exons of the most common isoforms of this 
gene, as an off the shelf assay was not available. To minimise pipetting error, robot 
programmed plate preparation was carried out; sample input was cross-checked prior to the 
plate being run. Samples were run in triplicate with all assayed primers and probes for that 
patient sample on the same plate. The mean threshold cycle (Ct) of the three values was used. 
Ct values that were more than 2 standard deviations from the other 2 samples were re-done.  
 The Ct is the point when the fluorescence signal is statistically significant to the 
baseline (Gibson et al., 1996). It is determined from a log-linear plot of the PCR signal versus 
the cycle umber (Livak & Schmittgen, 2001) and is utilised to provide reproducible 
quantification. Fluorescence values are recorded during every cycle, representing the amount 
of the candidate gene amplified at that time point (Higuchi et al., 1993). The more of the 
template that is present in the well at the start of the reaction means that fewer cycles are 
required for the Ct to be reached, always in the exponential phase of amplification. This 
means that the reaction is not limited by reaction components, removing a potential bias 
source (Bustin, 2000). Too great a primer concentration is another potential source of bias, as 
this may encourage mispriming and therefore the collection of a non-specific product. With 
the Ct methodology, this is again minimised (Bustin, 2000).  
2.3.5 Taqman Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
 Polymerase chain reaction (PCR) has revolutionised biology. A further development 
of this, Taqman chemistry, was first published in 1991 (Holland et al., 1991). It uses a 
fluorophore covalently attached to the 5’-end of the oligonucleotide probe and a quencher at 




counteracts the fluorescence emitted by the fluorophore when excited by the cycler’s light 
source via Fluorescence Resonance Energy Transfer (FRET). Probes are designed such that 
they anneal within a DNA region amplified by a specific set of primers. As the Taq 
polymerase extends the primer and synthesises the strand, the exonuclease activity of the Taq 
polymerase degrades the probe that has annealed to the template. Degradation of the probe 
causes release of the fluorophore, moving it away from the proximity of the quencher, thus 
allowing its detection. As a result, fluorescence detected is directly proportional to the 
fluorophore released and therefore the amount of DNA template present in the PCR. 
 The ABI Prism 7900HT (Life Technologies, USA) contains a built-in thermal cycler 
with 384-well positions, and is able to detect fluorescence between 500nm and 660nm. 
Fluorescence is induced during the RT-PCR by distributing laser light to all 384 samples 
contained in thin-walled reaction tubes via a multiplexed array of optical fibres. The resulting 
fluorescent emission returns via the same fibres. 
 The ABI prism establishes the levels of background fluorescence for each particular 
run. An algorithm is used to define a fluorescence background threshold. The algorithm then 
searches the data from each sample for a point that exceeds the baseline. The cycle at which 
this occurs is defined as the Crossing Threshold (Ct). After analysis by the SDS software 
(Applied Biosystems, USA), the resulting Cts are used to establish quantitative relationships 
with the assayed cDNA. The fewer cycles it takes to reach a detectable level of fluorescence, 
the greater the initial copy number of the target nucleic acids. 
 Methods to standardise this process, thus reducing the likelihood of errors being 
generated, have previously been outlined in this thesis. As part of the standard running 
protocol for the ABI Prism cycling conditions of 50°C for 2 minutes followed by 95°C for 10 
minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute were used. The raw Ct 




they were analysed using the delta-delta methodology of relative quantification (as previously 
described). 
 Standard curves for each of the assays used were performed with six differing 
dilutions (0.25 – 15 ng/µL) of cDNA. This showed correlation coefficients >0.99, 
demonstrating a precise log-linear relationship. 
2.3.6 Enzyme Linked Immuno-Sorbent Assay (ELISA) 
 ELISA is another well-established technique, which is commonly used to quantify 
the concentration of a chosen protein in a liquid sample. The technique ultilises antigen-
antibody affiliations, resulting in the creation of an antibody-antigen ‘sandwich’. The final 
layer of the sandwich is a flurophore whose emissions are then detected by a plate reader (at 
450nm). The density of the signal mirrors the presence of the target substance, enabling the 
concentration of the substance to be calculated. For the purposes of this thesis it was elected 
to analyse the concentration so the two most reliably detected cytokines IL-6 and IL-10 were 
used (Baigrie et al., 1992; Fragkou et al., 2014; Giannoudis et al., 2000; Mokart et al., 
2005b). Our group had previously tried the LUMINEX platform for multiplex cytokine 
analysis but had disappointing results with key cytokines such as TNF-α and IFN-γ being 
variably detectable. 
 For analysis citrated plasma was used; this was collected as previously described. 
The 2.0 mL Corning® cryogenic vials (Corning Incorporated, NY, USA) were allowed to 
acclimatise at room temperature for a period of 4 hours. Following acclimatisation they were 
centrifuged at 3000 RPM for 10 minutes in order to pellet any debris that may have been 
present in the sample. For both the IL-6 and IL-10 kits it was recommended to use a 1 in 2 





 A wash buffer solution, supplied as 25x concentrated was diluted with the 
recommended volume of deionised water. This was added to the ELx50 Auto strip washer 
(BIO-TEK Instruments, INC, Vermont, Canada) and the machine was primed prior to use. It 
was programmed to aspirate from the wells, and then fill the wells with 0.4 mL of diluted 
wash solution. This was allowed to soak for 15 seconds, and then aspirated. These steps were 
programmed to occur four times for each washing step. 
 The standards were provided in freeze-dried form and were reconstituted in their 
glass vials with the standard diluent buffer supplied. Following reconstitution the vials were 
gently mixed by flicking and a serial dilution was performed giving concentrations of 500, 
250, 125, 62.5, 31.2, 15.6, and 7.8 pg/mL for the IL-6 ELISA plates and 50, 25, 12.5, 6.25, 
3.12, 1.56, and 0.78 pg/mL for the IL-10 ELISA plates. 100 µL of the standards were plated 
sequentially in duplicate from wells A1 and B1 to A7 and B7 of the pre-coated 96 well 
ELISA plate. The final wells (A8 and B8) were plated with Standard Diluent Buffer (B) to act 
as the negative control (Figure 2.5).  
 Patient samples were diluted 2:1 and were plated along with the standards in 
duplicate on each plate. For the IL-10 assay samples were allowed to incubate for two hours 
in a SW-20C Water Bath (Julabo, Germany). For the IL-6 assay in addition to the patient 
samples and standards, a 50 µL volume of biotinylated anti-IL-6 (Biotin Conjugate) solution 
was added to each well aside from the chromogen blanks (A8 and B8). This was incubated at 
room temperature for two hours.  
 Following this step, both plates were washed on the ELx50 Auto strip washer (BIO-
TEK Instruments, Canada) plate washer, using the protocol previously described. Using a 
multichannel pipette a 100 µL volume of biotinylated anti-IL-10 (Biotin Conjugate) solution 
was added to each of the wells of the IL-10 plate except the chromogen blanks (A8 and B8). 
This was incubated at room temperature for one hour. The IL-10 plate was washed as 





 Using a multichannel pipette, a 100 µL volume of Streptavidin-HRP Working 
Solution was added to each well of both plates except the chromogen blanks. This working 
solution had been made up using 120 µL of the concentrated solution supplied with the kit 
and 12 mL of Streptavidin-HRP Diluent. The plates were incubated at room temperature for 
30 minutes and re-washed as described. 
 Again using a multichannel pipette, a 100 µL volume of Stabilised Chromogen was 
added to each well of both plates. Addition of this solution caused the contents of the wells to 
change colour to blue. This was incubated in the dark for a period of 25 minutes. Following 
this a 100 µL volume of Stop Solution was added to each well of both plates. This was mixed 
by gently tapping the side of each of the plates. The addition of this solution caused a colour 
change from blue to yellow. The plates were protected from light until they were read on a 
Synergy HT Plate Reader (Bio-Tek, Canada) at 450nm within two hours of the stop solution 
having been added. 
 The data for each plate was exported into a Microsoft Excel spreadsheet (Microsoft 
Inc., USA), from where it was analysed. Optical densities for each standard were plotted 
using Graph Pad Prism version 6.0g (GraphPad Software Inc, USA). These data were log 
transformed to create a standard curve. Unknown plasma concentrations were obtained from 
the standard curve and transformed back into raw figures. Samples lying outside the limits of 
detection for the standard curves were re-plated at an altered concentration based on whether 
they were below or above the standard curve values. The duplicate values were examined and 
if a difference between the two values obtained varied greater than 15% then these samples 
were re-plated. A mean value of the two concentrations was used for analysis. 
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Figure 2.5 - ELISA plate outline 
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2.3.7 Flow Cytometry 
 The use of flow cytometry in a clinical capacity is increasing; this has been largely 
driven by oncology with complex immune-phenotyping taking place to guide treatment 
options. However more recently this has been introduced into critical care research (Monneret 
& Venet, 2015). The current gold standard for the identification of an immunocompromised 
patient on the critical care unit is by determining the number of HLA-DR molecules per 
monocyte (Ab / C (CD14+)), (Docke et al., 2005). This test has previously been used in order 
successfully to randomise patients to receive immune stimulants (Meisel et al., 2009). As a 
result this test was employed as a standardised measure of the immune-competence of these 
two patient cohorts.  
 Blood is collected in a 4 mL EDTA anticoagulated tube with all samples stained <one 
hour following collection. The EDTA tube was gently agitated for 2 seconds on the vortex 
(Heidolph Reax top test tube shaker, Germany). 50 µL of blood was then aliquoted from the 
collection tube and added to a 5 mL FACS tube (Becton Dickinson, UK). The Quantibrite® 
Monocyte/HLA-DR antibody (Becton Dickinson, UK) was retrieved from the fridge and, after 
being gently mixed with a pipette, 20 µL of this was added to the FACS tube using a fresh 
pipette tip. This process was carried out in duplicate. The FACS tubes were gently agitated for 
5 seconds on the vortex and then incubated in the dark for 30 minutes at room temperature. A 
previously prepared lysis and fixation solution (FACS lysis solution Becton Dickinson, UK) 
diluted 1:10 with deionised water (Sigma, UK)) was retrieved from the refrigerator. This was 
warmed in the water bath at 37oC (SW-20C Water Bath, Julabo, Germany).  
 Following 30 minutes of incubation with the antibody the lysis (containing fixative) 
buffer was removed from the water bath and 500 µL was aliquoted into each of the FACS 
falcon® tubes (Becton Dickinson, UK). These were gently mixed by vortexing and re-







 After 15 minutes incubation, 1 mL of FACS buffer (2% fetal bovine serum (FBS) and 
Phosphate Buffered Saline (PBS) (StemCell, France)) is added to each tube. Caps were then 
added and the tubes were centrifuged at 300 x g (RCF) for 5 minutes with the brake on (3SR+ 
Bench-top Centrifuge, Thermo Scientific, UK). Following this the supernatant was aspirated 
with a pipette and the pellet was resuspended (by vortexing) in 500 µL of FACS buffer. The 
tubes were then immediately run on an LSR II flow cytometer (Becton Dickinson, UK) and 
1,500 monocyte events were collected for each tube, gating on CD14+ cells and then measuring 
the HLA-DR geometric mean fluorescent intensity (gMFI) of those CD14+ cells.  
 In addition to this as part of the protocol Quantibrite® Phosphatidylethanolamine (PE) 
coated beads (Becton Dickinson, UK) were run each week. These allowed gating (on the 
histogram setting) of HLA-DR expression, dividing them into low, low-medium, medium-high 
and high expression levels. These individual gMFI values for each of the four-gated parameters 
were calculated. A line of linear regression of Log10 PE molecules per bead against Log10 
fluorescence is plotted using the following equation: 
y = mx + c 
 
Where y is the log10 FL2 fluorescence and x is log10 PE molecules / bead population. 
 
 In order to determine bound anti-HLA-DR antibody (AB / c) per monocyte, the log10 
FL2 geometric means are substituted with the log10 FL2 median value of the monocyte 
population, and the equation is solved for x = log10 Ab / C. The antilog is determined to obtain 





Figure 2.6 - Representitive flow cytometry plot for gating lysed whole blood samples 
Cells were gated on CD14 (A). PE coated beads were used to calibrate the experiment, gave four defined 
population; low, low-medium, medium-high and high to allow accurate gate placement (B). A histogram 
plot showing preoperative (C) and postoperative (D) HLA-DR expression on the gated CD14+ cells. 
Using g(MFI), linear regression was performed to calculate the mAb / C. 
  
 Following cell culture PBMCs were stained in a similar manner, using 10 µL of 
Quantibrite® Monocyte/HLA-DR antibody (Becton Dickinson, UK) per 300,000 PBMCs in a 
5mL falcon® tube (Becton Dickinson, UK). These were incubated at room temperature for 30 
minutes, washed and resuspended as previously described. 2,000 monocyte events were 
collected for each tube, gating on forward scatter and side scatter, then CD14+ cells. Following 
this the positive cells were then assessed for their HLA-DR expression using geometric MFI. 








Figure 2.7 - Representative flow cytometry plot for gating cultured PBMCs 
Cells were gated according to their side and forward scatter properties in order to identify the monocyte 
subpopulation. This subpopulation was then gated according to CD14 expression. CD14+ cells were then 
analysed for HLA-DR geometric mean intensity (gMFI). 
2.3.8 Cell Culture 
 8 mL of peripheral blood were collected in BD Vacutainer™ Sodium Citrate CPT™ 
tubes (Becton Dickinson, UK) from a healthy control cohort. These were immediately 
centrifuged at 1,800 RCF for 30 minutes at 20oC with the brake off. The peripheral blood 
mononuclear cell (PBMC) layer was isolated and washed in Phosphate Buffered saline (Life 
Technologies, Carlsbad, CA) containing 2% human albumin solution (Sigma, UK). Cells were 
then counted with a haemocytometer under a light microscope.  
 Pooled healthy PBMCs were aliquoted (3x105 cells per well) into a 96 well plate and 
cultured in duplicate with Gibco® RPMI 1640 medium (Life Technologies, Carlsbad, CA) 
containing 30% patient serum, which was taken either preoperatively (preop) or at 24 hours 





2.3.8.1 Neutralising Experiments  
 Pooled healthy PBMCs were pre-incubated with an Fc Block™ (Becton Dickinson, 
UK) for 30min then incubated with 30% 24 hour serum and media pre-incubated with either 
IL-6 neutralising antibody 15 ng/mL (R&D systems, UK) or 5-10 µg/mL of IL-10 neutralising 
antibody (R&D systems, UK) for a minimum of 1 hour or with control non-specific goat IgG at 
the same dose (IL-6, IL-10: R&D systems, UK). These were cultured as described above.  
2.3.8.2 Stimulating Experiments 
 Pooled healthy PBMCs were incubated with 30% serum from either baseline or 24 
hours with and without 250 International Units of IFN-γ (R&D systems, UK) or Granulocyte-
macrophage colony-stimulating factor (GM-CSF) at a range of doses (2 – 20 ng/mL) (R&D 
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 Trauma remains one of the most frequent causes of death in those aged under 45 
(Polinder et al., 2012). As early mortality following trauma falls, attributable in part to 
advances such as the widespread introduction of damage control surgery and improved pre-
hospital care (Harris et al., 2012), late onset sepsis and multi-organ failure have now become 
the most frequent cause of complications and subsequent death in these patients (Lord et al., 
2014). An enhanced susceptibility to acquiring infection has been noted, with ventilated trauma 
patients’ risk of pneumonia being four times greater than ventilated non-trauma patients 
(Magret et al., 2010). The development of sepsis, from any source, in trauma patients is 
associated with a trebling of the mortality rate (Osborn et al., 2004). 
 The inflammatory paradigm in relation to severe trauma has changed substantially over 
time and this is characterised in more detail in Chapter one of this thesis. In short, the original 
description of an initial systemic inflammatory response syndrome (SIRS) followed by a 
compensatory anti-inflammatory response syndrome (CARS) (Dewar et al., 2009; Keel & 
Trentz, 2005; Mannick et al., 2001; Moore et al., 1996) has been supplanted by a description of 
simultaneous activation of inflammatory and anti-inflammatory pathways (Xiao et al., 2011). 
More specifically, it is now suggested that trauma induces activation of innate immune 
pathways, whilst concurrently suppressing adaptive immune pathways (Kasten et al., 2010). 
Precisely how swiftly the body mounts a response is unclear but recent data suggest the 
presence of altered inflammatory pathways within 12 hours and possibly within 4 hours of 
severe trauma (Xiao et al., 2011). 
 The Immunological picture is however clouded by blood transfusion, as this can be 
associated with unintended morbidity (Hill et al., 2003). Allogeneic blood products are 
transfused in up to 9% of trauma patients, with one third of this group requiring massive 
transfusion (Como et al., 2004). In the US approximately 10% of all red cell transfusions are 




allogeneic blood have long been appreciated and have even been exploited to prevent renal 
allograft rejection in the era prior to the development of effective immunosuppressants (Opelz 
& Terasaki, 1978). Clinical consequences of immune modulation by allogeneic blood include 
an increased susceptibility to infections and cancer recurrence. These transfusion-related 
immune modulatory (TRIM) effects of allogeneic blood transfusions are particularly well 
described in the perioperative period (Cata et al., 2013). Although infections have been 
previously associated with allogeneic blood transfusion in the setting of trauma some of these 
data are historical and precede the routine use of leukodepleted blood products (Flores et al., 
2001; Hill et al., 2003).  
 In the UK PRBCs can be stored for a maximum of 35 days prior to transfusion and in 
some countries for up to 42 days. During this time ‘storage lesions’ may develop which include 
morphological changes, acidosis, decreased 2,3 diphosphoglycerate and adenosine 
triphosphate, lipid peroxidation and apoptosis (Bennett-Guerrero et al., 2007). Although the 
vast majority of currently available evidence is composed primarily of retrospective, non-
randomised studies, there is a suggestion that the administration of older PRBCs is more likely 
to be associated with nosocomial infections and an increased mortality (Lelubre et al., 2009; 
Zimrin & Hess, 2009). The association between the duration of storage of PRBCs and poor 
outcome is particularly well described in trauma patients (Keller et al., 2002; Leal-Noval et al., 
2008; Murrell et al., 2005; Offner et al., 2002; Weinberg et al., 2008; Zallen et al., 1999) and 
intensive care unit (ICU) patients (Fernandes et al., 2001; Hebert et al., 2005; Marik & Sibbald, 
1993; Purdy et al., 1997; Sakr et al., 2007; Taylor et al., 2006). However, the precise 
mechanism by which PRBCs stored for prolonged periods increase susceptibility to infections 
remains elusive.  
 As a consequence it remains uncertain whether allogeneic blood transfusion as well as 
the age of the units of PRBCs transfused compounds an inherently immunosuppressive 




 The development of trauma-induced immunosuppression has been strongly linked with 
subsequent septic complications (Cheron et al., 2010; Tschoeke & Ertel, 2007). Specifically, 
decreasing monocyte Human Leukocyte Antigen-DR (mHLA-DR) expression in the early 
stages following trauma is associated with an increased propensity to subsequently develop 
infection (Cheron et al., 2010). Although quantification of mHLA-DR expression is gaining 
widespread acceptance as a biomarker for monitoring immunoparalysis and has been utilised in 
several interventional clinical trials of immunostimulants (Meisel et al., 2009; Nakos et al., 
2002), decreasing mHLA-DR expression does not always equate either to an increased 
mortality (Perry et al., 2003) or even to an increased incidence of infectious complications 
(Haveman et al., 2006). These inconsistencies, coupled with the need for a flow cytometer to 
perform the assay, have limited its more widespread introduction into the clinical setting 
(Fumeaux & Pugin, 2006). 
 An alternative strategy to characterise the immune response is to quantify the gene 
expression of a number of key cytokines and transcription factors which, when analysed 
together give an indication of the overall systemic inflammatory milieu. Previously this 
approach has been used to characterise the human immune response to infection (O'Dwyer et 
al., 2006; O'Dwyer et al., 2008; Pachot et al., 2005) and as a predictor of perioperative 
infectious complications (White et al., 2011).  
 This Chapter was designed first to document and describe very early temporal changes 
in inflammatory pathways in response to severe polytrauma and to describe associations 
between patterns of gene expression and important clinical outcomes. Second, it was designed 
to explore the hypothesis that blood transfusion contributes to an immunosuppressed phenotype 
in severely injured patients and may be associated with an increased risk of infectious 
complications. And third to assess the influence that older blood has when transfused. The 




measures of the activity of specific immune pathways (O'Dwyer et al., 2008; Pachot et al., 
2005). 
3.3 Methods 
The Methods for this Chapter are fully outlined in Chapter two of this thesis. 
 
3.4 Results 
 A total of 112 ICU patients suffering severe traumatic injury as their admission 
diagnosis were enrolled between September 2010 and October 2012. 
 Table 3.1 shows the baseline characteristics of these patients. The 16 healthy controls 
had a median age of 28 (IQR 25-29) and consisted of 10 males.  
 The results of the analysis of 11 cytokines are included. The pathways that these 
cytokines describe are outlined in Table 3.1.  
3.4.1 Immediate Immunological Response To Severe Trauma 
 All baseline blood samples (Time 0) were taken within 2 hours of the injury. Baseline 
interleukin 10 (IL-10) mRNA levels were raised in comparison to the control group (p<0.0001, 
Figure 3.1A).  
 In comparison with the control group Transforming Growth Factor beta (TGFβ), IL-23, 
RAR-related orphan receptor gamma (RORγt), forkhead box P3 (FOXP3), GATA-3 Tumor 
necrosis factor alpha (TNF-α), IL-23, IL-27 IL-12p35 and T-bet mRNA, mRNA levels were 
lower at baseline (Figure 3.1B-J, all p<0.0001). Interferon gamma (IFN-γ), levels at baseline 





 There was a modest correlation between ISS and IL-10 (Spearman’s ρ = 0.28, p=0.004, 
n=99 (Supplementary Figure 1)) and between ISS and TGFβ (Spearman’s ρ = 0.23, p=0.02, 
n=99) mRNA levels at baseline. 
 Early blood transfusion, as defined by transfusion prior to the baseline bloods being 
taken, was not associated with ISS or with subsequent mortality.  
3.4.2 Change in cytokine gene expression over time 
3.4.2.1 Anti-Inflammatory/Treg/Th2 Cytokines 
 IL-10 mRNA levels rose further over the initial 24 hours following trauma (p<0.0001) 
and then fell from 24 hours to the 72 hour time point (Figure 3.2A) although these levels 
remained greater than the time 0 IL-10 mRNA levels (p=0.01) for comparison of control versus 
time 72). GATA-3 mRNA levels fell further over the initial 24 hours (p<0.0001) and again 
when measured at 72 hours (p=0.03, Figure 3.2B). 
 TGF-β mRNA levels further decreased over the first 24 hours and then remained 
unchanged between 24 hours (p<0.0001) and the 72 hour time point (p=0.32, Figure 3.2C).  
 FOXP3 mRNA levels fell further over the initial 24 hours (p<0.0001) and levels at 72 
hours were then unchanged (p=0.11, Figure 3.2D). 
3.4.2.2 Pro-Inflammatory/Th1 Cytokines 
 TNF-α mRNA levels increased over the initial 24 hours (p<0.0001). No significant 









Table 3.1 - Selected cytokines & transcription factors & their related pathways 
  
Cytokine Immune Pathway 
Contributes to anti (-) 
or pro (+) 
Inflammatory 
phenotype* 
TNF-α Common end product of many innate & adaptive 
immune pathways 
+ 
IFN-γ Th1 effector cytokine + 
IL-12 Promotes differentiation to Th1 effector cells + 
T-bet  Transcription factor utilised by Th1 cells + 
IL-23 Promotes differentiation to Th17 phenotype + 
IL-27  Inhibits differentiation to Th17 phenotype - 
RORγT  Transcription factor utilised by Th17 cells + 
IL-10  Anti-inflammatory cytokine produced by many T 
cell subtypes & some macrophages 
- 
FOXP3 Transcription factor utilised by naturally occurring 
CD4+CD25+ Treg cells  
- 
GATA-3 Transcription factor utilised by Th2 cells - 
TGF-β  Induces widespread apoptosis, promotes Treg & 
Th17 cell development 
- 
*Cytokines and transcription factors will have diverse actions under different conditions and the descriptions above 





Figure 3.1 - Changes in mRNA between polytrauma patients on admission & healthy 
controls 
Candidate gene mRNA levels assayed from healthy controls (left) or at 2 hours following polytrauma 
(right) Graphs A–K, Median, interquartile range (box) and the 10th and 90th percentile (whiskers). All 





Table 3.2 - Patient characteristics of those suffering polytrauma 
  







Age 40.5 (29.3-57) 39.5 (30-53.3) 41 (28.3-62.3) Ns 
Male 88 (79%) 52 (76%) 36 (82%) Ns 
ISS 29 (20-36) 30 (21-38) 26 (20-34) Ns 
Head Injury 56 (50%) 36 (53%) 20 (45%) Ns 
Blunt 101 (90%) 63 (93%) 38 (86%) Ns 
Penetrating 11 (10%) 5 (7%) 6 (14%) Ns 
Scene sBP 123 (99-138) 123 (96-141) 117 (102-134) Ns 
ED sBP 121 (102-139) 120 (93-136) 124 (103-124) Ns 
Base Deficit (0hr) 4.1 (1.88-7.01) 4.4 (2.0-9.0) 3.4 (0.1-5.8) 0.03 
Lactate (0hr) 3.2 (1.6-5.0) 3.4 (1.9-5.5) 2.6 (1.3-4.3) Ns 
PRBCs (P/H) 0 (0-0) 0 (0-1) 0 (0-0) Ns 
Crystalloid (P/H) 100 (0-500) 250 (0-500) 0 (0-400) 0.05 
HTS (P/H)  0 (0-0) 0 (0-0) 0 (0-0) Ns 
PRBCs (24hr) 
Units 
4 (0-8) 4 (0-8) 3 (0-7.8) Ns 
FFP (24hr) 0 (0-6) 0 (0-8) 0.8 (0-6) Ns 
Cryo (24hr) 0 (0-2) 0 (0-2) 0 (0-2) Ns 
Platelets (24hr) 
Pools 
0 (0-1) 0 (0-1) 0 (0-1) Ns 
Crystalloid (24hr) 
mL 
2750 (1700-4700) 2720 (1672-4786) 2750 (1925-3513) Ns 
Colloid (24hr) 1375 (500-2000) 1500 (650-2063) 875 (0-2000) 0.03 
HTS (24hr) 0 (0-0) 0 (0-0) 0 (0-0) Ns 
MOD 43 (38%) 38 (56%) 5 (11%) 0.001 
Survival to 
Discharge 
92 (82%) 60 (88%) 32 (73%) 0.05 
 
Data are expressed as median and interquartile range or absolute counts with percentages in parenthesis. Colloid, (mL). 
Crystalloid, (mL). ED, Emergency Department. FFP, Fresh frozen plasma (Units) HTS, hypertonic saline (mL). ISS, injury 
severities score. Ns, non-significant. MOD, multiple organ dysfunction: This was defined, using the SOFA score, as the 
presence of ≥2 organs from the SOFA score being ≥3 in 24 hours.  Ns, non-significant. P/H, Pre-hospital. PRBC, packed red 
blood cells (Units).  
 













 IFN-γ mRNA levels fell over the initial 24 hours to a level that was lower than the 
control values (p=0.009). There was no change in IFN-γ levels from 24 hours to the 72 hour 
time point (p=0.20, Figure 3.2F). IL-12p35 mRNA levels fell over the initial 24 hours 
(p<0.0001), with levels continuing to fall further from 24 hours to the 72 hour time point 
(p=0.004, Figure 3.2G). T-bet mRNA levels fell over the initial 24 hours (p<0.0001), and 
continued to fall between the 24 hours and the 72 hour time point (p=0.04, Figure 3.2H).  
3.4.2.3 Th17 Cytokines 
 IL-23 levels fell further over the initial 24 hours (p<0.0001) and were unchanged from 
the 24 hour time point to the 72 hour time point (p=0.15, Figure 3.2I). IL-27 mRNA levels 
were unchanged from baseline to 24 hours (p=0.06) but fell between the 24 to the 72 hour time 
point (p<0.0001, Figure 3.2J). RORγt mRNA levels decreased further over the initial 24 hours 
(p<0.0001) and then remained unchanged from 24 hours to 72 hours (p=0.40, Figure 3.2K). 
There was no correlation between the magnitude of change in cytokine mRNA levels and ISS 
or between mRNA levels at 24 hours and ISS.  
Infection Frequency 
Infection 68 (61%) 
Pneumonia 45 (40%) 
Wound Infection 23 (21%) 
Bacteraemia 15 (13%) 
UTI 10 (9%) 
Other 7 (6%) 
Fungaemia 3 (3%) 
Variables are expressed as absolute counts and percentages of the total cohort in parenthesis. Some patients 







Figure 3.2 - Temporal changes in mRNA expression in polytrauma patients on 
admission, at 24 & 72 hours 
Candidate gene mRNA levels assayed from healthy controls (Control), at 2 hours following polytrauma 
(Admission), at 24 hours (24hr) and 72 hours (72hr) following admission. Graphs A–K, Median, 
interquartile range (box) and the 10th and 90th percentile (whiskers). All results are expressed as a relative 






3.4.3 Incidence of infection 
 Sixty eight (61%) patients developed an infection during their ICU admission. 
Pneumonia was the most frequent infection (n=45 (40%)) followed by wound infection (n=23 
(21%)) (Table 3.3) Following exclusion of likely contaminants bacteraemia was recorded in 15 
(13%) patients. The median time to the development of any infection was 4.5 days (2-7). The 
median time to the development of pneumonia was 4.5 days (3-6.75) and to a bacteraemia was 
8 days (5-10.5). 
 Those patients receiving antibiotics on admission to hospital were more likely 
subsequently to develop infection. This relationship was independent of ISS, presence of head 
injury, presence of thoracic injury or the presence of a penetrating injury. 
3.4.4 Cytokine gene expression and infection 
 At both the 24 hour (p=0.005) and the 72 hour (p=0.04) time points greater IL-10 
mRNA levels were associated with subsequent infection (Figure 3.3A, B). Higher IL-10 
mRNA levels at 24 hours were observed in those patients who subsequently developed a blood 
stream infection (p=0.0005, Figure 3.3C) and pneumonia (p=0.04, Figure 3.3D). Those patients 
whose T-bet levels fell the most over the initial 72 hours were more likely to develop infection 









Figure 3.3 - Associations between changes in mRNA in polytrauma patients & the 
development of late nosocomial infectious complications 
Candidate gene mRNA levels assayed at 24 hours (Graphs A, C, D) and 72 hours (B) and their 
relationship to all infection (Graphs A, B, D), Blood stream infection (C), or pneumonia (D). Graphs A–
D, Median, interquartile range (box) and the 10th and 90th percentile (whiskers). All results are expressed 






3.4.5 Cytokine gene expression and outcome 
 23 (19%) patients died during their hospital stay over the course of this study. The 
median time to death was 5 days (2-7). 
3.4.5.1 Anti-Inflammatory/Treg/Th2 Cytokines	
	 Higher IL-10 mRNA levels at 24 hours were associated with higher mortality rates 
(p<0.0001, Figure 3.4A) and those patients with the greatest rate of rise of IL-10 mRNA over 
the initial 24 hours were more likely to die (p<0.05, Figure 3.4B). Patients with IL-10 mRNA 
levels in the highest quartile at 24 hours were 7.6 times more likely to die (95% CI 2.08 - 33.3, 
p=0.002).  
3.4.5.2 Pro-Inflammatory/Th1 Cytokines 
 Those patients whose IFN-γ mRNA levels fell the most over the initial 24 hours were 
more likely to die subsequently (p=0.002, Figure 3.4C). 
 Those patients who demonstrated the greatest fall in T-bet mRNA levels over the initial 
24 hours were more likely to die subsequently (p=0.0009, Figure 3.4D). When divided into 
quartiles, those patients who were in the top quartile for the greatest fall in T-bet mRNA levels 
over the first 72 hours were 9 times more likely to die (CI 1.7 – 50, p=0.001). 
 At the 72 hour time point those patients with higher absolute levels of IL-12 mRNA 
levels were more likely to survive their ICU admission (p=0.004) and those patients with 
greatest decreases in IL-12 mRNA over the initial 72 hours (p=0.005) were more likely to die 





Figure 3.4 - Associations between changes in mRNA in polytrauma patients & survival to 
hospital discharge 
Candidate gene mRNA levels assayed at 24 hours (A), 24 / 0 hours (B-D), 72 hours (E, G), 72 / 0 hours 
(F) and their relationship to all outcomes (A-G) was calculated. Graphs A–G, Median, interquartile range 
(box) and the 10th and 90th percentile (whiskers). All results are expressed as a relative quantification 




3.4.5.3 Th17 Cytokines 
 At 72 hours an increased ratio of IL-23/IL-27 was associated with survival to ICU 
discharge (p=0.04, Figure 3.4G). 
3.4.6 Immediate Transfusion Of Blood Products (Prior To Baseline Blood 
Sampling) 
 27 (24%) patients received an immediate blood transfusion. In those patients receiving 
an immediate transfusion the median number of units of red cells transfused was 1.5 (1-2). 
Packed red cells were the only blood product transfused at this time. Immediate transfusion was 
not related to the ISS nor was it more common in those with a penetrating as opposed to a blunt 
mechanism of injury. There was no association between immediate blood transfusion and 
subsequent mortality. Those receiving immediate transfusions had a greater base deficit 
(p<0.0001) and a higher serum lactate (p=0.004; Table 3.4).  
3.4.7 Early Transfusion Of Blood Products (Within The First 24 Hours) 
 72 (64%) patients received an early transfusion. All patients who received packed red 
cells as an early transfusion also received a quantity of fresh frozen plasma (FFP), 
cryoprecipitate and platelets due to the protocolised nature of early transfusion in this 
institution (Supplementary Protocols 2 and 3). In those patients requiring early transfusion the 
median number of units of red cells transfused was 6 (interquartile range 4-10, maximum 53 
units), the median number of units of FFP was 4 (1.75-8), and the median number of pools of 
cryoprecipitate and platelets was 0.5 (0-2) and 1 (0-2) respectively. 21 (19%) patients received 
a massive transfusion (≥10 units/24 hours) within the first 24 hours. 
 Those patients requiring early transfusion had a higher ISS (p=0.0003), a greater base 
deficit (p<0.0001) and a higher serum lactate (p=0.0002). They were also less likely to survive 




there was no association between a penetrating or blunt mechanism of injury and the 
requirement for early transfusion (Table 3.5). 
3.4.8 Transfusion Of Blood Products & Infectious Complications 
 There was an association between immediate transfusion and fungaemia (p=0.01; 
Table 5.2). Of the 40 patients who did not receive an early transfusion one developed a blood 
stream infection whilst of the 72 patients who did receive an early blood transfusion 15 
subsequently developed a blood stream infection (OR 10.3 (1.3-81) p=0.008; Table 3.6). The 
mean time to the development of a blood stream infection was 8 days. There was no association 
between ISS and the development of blood stream infection. The organisms isolated are shown 
in Supplementary Table 7. The incidence of nosocomial infection at other sites is shown in 
Tables 3.4 and 3.5. 
3.4.9 Immediate Administration Of Other Fluids  
 61 (54%) patients received a median of 500mls (250-750mls) of crystalloid (sodium 
chloride 0.9%) prior to baseline blood sampling. Immediate administration of crystalloid was 
associated with higher TNF-α (p=0.02), IFN-γ (p=0.0001) and IL-10 (p=0.01) mRNA at 
baseline. These associations did not persist in the multivariate models. No association was 
detected between immediate transfusion of crystalloid and either infectious complications or 
mortality. 
 15 (13%) patients received immediate hypertonic saline (sodium chloride 5%). These 
patients were more likely to die (p=0.03). No association was detected between immediate 
hypertonic saline administration and infectious complications or any of the baseline candidate 
gene mRNA levels. 
 No other intravenous fluid therapy or blood product was administered prior to the 

























Age 41 (30-53) 39 (28.5-57) Ns 
Male Sex 20 (74.1%) 69 (81.2%) Ns 
ISS 30 (24-38) 29 (20-34) Ns 
TBI 8 (29.6%) 48 (56.5%) 0.01 
Blunt Injury 24 (92.3%) 75 (89.3%) Ns 
Penetrating Injury 2 (7.7%) 9 (10.7%) Ns 
Base Deficit 7.9 (4.8-14.1) 3.5 (1.6-5.7) <0.0001 
Lactate 4.9 (2.7-7.1) 2.9 (1.3-4.2) 0.004 
PRBC 1.5 (1-2) 0 (0-0) <0.0001 
MOD 14 (51.9%) 29 (34.1%) Ns 
ARDS 14 (51.9%) 22 (25.9%) 0.014 
All nosocomial Infections 19 (70.4%) 49 (57.7%) Ns 
Pneumonia 11 (40.7%) 27 (31.8%) Ns 
Bacteraemia 4 (14.8%) 10 (11.8%) Ns 
Fungaemia 2 (7.4%) 0 (0%) 0.01 
BSI 6 (22.2%) 10 (11.8%) Ns 
Wound Infection 4 (14.8%) 17 (20.2%) Ns 
UTI 5 (18.5%) 6 (7.1%) Ns 
Mortality at 24hr 0 (0%) 2 (2.4%) Ns 
Survival to hospital discharge 20 (74.1%) 72 (84.7%) Ns 
 
Data are expressed as median and interquartile range or absolute counts with percentages in parenthesis. AIS, 
Abbreviated injury score. ARDS, Acute respiratory distress syndrome: This was defined using the respiratory 
component of the daily sequential organ failure assessment (SOFA) scores and ARDS was deemed present if 
the respiratory component of the SOFA score was ≥3 for 2 consecutive days. BSI, blood stream infection 
(encompassing bacteraemia and fungaemia). ISS, injury severities score. Ns, non-significant. MOD, multiple 
organ dysfunction: This was defined, using the SOFA score, as the presence of ≥2 organs from the SOFA score 





3.4.10 Early Administration Of Other Fluids  
 109 (98%) patients received a median of 2920mls (2000-4600mls) of crystalloid 
(sodium chloride 0.9% or Plasma-Lyte) over the first 24 hours. The volume of crystalloid 
administered was associated with the ISS (r2 = 0.04, p=0.03) and with blood stream infections 
(p=0.03), but not with mortality. No association was detected between early crystalloid 
administration and any of the candidate gene mRNA levels. 
 22 (20%) patients received a median of 700mls (462-775mls) of hypertonic saline 
(sodium chloride 5%) in the first 24 hours. These patients had a higher ISS (p=0.01) and were 
more likely to die (p=0.02). Early administration of hypertonic saline was associated with 
higher TNF-α (p=0.0008), IL-12 (p=0.005), RORγt (p=0.03) and FOXP3 (p=0.003) mRNA at 
24 hours. On multivariate analysis the only independent association that remained was between 
higher TNF-α mRNA levels at 24 hours and the volume of hypertonic saline administered in 
the first 24 hours. 
 87 (78%) patients received a median of 1000mls (455-2000mls) colloid (Geloplasma®) 
in the first 24 hours. The volume of colloid was related to the ISS (r2 = 0.05, p=0.01) and larger 
volumes of colloid were associated with higher mortality (p=0.001). Larger volumes of colloid 
were associated with higher IL-10 mRNA levels at 24 hours (r2 = 0.12, p=0.002). On 
multivariate analysis there was no independent association between IL-10 mRNA levels and 
colloid administration. 
 No other intravenous fluid therapy or blood product was administered during the initial 






Table 3.5 - Patient characteristics of those suffering polytrauma at 24 hours 
  
 Transfused in 
1st 24 hours 
(n=72) 
No transfusion 
in 1st 24 hours 
(n=40) 
p-value 
Age 39.5 (30-57.8) 43 (27-57) Ns 
Male Sex 57 (79.2%) 32 (80%) Ns 
ISS 30 (22.5-41) 22 (17.5-32.8) 0.0003 
Head Injury 28 (38.9%) 28 (70%) 0.002 
Blunt Injury 62 (87.3%) 37 (94.9%) Ns 
Penetrating Injury 9 (12.7%) 2 (5.1%) Ns 
Base Deficit (0hr) 5.8 (2.6-9.6) 2 (0.6-4.3) <0.0001 
Lactate (0hr) 3.4 (2.45-6.05) 1.8 (1-3.6) 0.0002 
PRBC 6.5 (4-10) 0 (0-0) <0.0001 
FFP 4 (0.4-8) 0 (0-0) <0.0001 
PLT 1 (0-2) 0 (0-0) <0.0001 
Cryoprecipitate 0.5 (0-2) 0 (0-0) <0.0001 
MOD 31 (43.1%) 12 (30%) Ns 
ARDS 29 (40.3%) 7 (17.5%) 0.02 
All nosocomial Infections 47 (65.3%) 21 (52.5%) Ns 
Pneumonia 25 (35.2%) 12 (28.2%) Ns 
Bacteraemia 13 (18.1%) 1 (2.5%) 0.017 
Fungaemia 2 (2.8%) 0 (0%) Ns 
BSI 15 (20.8%) 1 (2.5%) 0.008 
Wound Infection 18 (25%) 4 (10%) Ns 
UTI 7 (9.7%) 4 (10%) Ns 
Mortality at 24hr 2 (2.8%) 0 (0%) Ns 
Survival to hospital discharge 54 (75%) 38 (95%) 0.008 
 
Data are expressed as median and interquartile range or absolute counts with percentages in parenthesis. AIS, 
Abbreviated injury score. ARDS, Acute respiratory distress syndrome: This was defined using the respiratory 
component of the daily sequential organ failure assessment (SOFA) scores and ARDS was deemed present if the 
respiratory component of the SOFA score was ≥3 for 2 consecutive days. BSI, blood stream infection (encompassing 
bacteraemia and fungaemia). FFP, fresh frozen plasma. ISS, injury severities score.. MOD, multiple organ dysfunction: 
This was defined, using the SOFA score, as the presence of ≥2 organs from the SOFA score being ≥3 in 24 hours. Ns, 
non-significant. PLT, platelets. PRBC, packed red blood cells. TBI, traumatic brain injury. UTI, urinary tract infection. 





3.4.11 Univariate Analysis Of The Association Between Blood Transfusion & 
Gene Expression  
3.4.11.1 Anti-Inflammatory Mediators 
 IL-10 (p=0.003; figure 3.5A) and IL-27 (p=0.04; figure 3.5B) mRNA levels were 
higher at 0-hour in those patients who had received an immediate blood transfusion. IL-10 
mRNA levels rose significantly over the initial 24 hours in all patients (p<0.0001) but to a 
greater extent in those receiving an early transfusion (p=0.01). At 24 hours IL-10 mRNA levels 
were higher in those patients who received early transfusions (p<0.0001; figure 3.5C). 
Similarly, there was a significant positive correlation between the number of red cells 
transfused and IL-10 mRNA levels at 24 hours (Spearman’s ρ 0.61, p<0.0001; figure 3.5D).  
 FOXP3 mRNA levels at 24 hours were lower in those patients receiving an early 
transfusion (p=0.01). The number of units of packed red cells transfused was inversely 
correlated with FOXP3 mRNA levels (Spearman’s ρ -0.39, p=0.0004). Those patients who 
received an early transfusion had lower GATA-3 mRNA levels (p=0.006) at 24 hours. 
 There was no association between transfusion and gene expression of anti-
inflammatory mediators at 72 hours. 
3.4.11.2 Pro-Inflammatory Th1 Mediators 
 In the group as a whole, TNF-α mRNA levels rose from baseline to 24 hours. This 
increase was less in those patients who received an early transfusion (p=0.015; figure 3.6A). 
Greater reductions in IFN-γ mRNA (p=0.035; figure 3.6B) and T-bet mRNA (p=0.03; figure 
3.6C) over the first 24 hours were seen in those patients receiving an early transfusion. There 
was no association between transfusion and gene expression of Th1 mediators at 72 hours. 
3.4.11.3 Pro-Inflammatory Th17 Mediators 
 RORyt mRNA levels at 24 hours (p=0.05; figure 3.7A) and 72 hours (p=0.02; figure 







Figure 3.5 - Associations between anti-inflammatory mRNA levels & blood transfusion 
following polytrauma 
Graphs A&B candidate gene mRNA levels at 2 hours following polytrauma and immediate transfusion of 
blood products. Graphs C&D candidate gene mRNA levels at 24 hours following polytrauma and early 
transfusion of blood products. (A-C) Median, interquartile range (box) and the 10th and 90th percentile 
(whiskers). (D) Association between the number of units of packed red blood cells (PRBCs) transfused and 
candidate gene mRNA levels at 24 hours (best-fit line (solid) and 95% confidence interval (dashed)). All 








Figure 3.6 - Associations between Th1 related mRNA levels & blood transfusion in the 
first 24 hours following polytrauma 
Ratio of candidate gene mRNA levels at 24 hours to levels at baseline (within 2 hours of the trauma) in 
relation to the transfusion of blood products over the first 24 hours (median, interquartile range (box) and the 
10th and 90th percentile (whiskers)). All results are expressed as a relative quantification ratio between 








Figure 3.7 - Associations between Th17 related mRNA & blood transfusion following the 
first 24 hours of polytrauma 
Candidate gene mRNA levels at 24 hours (A) and 72 hours (B) following polytrauma and early transfusion of 
blood products (median, interquartile range (box) and the 10th and 90th percentile (whiskers)). All results are 
expressed as a relative quantification ratio between candidate and reference genes. 
 
 
3.4.12 Multivariate Analysis Of The Influence of Allogeneic Transfusion 
 The results and selection of variables included in the univariate analyses are shown in 
Supplementary Tables 5 & 6.  
 The requirement for immediate transfusion remained independently associated with IL-
10 mRNA at time 0 (p=0.04). IL-27 mRNA at time 0 was not entered into the multivariate 
analysis because, apart from immediate transfusion, none of the associations on univariate 
analysis achieved a p-value of <0.1. 
 At 24 hours there was an independent association between the number of units of red 
cells transfused and IL-10 mRNA levels (p<0.0001), following backwards elimination.  
 There was an independent association between a lesser increase in TNF-α mRNA over 
the initial 24 hours (24 hours / 0 hours) and the requirement for early transfusion (p=0.05). 




associated with the magnitude of the decrease in IFN-γ mRNA over the initial 24 hours 
(p=0.006). Early transfusion was not independently associated with RORγt mRNA levels at 24 
hours in this model (Supplementary Table 6). 
3.4.13 Age Of Blood Analysis Cohort 
 
 From this group data were available for 64 patients who received a PRBC transfusion 
within 24 hours of admission. 53 (83%) patients were male and median patient age was 40.5 
years (IQR 31-59). Median ISS was 31.5 (IQR 23-43) and 55 (86%) patients suffered blunt 
injury. Median base deficit on admission was 4.9 mEq/L (IQR 2.4-8.8) and at 24 hours was 0.7 
mEq/L (IQR -0.7-2.6). 40 (63%) patients developed infectious complications and 15 (23%) 
patients died before hospital discharge. 
 Each patient received a median of 5 units (IQR 4-9.8) of PRBCs over the first 24 hours 
of hospital admission. Median age of the transfused PRBCs for each patient was 20 days (IQR 
17-22). Patients also received a median of 4 units (IQR 0-8) fresh frozen plasma (FFP) and 1 
unit (IQR 0-1) of platelets. Those patients receiving in excess of 35 units of PRBCs were 
excluded from the analysis (n=8). The Characteristics of the cohort are fully outlined in Table 
3.6. 
3.4.14 Univariate Analysis Of Age Of PRBCs Transfused & Gene Expression 
 At baseline (blood sample within 2 hours of the trauma) there was an association 
between FOXP3 mRNA levels and the median age of the transfused PRBCs (r2=0.18, p=0.001) 
and also between GATA-3 mRNA levels and the median age of the transfused PRBCs 
(r2=0.09, p=0.03). No other associations were detected between gene expression at baseline and 
the median age of the PRBCs.  
 Change in gene expression was expressed by taking a ratio of both the 24 hour or the 




decreasing IL-12 (r2=0.10, p=0.03), IL-23 (r2=0.10, p=0.03), RORγt (r2=0.19, p=0.003), 
FOXP3 (r2=0.09, p=0.04) and GATA-3 (r2=0.16, p=0.007) mRNA over 24 hours and 
increasing age of the transfused PRBCs.  
 











Male 33 (86.8) 20 (76.9) Ns 
ISS 34 (25 - 48) 27 (22 - 38) Ns 
Presence of TBI 17 (44.7) 10 (38.5) Ns 
Blunt Injury 33 (86.8) 22 (84.6) Ns 
Penetrating Injury 5 (13.2) 3 (11.5) Ns 
On Scene sBP 112 (90 - 135) 115 (94 - 130) Ns 
Emergency Department sBP 106 (80 - 139) 114 (93 - 120) Ns 
Base deficit (0hr) 4.7 (2.6 - 7.5) 5.2 (2.4 - 14.1) Ns 
Lactate (0hr) 2.9 (2.1 - 4.5) 3.5 (2.2 - 6.8) Ns 
pH (0hr) 7.29 (7.20 - 7.36) 7.29 (7.14 - 7.40) Ns 
Base deficit (24hr) 0.45 (-0.7 - 1.43) 2.4 (-1.3 - 3.2) Ns 
Number of PRBCs transfused 7 (4 - 10) 5 (4 - 8) Ns 
Massive Transfusion (≥10 
units/24hrs) 
6 (16.0) 5 (19.2) Ns 
All nosocomial Infections 24 (63.2) 16 (62.0) Ns 
Pneumonia 13 (34.2) 9 (35.0) Ns 
BSI 8 (21.1) 4 (15.4) Ns 
Wound Infection 11 (29.0) 4 (15.4) Ns 
UTI 5 (13.2) 1 (3.8) Ns 
Survival To Hospital Discharge 30 (79.0) 19 (73.1) Ns 
Data are expressed as median (interquartile range) or n (%). ISS, Injury Severity Score; TBI, Traumatic Brain 
Injury; sBP, Systolic Blood Pressure; PRBCs, Packed Red Blood Cells; BSI, Blood stream Infection (bacteraemia 
or fungaemia); UTI, Urinary Track Infection. *Patients divided into two groups based on median age of PRBCs 






Figure 3.8 - Associations between the median age of PRBCs transfused in the first 24 
hours following injury & the change in candidate gene expression 
Over 72 hours (A and B) and 24 hours (C). Results displayed as best-fit line (solid) and 95% confidence 




 There was an association between decreasing IL-12 mRNA over 72 hours (r2=0.20, 
p=0.01) and increasing age of the transfused PRBCs. There was also an association between 





 No associations were detected between changes in IL-10, TNF-α, IFN-γ, T-bet, and IL-
27 gene expression and the age of the transfused PRBCs.  
3.4.15 Multivariate Analysis Of Age Of PRBCs Transfused & Gene Expression 
 Multivariate linear regression models were created to test for independent associations 
between change in gene expression and the median age of transfused PRBCs in cases where a 
univariate association was detected. The selection of predictor variables is outlined in the 
methods and presented in Supplementary Table 8.  
 For decreasing IL-12 over 24 and 72 hours, decreasing RORγt over 24 hours and 
increasing TGFβ over 72 hours an independent association between change in gene expression 
and the median age of the PRBCs transfused was also present (Supplementary Table 8). In the 
case of decreasing FOXP3, GATA-3 and IL-23 over 24 hours the variation in gene expression 
levels was better explained by variations in patient age as opposed to variations in the median 
age of the PRBCs (Supplementary Table 8). Supplementary Table 9 demonstrates the model, 
and model performance with all predictor covariates included. 
3.4.16 Age of PRBCs and infections 
 No associations were detected between the age of PRBCs transfused and nosocomial 
infections or in-hospital mortality. 
 
3.5 Discussion 
 Here we present data demonstrating that a well-developed, directional inflammatory 
response is present within 2 hours of severe injury. The very early elevation of the prototypical 
anti-inflammatory cytokine IL-10 attests to the immunosuppressive nature of this initial 
response. Immediate reduced activity in the pro-inflammatory Th17 pathway, as evidenced by 




cytokine, IL-23, further adds to this pattern. There is an immediate rise in levels of the Th1 
effector cytokine (IFN-γ), however levels of this cytokine fall below the control cohort after 24 
and 72 hours. The pro-inflammatory Th1 pathway demonstrates a suppressed pattern over the 
initial 24 hours with falling levels of promoters of the Th1 pathway (IL-12) and Th1 specific 
transcription factors (T-bet). In addition, TNF-α levels immediately fall compared to the 
control cohort. These values rise at 24 hours, however still remaining below the assayed 
healthy control cohort, staying static at 72 hours. This rapid, predominantly anti-inflammatory 
response to trauma is largely unexpected in the context of previous publications (Mannick et 
al., 2001; Xiao et al., 2011). It is very significant that the magnitude of the early anti-
inflammatory response or the failure to mount or maintain a pro-inflammatory response is 
closely associated with the acquisition of subsequent infections and also with death.  
 Utilising this same panel of interlinked cytokines and transcription factors, the 
immunomodulatory effects of the transfusion of blood and blood products in patients with 
severe traumatic injury was also investigated. This demonstrated that the immunosuppressive 
nature of the acute traumatic immune response is compounded by the transfusion of allogeneic 
blood. This is again characterised by the dramatic and immediate up-regulation in gene 
expression of the archetypal anti-inflammatory gene, IL-10, while a concurrent immediate rise 
in IL-27, a gene known to vigorously suppress the pro-inflammatory Th17 pathway supports 
this concept (Hunter & Kastelein, 2012). This is followed by a decrease in RORγt, which is 
further evidence for a repressed Th17 activity associated with blood transfusion in trauma 
patients. Although developing at a slightly slower pace, the pro-inflammatory Th1 pathway 
demonstrates a reciprocal down-regulation, with greater falls in IFN-γ, and the Th1 specific 
transcription factor, T-bet, in those patients receiving blood products in the first 24 hours 
following severe trauma. Although TNF-α gene expression increased in the cohort of trauma 
patients as a whole over the initial 24 hours; the rate of rise was reduced in those patients 
receiving early transfusion of blood products. These alterations then become more pronounced 




increased severity of injury and shock, as well as an increased incidence of nosocomial 
infection and an increased risk of death.  
 A further analysis investigated the relationship between the duration of storage of 
PRBCs prior to transfusion and the resultant immunomodulation. We identified that a pattern 
of altered gene expression consistent with greater immunosuppression is associated with the 
transfusion of older PRBCs. This showed reductions in the activity in the pro-inflammatory 
pathways as evidenced by reduced gene expression of the prototypical Th1 polarising cytokine, 
IL-12, as well as those involved in Th17 function, IL-23, and RORγt. The increased expression 
of the apoptotic and anti-inflammatory gene, TGF-β, with increasing age of transfused PRBCs 
further points to the immunosuppressive nature of the response.  
 Whilst it has been accepted that severe traumatic injury leads to swift alterations (<12 
hours) in gene expression in up to 80% of the total genome, precisely how rapidly this occurs 
has yet to be defined (Xiao et al., 2011). Also lacking to date has been a robust analysis of the 
time course of changes in gene expression of key cytokines and how these relate to important 
clinical variables. To further investigate these issues reliably an appropriate choice of 
laboratory technique is essential.  
 Available methodologies include analysis of the protein product and whole genome 
gene expression techniques. Protein analysis, however, has proven to lack sensitivity in vivo 
and has consistently failed to detect multiple target proteins both in trauma studies and in 
studies of ICU sepsis (Gouel-Cheron et al., 2012; O'Dwyer et al., 2006). It is interesting that 
previously IL-10 protein was specifically found to be undetectable in the peripheral blood of 
severely injured trauma patients despite other laboratory evidence of overt immunoparalysis 
(Gouel-Cheron et al., 2012).  
 Whilst genome wide gene expression studies provide a powerful overview of 




the analysis of subtle changes in the expression levels of individual genes. In contrast, 
quantification of mRNA levels of key cytokines using PCR technologies has proven accurate as 
a measure of the strength and direction of the immune response when the candidate genes are 
carefully selected to represent specific immune pathways (O'Dwyer et al., 2006; O'Dwyer et 
al., 2008; Pachot et al., 2005). Furthermore, the additional analysis of transcription factors 
specific for T cell subtypes allows inferences to be made as regards the balance of activity 
between competing T helper cell subtypes and to elucidate potential cellular sources of 
cytokines of interest (Pachot et al., 2005). 
 Utilising this technique we observed a 6 fold increase in IL-10 gene expression 
occurring within 2 hours of major trauma. Levels continue to increase dramatically over the 
initial 24 hours, peaking prior to day three. To date, sampling limitations have resulted in the 
best estimate of an immunological response to trauma as occurring initially between 4-12 hours 
(Xiao et al., 2011). The source of this excess IL-10 remains unclear from our data. As levels of 
the Treg cell specific transcription factor FOXP3 and the Th2 specific transcription factor 
GATA-3 both fall in response to severe trauma these T cell subtypes are unlikely to contribute 
to the observed excess IL-10 gene expression. This is surprising given that Treg cells are thought 
to increase, both as a proportion of total T lymphocytes and as absolute counts, following 
trauma, due in part to their resistance to apoptosis (Venet et al., 2008). It seems clear, however, 
that FOXP3 expression must increase in the presence of enhanced natural Treg cell activity and 
therefore the fall in FOXP3 mRNA probably indicates lowered natural Treg cell activity in our 
cohort (Campbell & Ziegler, 2007). Alternative sources of IL-10 are abundant amongst innate 
and adaptive cell types and include dendritic cells, macrophages, mast cells, eosinophils, 
neutrophils, CD4+ and CD8+ T cells, B cells as well as release from damaged muscle or from 
the endothelium (Ouyang et al., 2011). It is also interesting that we found only relatively 
modest associations between IL-10 levels and the severity of injury, which indicates a large 
amount of inter-individual variability in IL-10 gene expression. It is interesting to postulate that 




al., 2014). By normalising candidate gene PCR expression data to reference genes which were 
demonstrated to be expressed at stable levels in these patients (ATP5B and GAPDH) we were 
able to correct for the effect of relative changes in the total leukocyte population in individual 
whole blood samples (Vandesompele et al., 2002). We cannot, however exclude the possibility 
that the observed changes in mRNA levels are explained, at least in part, by alterations in the 
relative abundance of specific leucocyte subpopulations collected in the whole blood samples 
from which the RNA was extracted for this thesis (Laudanski et al., 2006). It is also plausible 
that small variations in the qRT-PCR assay could have led to changes in the amplified signal 
despite having made every effort to standardise the process; (templates (primers and probes), 
mRNA (concentrations and RNA integrity), the reverse transcription step and reference genes) 
as well as a single operator (HDTT). 
 IL-6 is a notable omission from our panel of cytokines that is deserving of further 
explanation. Recently, IL-6 protein levels following trauma were found to be increased (Gouel-
Cheron et al., 2012). However, the exact role of IL-6 in this scenario is unclear. Although 
commonly considered a classical pro-inflammatory cytokine, IL-6 is also known to exert strong 
anti-inflammatory effects by promoting Th2 differentiation and inhibiting Th1 polarisation 
(Diehl & Rincon, 2002). Indeed, in the setting of severe injury higher initial IL-6 levels were 
associated with a propensity to develop infectious complications later (Gouel-Cheron et al., 
2012). Consequently, we omitted this cytokine from our analysis as we found it difficult to 
ascribe to it an unambiguous inflammatory direction in the setting of trauma. 
 An early, dominant anti-inflammatory response would contradict paradigms of 
inflammation, which describe either a sequential SIRS and CARS response (Mannick et al., 
2001; Moore et al., 1996) or parallel SIRS and CARS responses to severe injury (Xiao et al., 
2011). However, a review of the data, which utilise cytokine quantification to support the 
presence of a dominant early SIRS response following trauma, finds that the conclusions rely 




inflammatory cytokines (Marik & Flemmer, 2012). In contrast, there is an abundance of 
descriptions of lymphocyte anergy and apoptosis and impaired monocyte phagocytosis and 
antigen presentation in response to trauma (Cheron et al., 2010; Faist et al., 1988; Faist et al., 
1996; Gouel-Cheron et al., 2012; Kampalath et al., 2003; Tschoeke & Ertel, 2007). It is 
plausible then that this paradigm requires further revision with lesser emphasis on the systemic 
pro-inflammatory response to severe injury. Interestingly, the inflammatory paradigm is also 
being reevaluated in other scenarios where traditionally a pro-inflammatory state was 
considered dominant. Ancillary treatment of ICU sepsis has progressed from futile attempts to 
blunt the host immune response to more promising therapies with immunostimulants (Fisher et 
al., 1996; Meisel et al., 2009; Sprung et al., 2008). Similarly, although it has been a commonly 
held belief that endurance exercise induces a SIRS type response, analysis of cytokine levels 
demonstrates a marked rise in IL-10 following an exercise protocol with no immediate rise in 
TNF-α observed (Pournot et al., 2011). 
 In those patients with less severe injuries it may be plausible to suggest that elevated 
IL-10 levels in peripheral blood are the systemic manifestations of a CARS response to a 
localised injury which itself has initially induced a compartmentalised SIRS pro-inflammatory 
response. However, as the vast majority of the patients recruited to this study suffered very 
severe polytrauma, as distinct from a minor discrete injury, any pro-inflammatory response 
should be easily detectable systemically and not localised to a specific tissue bed. It was 
surprising therefore that key markers of innate immunity and activity of the pro-inflammatory 
Th1 and Th17 pathways, aside from the admission rise of IFN-γ, were reduced by trauma over 
the course of three days of sampling.  
 A developing anti-inflammatory profile has been associated with an increased 
susceptibility to develop infectious complications both following severe trauma and in the 
perioperative period (Cheron et al., 2010; White et al., 2011). Similarly, we hypothesised that 




complications, particularly in the setting of reduced pro-inflammatory, bactericidal cytokine 
gene expression. In that context, the association between late infections and excess IL-10 
mRNA is unsurprising and may be very significant in terms of potential novel 
immunomodulating treatments. It is notable that the tendency to develop definitive blood 
stream infections was particularly strongly associated with excess IL-10 production. 
Manipulating the immune response of trauma patients has previously met with mixed results 
(Spruijt et al., 2010). However, the lack of robust diagnostics to characterise a group, which 
may derive maximum benefit coupled with late administration of the treatment, may account 
for the disappointing results. Whilst previously described associations between trauma induced 
immunosuppression and subsequent infections require repeated assessment of HLA-DR 
expression up to the fourth day following trauma our data demonstrates an association at 24 
hours between excess IL-10 and subsequent infection (Cheron et al., 2010). It is notable that in 
critically ill septic patients IL-10 is partially responsible for the proposed endocytosis of HLA-
DR molecules in monocytes, which is a characteristic of the septic immunoparalysed patient 
(Fumeaux & Pugin, 2002). A similar mechanism following severe injury may help explain the 
apparent association between excess IL-10, reduced cell wall HLA-DR and the susceptibility to 
develop infectious complications.  
 The association between early gene expression and outcome is quite striking. Those 
patients identified as having the greatest IL-10 production have a 7.6 fold increased risk of 
death. Reduced activity of pro-inflammatory pathways is equally associated with poor 
outcome. Whether these associations invoke causation or are an epiphenomenon remains 
unclear at present. One could hypothesise that excess IL-10 and a relative deficiency of pro-
inflammatory compounds leads to an enhanced susceptibility to develop infectious 
complications, which in turn leads to greater mortality. However, most deaths in our patient 
group occurred relatively early and as a consequence we failed to describe an association 
between infection and mortality. When early deaths were excluded from the analysis then a 




described a significant association between sepsis and death following trauma in a much larger 
cohort of 30,000 patients, which included patients with milder injuries (Osborn et al., 2004). 
Furthermore, if the excess IL-10 produced is more than just an epiphenomenon then it plausibly 
has more diverse detrimental effects than simply promoting immunoparalysis following 
trauma.  
 It is difficult to understand the advantage accruing to an organism from an anti-
inflammatory response to severe trauma. Although the associations between an anti-
inflammatory cytokine profile and blood transfusion are interesting the study is not powered to 
derive firm conclusions from these data. Perhaps the cells producing IL-10 are primarily 
concerned with tissue repair and systemic immunoparalysis is an unintended effect. 
Furthermore, it is a well described strategy of microorganism to evade capture by the host 
immune response by stimulating the production of IL-10 in dendritic cells (Jang et al., 2004; 
Netea et al., 2004) and it is plausible that damage associated molecular patterns (DAMPs) 
invoke a similar response with no host advantage accruing. Further studies may answer these 
questions. 
 What has been less clear in the trauma literature is whether blood transfusion 
exacerbates this underlying immunosuppressive response to injury described here. The 
utilisation of multivariate regression analysis indicates that the transfusion of blood products is 
associated with a more immunosuppressive pattern of gene expression, independent of a 
number of key variables, which describe the extent of tissue injury, early tissue ischaemia and 
shock. It is plausible, therefore, that transfusion of blood products exerts a significant direct 
influence on the pro - / anti - inflammatory balance of the immune response following severe 
trauma. Allogeneic blood transfusions are well known to possess immunomodulatory 
properties which are mediated through multiple mechanisms, including the presence of soluble 
biological response modifiers and the persistence of residual white blood cells despite 




blood in particular can induce host regulatory T cell (Treg) activation and impair innate 
immunity, possibly through the direct administration of allogeneic cytokines (Baumgartner et 
al., 2009a; Baumgartner et al., 2009b; Escobar et al., 2007; Patel et al., 2006). 
 The best-described practical consequence of the immunosuppression associated with 
blood transfusion is an enhanced susceptibility to infectious complications. In the perioperative 
setting blood transfusion has been associated with an increased risk of infections (Cata et al., 
2013; Jensen et al., 1992). These findings are not universal however, particularly in patients 
receiving leukodepleted blood (Cata et al., 2013). An increase in infectious complications has 
also been noted in trauma patients, although some animal models suggest that it is the 
haemorrhage itself, which is responsible for exacerbating immunosuppression (Cue et al., 
1992; Jackman et al., 2012). The commonest infectious complication reported in trauma 
patients is pneumonia (Magret et al., 2010). However, pneumonia is a complex end-point in 
trauma patients, as significant numbers of patients suffer thoracic injuries with associated 
pulmonary infiltrates, which are frequently misdiagnosed as pneumonia. Using a more robust 
measure of definitive infection, namely blood stream infection, we report that in our cohort 
there is an excess of patients developing blood stream infections amongst those receiving a 
transfusion of blood or blood products. Although there is also an increased mortality amongst 
those who were transfused, these patients are also more severely injured. 
 There remains a paucity of data on the time course of the immune response associated 
with transfusion in trauma patients. However, cytopenic haematology patients have been 
previously noted to exhibit raised TGFβ levels within an hour of transfusion (Apelseth et al., 
2011). A similarly swift alteration in gene expression was noted in the cohort described here. 
Our blood samples were taken in the emergency department a maximum of 2 hours following 
the traumatic insult. In many individual cases the changes in gene expression occurred 




 The pattern of immune response we describe evolves over time and includes an 
immediate activation of anti-inflammatory pathways followed later by suppression of pro-
inflammatory innate, Th1 and Th2 pathways. A network of interlinked immune responses may 
account for this temporal relationship, with the initial rise in IL-10 requiring time to affect pro-
inflammatory responses. However, in this cohort all the immediate transfusions (0-2 hours post 
trauma) consisted solely of packed red cells whilst all of the transfusions required from this 
time point to 24 hours also included fresh frozen plasma and platelets. It is possible, therefore 
that the various blood products had differing effects on the immune response. It has been 
demonstrated, for example, that fresh frozen plasma contains a predominance of Th2 cytokines, 
whereas platelet transfusions have been noted to cause an increase in TGF-β levels (Apelseth et 
al., 2011; Theusinger et al., 2011). It is, however, impossible to differentiate the in vivo effects 
of different blood products in observational studies of trauma victims given their protocolised 
co-administration in this setting. 
 The observational data presented in this facet of the Chapter should be viewed as 
hypothesis generating. The inclusion and exclusion criteria for the ACIT2 study may have 
created a selection bias resulting in the under-recruitment of rapidly bleeding patients dying 
acutely of haemorrhagic shock. This may partially account for the low mortality rate observed 
in the first 24 hours in this cohort and how this potential selection bias may affect the results is 
unclear. It is possible that unknown confounding variables affecting gene expression were 
omitted from our multivariate regression analysis, despite the inclusion of three variables 
descriptive of the severity of shock (on scene blood pressure, initial serum lactate and base 
deficit) in addition to the ISS. It is also plausible that the requirement for blood transfusion may 
simply identify those patients with a greater severity of injury more accurately than the ISS and 
perhaps define tissue ischaemia more accurately than lactate, base excess or blood pressure 
measurements. Although no distinct pattern of gene expression was independently associated 
with non-blood based intravenous fluid therapies over the initial 24 hours it is possible that 




potential confounders remain difficult to resolve in the clinical setting. Observations of similar 
gene expression patterns in other patient groups receiving blood transfusion, as well as 
investigations in subjects receiving semi-elective blood transfusion who are not critically ill, 
together with in vivo and in vitro laboratory studies may help to clarify the specific 
immunological effects of allogeneic blood transfusion.  
 It is also possible that significant numbers of residual allogeneic leukocytes persist 
even in leukodepleted packed red cells and thereby confound the analysis of patient mRNA 
levels as a result of contamination. This could be of particular concern in the setting of massive 
transfusion. However, it has been previously demonstrated that leukodepleted packed red cells 
contain no detectable DNA and that the postmortem analysis of patients receiving massive 
transfusions failed to detect foreign DNA (Graham et al., 2007). 
 A potential limitation of our findings is the use of gene expression data at the mRNA 
level as opposed to analysing protein expression. However, as has been previously discussed, 
our previous experience with protein analysis in the acute setting has been disappointing, in 
that the assays utilised lacked sensitivity and accuracy in vivo (O'Dwyer et al., 2006; O'Dwyer 
et al., 2008). It has been suggested that the lack of correlation between mRNA and protein 
levels can be explained by the technical limitations of the methods used to determine protein 
expression levels (Hack, 2004). Such limitations are particularly evident when studying genes 
expressed at relatively low levels, given that commercially available kits lack the required 
sensitivity. Importantly however, investigators have reproducibly found positive correlations 
between mRNA and protein expressed at low levels using isotope coded affinity tags to 
quantify protein expression (Fu et al., 2007) 
 The transfusion of PRBCs stored for longer periods was originally thought to be 
associated with equivocal effects (Marik & Sibbald, 1993). However, there is now an 
increasing body of evidence associating the use of older PRBCs with harm. Transfusion of 




failure in trauma patients (Offner et al., 2002; Zallen et al., 1999) and following cardiac 
surgery, transfusion of PRBCs stored for more than 28 days has been associated with a 2.5 fold 
increase in pneumonic complications (Leal-Noval et al., 2008; Vamvakas & Carven, 1999). 
Following colorectal cancer surgery transfusion of PRBCs stored beyond 20 days more than 
doubled the risk of postoperative infections (Mynster & Nielsen, 2000). In addition, the 
duration of storage of PRBCs has been independently associated with an increased risk of death 
in trauma patients (Weinberg et al., 2008) and following cardiac surgery (Koch et al., 2008). 
Interestingly, the mortality data suggests that older PRBCs exert a detrimental effect only when 
transfused in larger quantities with smaller volume transfusion of older blood having little 
effect on mortality (Weinberg et al., 2008). However, these data are largely retrospective and 
consequently prone to potential bias. Most recently the results of two large randomised 
controlled trials prospectively assessing the impact of the age of blood transfused in sepsis 
(Lacroix et al., 2015) and cardiac surgery (Steiner et al., 2015) demonstrated equivalence 
between the two groups. However, a recent meta-analysis incorporating trauma and cardiac 
surgery patients still suggests that in these cohorts those receiving ‘older’ PRBCs may be more 
susceptible to nosocomial infections (Ng et al., 2015). 
 Prolonged storage of PRBCs can induce ‘storage lesions’ the clinical consequences of 
which are unclear (Lelubre & Vincent, 2011). In particular, whether these lesions could be 
responsible for increasing susceptibility to nosocomial infections and increasing mortality 
remains uncertain. Already in this Chapter we have described an association between the 
transfusion of PRBCs and an excess of infectious complications following major trauma. 
Importantly, here, we also offer a plausible mechanism for the detrimental effect of PRBCs by 
describing a pattern of gene expression that was consistent with immunosuppression and was 
independently associated with transfusion. Here we demonstrate that the administration of older 
PRBCs exacerbates this transfusion induced immunosuppressed phenotype, thereby perhaps 




 A reduction in IL-12, IL-23 and RORγt gene expression in association with an increase 
in TGF-β gene expression is consistent with an immunosuppressed phenotype. IL-12 is a pro-
inflammatory cytokine, produced primarily by dendritic cells and macrophages, that vigorously 
promotes the differentiation of naïve T cells into an IFN-γ producing Th1 phenotype (Del 
Vecchio et al., 2007). Th1 cells are an essential link between innate and adaptive immunity and 
are particularly important for effective bactericidal activity on intracellular pathogens 
(Kitamura et al., 2005). IL-23 is a cytokine, again produced primarily by dendritic cells and 
macrophages, that promotes differentiation to a Th17 phenotype (Korn et al., 2009). RORγt is a 
transcription factor specific to terminally differentiated Th17 cells (Korn et al., 2009). Th17 
cells are a branch of the adaptive immune system and appear to deal primarily with organisms 
inadequately subdued by Th1 or Th2 immunity and that seem to require a very robust 
inflammatory response (Korn et al., 2009). TGF-β is produced by multiple lineages of 
leukocytes and stromal cell (Li et al., 2006). Although a paracrine source of TGF-β may be 
necessary for Th17 development (Korn et al., 2009) this cytokine is better known for inducing 
widespread apoptosis and limiting the pro-inflammatory Th1 response (Li et al., 2006). 
 Whilst we previously reported in this Chapter that expression of the prototypical anti-
inflammatory gene, IL-10, increases in response to trauma and in response to allogeneic blood 
transfusion in trauma patients, in this cohort IL-10 gene expression was not associated with the 
age of the transfused PRBCs. It is plausible that this analysis was underpowered to detect such 
an association. We did however detect greater increases in another potent anti-inflammatory 
gene, TGF-β, in those patients receiving older PRBCs.  
 An association was also detected between decreasing FOXP3 and GATA-3 and the age 
of the PRBCs, transcription factors specific to the immunosuppressive Treg cell response and 
the Th2 response respectively (Vignali et al., 2008; Zheng & Flavell, 1997) and as such these 
findings would not support the hypothesis that transfusion of older PRBCs induces a greater 




variables at baseline and the age of PRBCs prior to transfusion. Therefore the validity of the 
association at 24 hours is questionable. Furthermore, the multivariate analysis suggested that 
patient age was a more important variable in explaining gene expression variation in GATA-3 
and FOXP3 than the median age of the PRBCs. Whilst this may also be true for the change in 
IL-23 gene expression over 24 hours an additional marker of reduced Th17 activity, RORγt, 
remained independently associated with the transfusion of older PRBCs. 
 Although we hypothesise that the described gene expression profiles may potentially 
lead to an increased risk of subsequent infectious complications this analysis was not powered 
to detect such an association. These data do, however, provide a plausible mechanistic link 
between older PRBCs reducing the effectiveness of essential bactericidal functions and thereby 
rendering patients more susceptible to later infectious insults. This is an important distinction 
from suggesting that older PRBCs may directly introduce infection to the host. Earlier in this 
Chapter we have reported a median time lag of 7 days between the appearance of 
immunosuppressive gene expression patterns and the detection of a bacteraemia, which 
supports the concept that these changes are associated with an enhanced susceptibility to later 
infectious insults as opposed to representing an early immune response to infection. 
 This facet of the Chapter has a number of limitations. As has been previously discussed 
retrospective observational cohort studies are prone to systematic biases, unknown confounders 
and the possibility of Type 1 errors, and must be viewed as hypothesis generating. In this aspect 
of the Chapter, while the expression of a number of inflammatory mediators are significantly 
associated with the age of blood transfused, the accompanying r2 values that we present are low 
implying that age of blood might account for only a small proportion of the variation in the 
gene expression. However, there will be multiple influences present in trauma patients 
influencing gene expression and it would be surprising if any single factor, such as age of 
blood, had a dominant effect on the inflammatory response. Our data suggests that the age of 




outcomes. Importantly, unlike many other factors influencing the inflammatory response to 
major trauma, it is potentially modifiable. As before it is possible that unknown confounding 
variables were omitted from our multivariate regression analysis despite the inclusion of 
variables descriptive of shock on admission and at 24 hours, the ISS, the volume of transfused 
PRBCs and a common adjustment model with the same confounders considered in each case. 
There is no evidence-based consensus in the literature as to what constitutes ‘old or ‘young’ 
blood so as a consequence rather that dichotomising the age of blood into inexact groups, the 
age of blood was examined as a continuous (ordinal) variable in order to minimise bias. Again 
this is a limitation of a retrospective observational analysis rather than a randomised controlled 
trial. The inclusion of patients receiving both large and small volume transfusions may obscure 
important associations as it has been suggested that small volume transfusion of old blood does 
not adversely affect mortality (Weinberg et al., 2008). In addition to this the variability 
between patients receiving large and small volumes of PRBCs may mean that differences 
between the calculated (median) age of the blood transfused in different patients may be 
underestimated. Patient numbers preclude meaningful sub-analyses. There were some baseline 
associations between FOXP3 and GATA-3 gene expression and the age of transfused PRBCs, 
which introduces bias in the interpretation of alterations in Treg and Th2 cell types at 24 hours.  
 
3.6 Conclusions 
 A well-developed cytokine response to severe trauma is present within 2 hours of the 
injury. Excess and rising key anti-inflammatory cytokines coupled with unchanged or falling 
levels of key pro-inflammatory cytokines and associated transcription factors describes an anti-
inflammatory direction to this response over the first three days following injury. The 
magnitude of this response at 24 hours is associated with excess infections and with excess 
mortality. The primarily immunosuppressive inflammatory response to polytrauma may be 




Furthermore, transfusion was associated with an increased susceptibility to nosocomial 
infections and an increased risk of death. Further clinical and in vitro investigations will be 
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 The host immune response to major physiological insults has previously been thought 
to encompass a distinct early pro-inflammatory phase, termed the systemic inflammatory 
response syndrome (SIRS) followed sequentially by an anti-inflammatory phase, termed the 
compensatory anti-inflammatory response syndrome (CARS), (Hotchkiss & Karl, 2003). This 
immunological response is further expanded upon in Chapter one of this thesis. In the 
perioperative literature evidence supporting this paradigm in patients undergoing major non-
cardiac surgery is limited to small studies that profile a limited selection of important plasma 
cytokines (Jhanji et al., 2010; Novotny et al., 2012). A further limitation of these studies is the 
selection of candidate cytokines, such as interleukin-6 (IL-6), based on the relative abundance 
of target protein as opposed to their unambiguous and reproducible effects on host immunity 
(Diehl & Rincon, 2002). As has been alluded to in Chapter three, advances in qualitative real-
time polymerase chain reaction (qRT-PCR) technology now permit a more sensitive and 
widespread assessment of gene expression in vivo by quantifying messenger RNA (mRNA) 
levels as a surrogate (O'Dwyer et al., 2006). Furthermore, careful selection of key cytokines in 
conjunction with specific transcription factors allows inferences to be made as to the activity of 
specific inflammatory pathways (Pachot et al., 2005). Previously our group has described 
immune alterations following thoracotomy (White et al., 2011) and severe polytrauma (Chapter 
three), and their relation to infectious complications utilising this methodology (White et al., 
2011). 
 Recent data challenges the sequential SIRS / CARS paradigm, particularly in the 
setting of severe sepsis and blunt trauma (Hotchkiss et al., 2013; Xiao et al., 2011). A novel 
emphasis on an early and more dominant immunosuppressive phenotype associated with an 
enhanced susceptibility to develop infectious complications is emerging. Importantly, high-risk 




hospital acquired pneumonia (Pearse et al., 2006), with preliminary reports suggesting the 
presence of a postoperative functional immunoparalysis (Veenhof et al., 2011). 
 The immunological picture is also clouded by allogeneic transfusion. The 
immunomodulating qualities of blood transfusion have long been appreciated and have even 
been exploited to prevent renal allograft rejection in the era prior to the development of 
effective immunosuppressant drugs (Opelz & Terasaki, 1978). The unintended clinical 
consequences of immune modulation by allogeneic blood in the perioperative period include an 
increased susceptibility to infectious complications and cancer recurrence (Cata et al., 2013; 
Jensen et al., 1992). As inpatient non-cardiac surgery has recently been associated with much 
higher than anticipated mortality rates it is now imperative that all potentially avoidable causes 
of excess morbidity in this population are investigated and addressed (Pearse et al., 2012). 
Whilst preoperative anaemia is associated with a doubling of in-hospital mortality it remains 
unclear whether the anaemia itself or its treatment with allogeneic blood is responsible (Baron 
et al., 2014). Furthermore, perioperative blood transfusions are not universally associated with 
an increase in complications particularly when patients receiving leukodepleted blood are 
included (Cata et al., 2013; Lapierre et al., 1998). Also lacking from the current literature is an 
analysis of alterations in key inflammatory pathways associated with the transfusion of 
leukodepleted blood following major elective surgery. 
 In this chapter we explore the hypothesis that major gastrointestinal surgery is 
associated with an early postoperative immunosuppressive pattern of gene expression, which is 
quantitatively associated with susceptibility to later infectious complications and that this 
phenomenon may be compounded by allogeneic transfusion.  
4.2 Methods 







 119 patients (mean age 65, range 57-72, 62% male) undergoing scheduled major 
abdominal surgery were included. Patient characteristics are shown in Table 4.1. 
4.3.2 Change In mRNA Levels Over The Initial 48 Hours 
 IL-10 mRNA levels increased from baseline to 24 hours (Figure 4.1A). FOXP3 and 
GATA-3 mRNA levels both decreased over this period (p<0.0001 for both). IFN-γ (Figure 
4.1B), IL-12, T-bet (p<0.0001 for all) and TNF-α (p=0.002) mRNA levels all decreased over 
the initial 24 hours. TNF-α mRNA levels then increased from 24 hours to 48 hours (p=0.0002,) 
but the median 48 hour TNFα mRNA level remained less than the baseline level (p=0.004). IL-
23 (p=0.002), IL-27 (p=0.01) and RORγt (p<0.0001) mRNA levels all decreased over the 
initial 24 hours.  
 The TNF-α / IL-10 mRNA ratio decreased over the initial 24 hours (Figure 4.1C). The 
TNF-α / IL-10 mRNA ratio then increased from 24 to 48 hours (p<0.0001) but the 48 hour 
median value remained below the median baseline value (p<0.0001). With the exception of 
TNF-α, no changes in gene expression were detected between 24 and 48 hours for any of the 
other mediators assessed. Quantification of the median fold-change in mRNA levels from 
baseline to 24 hours is presented in Supplementary Table 10. 
4.3.3 Postoperative Infections 
 44 (37 %) patients developed postoperative infections a median of 9 (IQR 5 – 11) days 
following the operation. The sites of infection and isolated organisms are shown in Table 4.2. 
Patients developing infections stayed longer in hospital (14 (8 – 19) vs 7 (5 – 10) days, 
p<0.0001). A range of demographic and clinical data did not distinguish between those who did 




 No associations were detected between the baseline mRNA levels and the occurrence 
of postoperative infectious complications. Levels of IL-10 mRNA at 24 hours (p=0.007, Figure 
4.2A) and 48 hours (p=0.03) were higher in those who developed infectious complications.  
Levels of FOXP3 (p=0.02) and GATA-3 (p=0.005) mRNA at 24 hours were lower in 
those who developed infectious complications.  
 Levels of T-bet (p=0.04), IL-12 (p=0.04) and TNF-α (p=0.03, Figure 4.2B) mRNA at 
24 hours and levels of TNF-α mRNA at 48 hours (p=0.03) were lower in those who developed 
infectious complications.  
 Levels of IL-23 (p=0.02) and RORγt (p=0.04) mRNA at 24 hours were lower in those 
who developed postoperative infections. Changes in IL-27 mRNA levels were not associated 
with postoperative infectious complications.  
 The TNF-α / IL-10 mRNA ratio at 24 hours (p=0.004, Figure 4.2C) and at 48 hours 
(p=0.005, Figure 4.2D) was lower in those patients developing infectious complications.  
4.3.4 In-Hospital Mortality 
 Three (2.5%) patients died in hospital on the 7th, 9th and 63rd postoperative day. None 
of the following, age, diabetes, smoking history, ASA, length of operation, cancer diagnosis, 
planned ICU admission, preoperative immunosuppression or postoperative infections was 
found to be associated with in-hospital mortality.  
 IL-23 mRNA levels at 24 and 48 hours (p=0.03 for both), RORγt mRNA levels at 48 
hours (p=0.04) and the TNF-α / IL-10 mRNA ratio at 24 hours (p=0.01) were lower in those 





Table 4.1 - Patient characteristics of those undergoing major abdominal surgery 
 
  






    
Age (years) 66 (59 – 75) 64 (56-71) Ns 
Male sex  27 (61%) 47 (63%) Ns 
Diabetes  8 (18%) 12 (16%) Ns 
Current smokers  10 (23%) 14 (19%) Ns 
Smoking history  21 (48%) 43 (57%) Ns 
Cancer diagnosis  24 (55%) 53 (71%) Ns 
Preoperative 
immunosuppression  
6 (14%) 11 (14%) Ns 
Duration of operation (mins) 243 (176 – 313) 195 (142 – 295) Ns 
Endoscopic surgery 8 (18%) 24 (32%) Ns 
Planned postoperative 
intensive care unit admission  
34 (77%) 50 (66%) Ns 
ASA grade 3 or 4  13 (30%) 23 (31%) Ns 
By surgical specialty n (%) 
General surgery 4 (44%) 5 (55%)  
Upper gastrointestinal 9 (33%) 18 (67%)  
Colorectal 18 (37%) 31 (63%)  
HPB 11 (37%) 19 (63%)  
HPB + colorectal 1 (33%) 2 (67%)  
General surgery + colorectal 1 (100%) 0 (0%) Ns
1 
Intraoperative blood 
transfusion (%) 6 (14%) 4 (5%) 
Ns 
Blood transfusion first 24hr 
(%) 10 (23%) 5 (7%) 
0.02 
In hospital death  1 (2%) 2 (2.5%) Ns 
Data are described as medians with interquartile range or numbers with percentages in parenthesis. ASA, American 
Society of Anaesthesiologists. HPB, Hepato-Pancreato-Biliary. 1 represents a Fisher’s exact test incorporating all 







Figure 4.1 - Perioperative changes in gene expression 
Graphs represent the change in mRNA levels from the preoperative sample (baseline) to 24 hours 
postoperatively. The Y axis is scaled to Log2, mRNA results are expressed as a relative quantification ratio 









Figure 4.2 - Gene expression & postoperative infection 
Graphs A-B demonstrate univariate analysis of candidate gene mRNA levels at 24 hours and the occurrence of 
nosocomial infectious complications. Graph C demonstrates a univariate analysis of a ratio of candidate gene 
mRNA levels and the occurrence of nosocomial infectious complications. Graph D demonstrates the 
relationship with candidate genes assessed at 48 hours. Graphs A-D represent median, interquartile range (box) 
and the 10th and 90th percentile (whiskers). All results are expressed as a relative quantification ratio between 




Table 4.2 - Outline of the infectious complications in the postoperative period following 
major abdominal surgery 
  Infection site Number 
of 
episodes 
Organisms Median time to 
development of 
infection (days) 
    
Bloodstream  11 E. coli (4) ESBL E. coli (1)  
E. coli + E. faecium (1) 
E. faecium (1) 
K. pneumoniae (1) 
S. aureus (1) 
P. aeruginosa (2) 
 
17 (6 – 28) 
Pneumonia  9 Culture negative (5) Candida glabrata (1) 
K. pneumoniae (1) 
Organism of the coliform group (1) 
S. maltophilia (1) 
 
7 (4 -16) 
Surgical Site  24 Culture negative (11) B. fragilis (1) 
E. coli (4), 
ESBL E. coli (1) 
Mixed anaerobes (1) 
Organism of the coliform group (2) 
Organism of the coliform group + E. 
faecalis (1) 
Organism of the coliform group + 
MRSA(1) 
Organism of the coliform group + S. 
aureus (1) 
P. aeruginosa (1) 
 
10 (4 -14) 
Urinary tract  15 Candida albicans (1) Culture negative (2) 
E. coli (6) 
ESBL E. coli (1)  
Mixed growth (2) 
Organism of the coliform group (2) 
P. aeruginosa (1) 
 
8 (6 -12) 
Intra-abdominal  17 Culture negative (6) E. coli (2) 
E. coli + E. faecium (1) 
ESBL E. coli + VRE(1) 
E. faecalis (1) 
E. faecium + Candida albicans (1) 
Candida albicans (1) 
E. cloacae (1) 
E. cloacae + Organism of the 
coliform group (1) 
E. Aerogenes + P. aeruginosa (1) 
VRE (1) 
 




2 K. pneumoniae (1) Organism of the coliform group (1) 15 (3 -27) 
Skin  1 Varicella zoster virus (VZV)  30 
Data refer to the number of episodes of infection from a particular site. Some patients may have more than one 
episode of infection. The number in parenthesis in the organisms column the number of episodes of infection 
attributable to that organism. ESBL, Extended-spectrum beta-lactamase; MRSA, methicillin-resistant S. aureus; 




4.3.5 Blood Transfusion 
 A total of 15 (13%) patients were transfused a median of 2 units (IQR 1-2) of PRBC in 
the initial 24 hours. Ten of these patients received intraoperative transfusion, eight 
postoperative transfusion and three patients received PRBC both intra-operatively and 
postoperatively.  
 No other blood product was transfused during this time period. Older patients 
(p=0.0002) and those with a diagnosis of cancer (p=0.02) were more likely to receive PRBC 
transfusions. Smokers were less likely to receive a blood transfusion (p=0.04). The requirement 
for blood transfusion was not related to the duration of the operation, whether the procedure 
was endoscopic or open or the ASA grade (Table 4.3). Patients receiving PRBC were more 
likely to develop postoperative infections (OR 5.5 (1.3 – 12.8); p=0.02 (Fisher’s exact test), 
Figure 4.3A) and were more likely to die in-hospital (OR 15.7 (1.3 – 185.3); p=0.04 (Fisher’s 
exact test), Figure 4.3B).  
4.3.6 Blood Transfusion & Gene Expression 
 On univariate analysis, IL-12 mRNA levels at 24 hours (p=0.02) and TNF-α mRNA 
levels at 48 hours (p=0.01) were lower in those who received a blood transfusion in the first 24 
hours postoperatively. IL-23mRNA levels at 24 (p=0.007) and at 48 hours (p=0.03) and RORγt 
mRNA levels at 24 hours (p=0.004) and at 48 hours (p=0.006) were lower in those receiving a 
blood transfusion over the first 24 hours postoperatively. The TNF-α / IL-10 mRNA ratio at 24 
hours (p=0.0006) and at 48 hours (p=0.01) was lower in patients receiving blood transfusion 
over this period (Figure 4.4A-H).  
 FOXP3 mRNA levels at 24 hours (p=0.004) and at 48 hours (p=0.02) and GATA-3 
mRNA levels at 24 hours (p=0.02) were lower in those who received blood transfusion in the 
initial 24 hours postoperatively. IL-10, IFN-γ, T-bet and IL-27 mRNA levels were unrelated to 






Figure 4.3 - Perioperative blood transfusion, infectious complication & survival 
Graph A represents the proportions of patients developing postoperative infectious complications 
amongst those patients receiving a blood transfusion in the first 24 hours and in those patients not 
receiving a blood transfusion during this time period. Graph B represents the proportions of patients 
either dying in hospital or surviving to hospital discharge amongst those patients that received a blood 
transfusion in the first 24 hours (2 patients died out of a total of 15) and in those patients that did not 






Figure 4.4 - Perioperative blood transfusion & gene expression 
Graphs A-H represent the mRNA levels of candidate genes following scheduled abdominal surgery in those 
patients who received a transfusion prior to this time point and in those patients that did not. (median, 
interquartile range (box) and the 10th and 90th percentile (whiskers)). All results are expressed as a relative 





4.3.7 Mean Age Of The Transfused Blood & Gene Expression  
 The age of the blood was calculated as the number of days from collection from a 
blood donor to transfusion. No association was detected between the mean age of the units of 
blood transfused and gene expression for any of the selected genes.  
4.3.8 Postoperative Infections 
 With the exception of perioperative blood transfusion, a range of demographic and 
clinical data did not adequately distinguish between those who did and did not develop 
infection (Table 4.1).  
4.3.9 Multivariable Analysis 
 Selection of variables to be included in the multivariate analysis is described in the 
methods section of this Chapter. IL-12, RORγt, TNF-α / IL-10 and FOXP3 mRNA levels at 24 
hours along with RORγt, TNF-α / IL-10 and FOXP3 mRNA levels at 48 hours were 
independently associated with transfusion in the first 24 hours (Supplementary Table 11). 
There was no independent association between GATA-3 and IL-23 mRNA levels at 24 hours 
and between IL-23 and TNF-α mRNA levels at 48 hours and blood transfusion within the first 
24 hours.  
 There was an independent association between the occurrence of infectious 
complications and the requirement for blood transfusion in the first 24 hours postoperatively 






Table 4.3 - Characteristics of patients requiring perioperative blood transfusion 











Age (years) 77 (72 – 81) 63 (56-70) 0.0002 
Male sex 9 (60%) 64 (62%) Ns 
Diabetes 3 (20%) 18 (17%) Ns 
Current smokers 0 (0%) 24 (23%)  0.04 
Smoking history  4 (27%) 60 (58%) 0.02 
Cancer diagnosis  14 (93%) 62 (60%) 0.02 
Preoperative 
immunosuppression  4 (29%) 12 (12%) Ns 
Duration of operation (mins) 240 (150 – 400) 212 (145 – 296) Ns 
Endoscopic surgery  2 (13%) 30 (29%) Ns 
Planned postop ICU 
admission  13 (87%) 70 (68%) 
Ns 
ASA grade 3 or 4  9 (60%) 29 (28%) Ns 
By surgical specialty n (%) 
General surgery 0 (0%) 8 (7%)  
Upper gastrointestinal 4 (27%) 23 (22%)  
Colorectal 5 (33%) 44 (43%)  
HPB 5 (33%) 25 (24%)  
HPB + colorectal 1 (7%) 2 (2%)  
General surgery + colorectal 0 (0%) 1 (1%)  Ns
1 
Postoperative infections n (%) 10 (66%) 34 (33%) 0.02 
In hospital death n (%) 2 (13%) 1 (1%) 0.04 
Data are described as medians with interquartile range or numbers with percentages in parenthesis. mRNA levels are 
expressed as a relative quantification ratio between the candidate and the reference genes. HPB, Hepato-Pancreato-





 In this chapter we determined levels of mRNA for a panel of interlinked cytokines and 
related transcription factors and demonstrated that a specific pattern of altered gene expression 
is apparent within 24 hours of major gastrointestinal surgery. The four-fold up-regulation in 
expression of the archetypal anti-inflammatory gene, IL-10, in conjunction with decreasing 
gene expression for mediators descriptive of pro-inflammatory activity in the Th1 and Th17 
pathways and a seven-fold decrease in the TNF-α / IL-10 gene expression ratio, points to the 
immunosuppressive nature of this response (Supplementary Table 10). A further analysis was 
carried out examining the effects of allogeneic transfusion following major gastrointestinal 
surgery, which displayed a pattern of gene expression consistent with greater 
immunosuppression when compared with a cohort not receiving a blood transfusion. This 
observation was independent of variables descriptive of the extent of surgical trauma. The gene 
expression data presented suggests that blood transfusion in this setting may be associated with 
specific immune defects in innate immunity and in Th1 and Th17 pathways. These patients also 
had an excess of postoperative infectious complications when compared with patients who did 
not receive a blood transfusion; an observation that was again independent of the duration of 
the surgical procedure. 
 The data we report are consistent with the recent reappraisal of the sequential SIRS / 
CARS paradigm in other settings (Hotchkiss et al., 2013; Xiao et al., 2011). A growing 
appreciation of the importance of an exaggerated immunosuppressive response has led directly 
to preliminary trials of immune stimulants in an effort to reduce the incidence of nosocomial 
infections in susceptible sepsis and trauma patients (Meisel et al., 2009; Nakos et al., 2002). 
Perioperative patients are a similarly susceptible group with comparable rates of nosocomial 
infections (Canet & Gallart, 2013). Indeed, there is precedent for immune stimulation in the 
perioperative period; subcutaneous IFN-γ facilitates release of pro-inflammatory bactericidal 




in order to demonstrate meaningful impacts on important postoperative endpoints trials must be 
adequately powered and utilise immunodiagnostics to target high-risk patients in conjunction 
with monitoring the treatment response.  
 IL-10 induces host immunosuppression through a variety of mechanisms, including 
inhibition of MHC class ΙΙ expression on macrophages and suppression of pro-inflammatory 
cytokines and chemokines in a number of different cell types (Couper et al., 2008). The cellular 
source of the excess IL-10 mRNA in our patients is unclear from the whole blood analysis 
performed. Although natural Treg (nTreg) cells have consistently been associated with the 
development of impaired immunity, levels of the nTreg cell specific transcription factor FOXP3 
have been shown to decrease over the postoperative period (Couper et al., 2008) as was the 
case in this Chapter. Alternative sources of IL-10 unrelated to FOXP3 expression are abundant 
amongst innate and adaptive cell types and include inducible Treg cells, Th2 cells, dendritic 
cells, macrophages, mast cells, eosinophils, neutrophils, CD4+ and CD8+ T cells, B cells as well 
as damaged muscle or the endothelium (Ouyang et al., 2011). Flow cytometry experiments 
would assist in identifying the source of IL-10.  
 Excess IL-10 enhances susceptibility to usually benign infectious pathogens (Meghari 
et al., 2008). IL-10 gene expression can also be up-regulated directly by a pathogen as an 
evolutionary mechanism to evade host defenses (Carey et al., 2012). We report that raised IL-
10 gene expression on the first postoperative day increases the risk of infections diagnosed 
approximately a week later. It remains unclear whether this represents unrecognised infection 
present on day one or merely an immune environment conducive to later bacterial invasion. 
Whilst ultrasensitve microbial detection tests, such as 16s PCR, may confirm or refute the 
presence of circulating microbes in the early postoperative period it would be unsurprising to 
detect episodes of bacteraemia following gastrointestinal surgery and their relevance would 
therefore be uncertain. Whether suppressed pro-inflammatory pathways are a direct 




supported by animal models and ex vivo human data (Carey et al., 2012). Furthermore, the 
immune defect is likely to be multifaceted with a possible additive effect resulting from pro-
inflammatory pathways in conjunction with excess IL-10 gene expression. Whilst reduced gene 
expression of mediators descriptive of the pro-inflammatory Th1 and Th17 pathways are 
associated with infectious complications the TNF-α / IL-10 mRNA ratio separates these groups 
more clearly. 
 Multiple factors are likely to trigger and modulate the immune response in this setting. 
Both circulating endotoxin from the gastrointestinal lumen and the presence of endogenous 
intracellular ‘alarmins’ released following tissue trauma have been implicated (Marshall, 2010; 
Zhang et al., 2010). Volatile anaesthetic vapours, hypnotics and analgesics are all likely to 
exert some influence on the immune phenotype observed in the perioperative period 
(Fahlenkamp et al., 2014). The influence of these treatments are described in more detail in 
Chapter one of this thesis.  
 Although numerous small studies have suggested that perioperative allogenic blood 
transfusion may induce immune modulation which creates an environment that promotes both 
microbial growth and tumorigenesis their conclusions are limited by small cohort size, in vitro 
and ex vivo assays and insensitive protein assays (Blajchman, 2002; Decker et al., 1996; Jensen 
et al., 1992; Kirkley et al., 1998; Nielsen et al., 1991; van Twuyver et al., 1991; Waymack et 
al., 1986). These studies largely predate the routine leukodepletion of transfused blood and 
suggest a causal relationship between immune modulation and the infusion of allogeneic 
leukocytes; a biological effect which could be ameliorated by pre-storage leukodepletion 
(Blajchman, 2002). It cannot therefore be inferred that a similar immunological response will 
be observed following exposure to a leukodepleted product. In contrast, the packed red cells 
transfused in the study reported here were universally leukodepleted. The results we present 
suggest that the immunosuppression observed following perioperative transfusion may not be 




despite a 3 log reduction in leukocyte numbers achieved following current filtration techniques 
some leukocytes do persist and these retain the ability to influence host immune responses 
(Blajchman, 2002). 
 In Chapter three, using a similar methodology we described an excess in blood stream 
infectious complications amongst severely injured trauma patients receiving leukodepleted 
blood transfusion in conjunction with a gene expression profile characterised by specific 
deficits in Th1 and Th17 pathways. Clearly patients who receive a blood transfusion outside of 
the context of a randomised controlled trial will differ from those who do not require 
transfusion and it is important to attempt to control for these factors. In the previously reported 
trauma cohort (Chapter three) the described observations were independent of the severity of 
injury and degree of shock at presentation. Similarly, in this perioperative cohort, although on 
univariate analysis there was a trend towards longer and therefore potentially more complicated 
surgery being associated with postoperative infections and to a lesser degree with blood 
transfusion, a multivariable analysis confirmed that the association between blood transfusion 
and both infectious complications and gene expression patterns were independent of the 
duration of surgery. Although we describe an association between blood transfusion, an 
immunosuppressive pattern of gene expression and excess infectious complications it may be 
that, despite adjustment for known confounders, the need for blood transfusion is a surrogate 
marker of severity of surgical stress or an unmeasured pre-morbid condition and thus a 
causative role in postoperative immune phenotype is suggested but not proven. However, the 
consistency of these data from two distinct patient populations, post major gastro-intestinal 
surgery patients and trauma patients, strengthens our underlying hypothesis.  
 The association between blood transfusion and infectious complications in the 
perioperative period has been well described previously (Bennett-Guerrero et al., 2007; 
Horvath et al., 2013; Jensen et al., 1992). This association appears to be consistent amongst 




size is potentially quite substantial with one recent estimate quantifying the increased risk of 
infection at 29% for each unit of blood transfused (Horvath et al., 2013). That we were able to 
describe a similar association between blood transfusion and nosocomial infection in a smaller 
cohort of patients may be related to this effect size, in addition to the selection of an at-risk 
population using patient age, gastrointestinal surgery under general anaesthesia and the 
requirement for inpatient treatment as inclusion criteria. The postoperative infection rates we 
report are consistent with similar patient populations (Pearse et al., 2014). This study also 
described an association between blood transfusion and mortality. However, whilst the 
mortality rate is consistent with similar populations (Pearse et al., 2014), with only 3 deaths 
occurring in the cohort as a whole no conclusions regarding causation should be inferred from 
this association.  
 It is unsurprsing that we did not observe an association between increasing age of the 
transfused blood and either perioperative infectious complications or patterns of gene 
expression as this study was underpowered to detect such an association. There is much current 
debate surrounding the potential pathogenicity associated with blood stored for excessive 
periods prior to transfusion. In the perioperative period blood stored for longer periods has been 
linked to an excess of infectious complications (Leal-Noval et al., 2003; Mynster & Nielsen, 
2000; Vamvakas & Carven, 1999). .  
 A limitation of this Chapter is that the candidate gene approach necessarily excludes 
many genes with potent pro and anti-inflamatory effects and therefore provides an incomplete 
picture of the whole genome response. Measures utilised in this Chapter such as TNF-α / IL-10 
gene expression ratios can give a broad indication of immune competence but could also be 
criticised for being too reductionist. It seems unlikely, however, that an exuberant pro-
inflammatory response could occur in conjunction with a significant reduction in the TNF-α / 
IL-10 gene expression ratio and marked downregulation of Th1 and Th17 pathways. The 




pro and anti-inflammatory effects, such as IL-6, where the overall effect on patient phenotype 
remains unclear (Diehl & Rincon, 2002).  
4.5 Conclusions 
 Major gastrointestinal surgery is associated with a distinctive gene expression pattern 
that includes a dramatic up-regulation of the anti-inflammatory cytokine IL-10, in conjunction 
with evidence of depressed pro-inflammatory immune pathways. The extent of this response is 
associated with an excess of infectious complications. The transfusion of leukodepleted 
allogeneic blood during or immediately after major gastrointestinal surgery is associated with 
patterns of gene expression consistent with immunosuppression and specific deficiencies in 
innate immunity and Th1 and Th17 pro-inflammatory immune pathways. A mechanistic link 
between allogenic perioperative blood transfusion, defects in essential bactericidal pathways 
and an excess of nosocomial infections is suggested but not proven. Further research is 









 MHC Class II Antigen Density Chapter Five:
On In Vivo Monocytes & Cultured Healthy 
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‘Features of postoperative immune suppression are reversible with interferon gamma and 
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 Following major surgery and severe polytrauma patients experience a period of 
immune suppression, which can predispose to the development of postoperative infections 
(Mokart et al., 2011). Infectious complications result in considerable morbidity and are 
observed in over 30% of older patients undergoing major surgery (Pearse et al., 2014) and up to 
70% of patients suffering severe polytrauma (Chapter three). Postoperative immune 
dysfunction is mediated partly by tissue injury and the consequent release of intracellular 
alarmins such as mitochondrial DNA fragments (Zhang et al., 2010). The cellular and 
transcriptomic features of tissue damage induced immune modulation are now well 
characterised (Gaudilliere et al., 2014; Pillay et al., 2012; Xiao et al., 2011). Key reproducible 
cellular features of this response include a consistent fall in monocyte HLA-DR (mHLA-DR) 
expression (Cheron et al., 2010; Mokart et al., 2011; Wakefield et al., 1993) and an expansion 
of cells with phenotypic similarities to myeloid derived suppressor cells (Gaudilliere et al., 
2014; Pillay et al., 2012; Pillay et al., 2013). These alterations are quantitatively associated 
with infectious complications and poor functional recovery (Cheron et al., 2010; Gaudilliere et 
al., 2014; Mokart et al., 2011). Although the immune suppressive effect of major tissue damage 
has been shown to be reversible with interferon gamma (IFN-γ) treatment in the context of 
traumatic injuries (Dries et al., 1994; Nakos et al., 2002; Polk et al., 1992), in the perioperative 
period the specific additional immunomodulating effects attributable to such factors as 
prolonged anaesthetic administration, opioid analgesics, premorbid conditions and blood 
transfusion require further consideration (Matsuoka et al., 2001; O'Dwyer et al., 2015; Vallejo 
et al., 2004).  
 There is similar consistency amongst the transcriptomic data available following major 
surgery and severe polytrauma (Baigrie et al., 1992; Mokart et al., 2005a; Xiao et al., 2011). A 




features of functional immune suppression and the correlation between circulating levels of this 
cytokine and infectious complications.  
 Although many essential pro-inflammatory effects are mediated through IL-6 pathways 
this cytokine has also been shown to drive differentiation of T helper cells to a T helper cell 
type 2 (Th2) subtype and to inhibit Th1 maturation through a Suppressor of Cytokine Signalling 
1 (SOCS1) dependent suppression of IFN-γ signalling (Diehl & Rincon, 2002; Sofi et al., 
2009). These latter effects could be broadly construed as anti-inflammatory and may induce an 
immune environment in which host bactericidal abilities are impaired, thereby increasing 
susceptibility to infectious complications. Furthermore, the purported mechanism of action 
suggests that restoring IFN-γ activity may reverse the downstream consequences. 
 IL-10 on the other hand is a prototypical anti-inflammatory cytokine, originally 
described as a product of Th2 cells, acting to inhibit Th1 cytokine production (Fiorentino et al., 
1989). Latterly production of IL-10 has been described from a wide variety of cell types 
including monocytes, macrophages, dendritic cells as well as other T cell subsets (Couper et 
al., 2008). Previous research has demonstrated that IL-10 mediated STAT-3 phosphorylation 
(Liu et al., 2013b) and E3 ubiquitin-ligase March-I activation (Mittal et al., 2015; Mittal & 
Roche, 2015) can impede antigen presentation. In addition to this IL-10 is known to activate 
the PI3K-Akt-GSK signalling pathway, thus suppressing inflammatory gene expression 
(Antoniv & Ivashkiv, 2011). 
 GM-CSF is a growth factor that has been utilised in the sepsis literature as a global 
immune stimulant (Bo et al., 2011; Mathias et al., 2015). Treatment has been shown to 
improve the survival, proliferation, phagocytosis, and the bactericidal ability of neutrophils and 
monocytes (Meisel et al., 2009). In addition to this it has been shown to upregulate monocyte 
MHC class II molecule expression as well as increasing endotoxin-induced ex vivo pro-




 In this Chapter we hypothesise that increased levels of IL-6 and IL-10 following major 
surgery may promote an immunosuppressed phenotype that can be reversed with IFN-γ or GM-
CSF. In order to explore this hypothesis we aimed to describe the patterns of IL-6 and IL-10 
production in response to major gastrointestinal surgery and the relationship between both 
cytokines and infectious complications. We also aimed to explore the role of IL-6 and IL-10 
dependent pathways in postoperative immune suppression and to determine whether this 
immune suppression might be reversed by IFN-γ or GM-CSF.  
5.2 Methods 




 108 patients (mean age 65, range 46–87, 59% male) undergoing elective major 
abdominal surgery were included. 41 (38%) patients developed a postoperative infection. 
Further patient characteristics have previously been outlined in Chapter four (Tables 4.1 & 4.2). 
5.3.1.2 METS 
 A comparable cohort to the VISION study made up of 12 patients (median age 68, IQR 
65-78, 42% male), undergoing elective major abdominal surgery were recruited. 
5.3.2 Postoperative Infections 
 In the perioperative cohort infectious complications developed a median of 9 (IQR 5–
11) days following the procedure with those patients developing infections staying longer in 
hospital (14 (9–19) vs. 7 (5-9) days, p<0.0001). A range of demographic and clinical data did 




5.3.3 Perioperative IL-6 & IL-10 levels 
 IL-6 and IL-10 levels increased 19-fold and 5-fold respectively from baseline to 24 
hours postoperatively (p<0.0001). These levels were unchanged between 24 and 48 hours 
postoperatively for IL-6 (Figure 5.1A & B), but fell for IL-10 (p=0.0004). Baseline IL-6 and 
IL-10 levels were higher in patients with a diagnosis of cancer, p=0.02 and p<0.05, Figure 5.1C 
& D). None of age, sex, smoking history, immunosuppression or diabetes was associated with 
baseline levels of either cytokine. At 24 hours greater levels of IL-6 and IL-10 were assayed in 
patients who would subsequently develop infections (p<0.0001 and p=0.0019, respectively; 
Figures 5.2A & B). This association was observed with both cytokines in intra-abdominal 
infections (p=0.004 and p=0.0019, respectively; Figures 5.2C & D) and surgical site infections 
(p=0.001 and p=0.0009, respectively; Figures 5.2E & F) but not pneumonia. IL-6 and IL-10 
levels at 24 hours were directly correlated with the length of the procedure (Spearman’s ρ 0.26, 
p=0.01 and Spearman’s ρ 0.23, p=0.03, respectively). The levels were lower in patients who 
underwent endoscopic procedures (p=0.0001 and p=0.0007, respectively) and were higher in 
patients who received an epidural, in conjunction with their general anaesthetic (p=0.006 and 
p=0.03, respectively).  
 A multivariable linear regression model confirmed that the association between IL-6 or 
IL-10 levels at 24 hours and postoperative infectious complications remained when corrected 
for the differences in the above variables. 
 This pattern was replicated at 48 hours however with only IL-6 levels showing 
associations with those patients subsequently developing infections (p=0.003) and higher in 
patients who had longer procedures (Spearman’s ρ 0.23, p=0.03). Both IL-6 and IL-10 levels 
were lower in patients who had endoscopic procedures (p=0.0002 and p=0.0076, respectively) 
and higher in patients who received an epidural (p=0.02 and p<0.05, respectively). The 
association between IL-6 levels at 48 hours and infectious complications again remained when 




Table 5.1 - Assayed IL-6 & IL-10 serum levels & their relationship to late nosocomial 


























n=67 (60%) p-value 
IL-6: VISION    
Pre-Op 3.7 (2.8 – 13) 3.0 (2.4 – 4.8) Ns 
24hrs  101 (49 – 242) 39 (19 – 92) 0.0002 
48hrs  80 (31 – 170) 34 (16 – 79) 0.003 
IL-10: VISION    
Pre-Op 0.8 (0.4 – 1.5) 0.8 (0.4 – 1.3) Ns 
24hrs 5.2 (3.5 – 8.2) 2.8 (2.1 – 4.7) 0.0019 
48hrs 2.5 (1.7 – 4.9) 2.1 (1.5 – 4.2) Ns 










IL-6: METS  
Pre-Op 2.8 (1.1 – 4.0) 
24hrs  228 (75 – 470) 
48hrs  137 (55 – 168) 
IL-10: METS  
Pre-Op 0.4 (0.2 – 1) 
24hrs 3.9 (1.5 – 6.8) 
48hrs 1.7 (1.1 – 2.5) 
 







Figure 5.1 - IL-6 & IL-10 plasma levels, the influence of surgery & perioperative cancer 
Changes in IL-6 (A) and IL-10 (B) concentration following major gastrointestinal surgery. Preoperative 
IL-6 (C) and IL-10 (B) protein levels were raised in patients who had a diagnosis of cancer. All data 






Figure 5.2 - Differences in IL-6 & IL-10 levels between those patients suffering any 
postoperative infection 
All postoperative Infections (A & B). abdominal infection (C & D) or postoperative surgical site infection 
(E & F). Infections were defined according to the CDC criteria. All data displayed as median and 




 The METS cohort demonstrated comparable temporal changes in IL-6 and Il-10 levels 
(Table 5.2), however as a smaller cohort (n=12) they were not powered to detect clinical 
correlations. 
5.3.4 Effect Of Elective Major Abdominal Surgery On Monocyte HLA-DR 
Expression 
 A total of 12 consecutive patients from the METS study were recruited with 
CD14+HLA-DR analysis performed on a flow cytometer at 3 time points; preoperatively, at 24 
hours and 48 hours. At 24 and 48 hours there was a significant reduction in the number of 
mAb/C of HLA-DR (p<0.0001) when compared to the preoperative sample.  
 
Figure 5.3 - Effect of elective major abdominal surgery on monocyte HLA-DR expression 
Representative flow cytometry plots (A-D): EDTA anticoagulated blood was immediately stained with the 
combination CD14 / HLA-DR antibody, cells were gated on CD14 (A). PE coated beads were used to 
calibrate the experiment, these gave four defined population; low, low-medium, medium-high and high to 
allow accurate gate placement (B). A histogram plot showing preoperative (C) and postoperative (D) HLA-
DR expression on the gated CD14+ cells. Using geometric mean fluorescent intensity (gMFI) linear 
regression was performed to calculate the number of antibodies per CD14+ cell (mAB / CD14+). This 
showed a statistically significant change from baseline, graph displays all patients (n=12), with the red 





5.3.5 Effect Of Postoperative Serum On Healthy Control mHLA-DR Expression 
& Following IL-6 Neutralisation 
 Serum was collected from 8 patients preoperatively and again at 24 hours. Details of 
these patients are given in Supplementary Tables 13 & 14. Healthy control mHLA-DR 
geometric MFI fell when incubated with serum collected 24 hours following major surgery 
when compared with gMFI levels following incubation with preoperative serum (Figure 5.3A, 
P=0.008, n=8). Pre-incubation with IL-6 neutralising antibody did not alter this reduction in 
geometric MFI (Figure 5.3B, P=0.95). Serum from a further 8 patients was collected 
preoperatively and at 24 hours. Patient characteristics outlined in Supplementary Table 13. 
 
Figure 5.4 - Perioperative serum, healthy PBMCs, & the effects of IL-6 neutralisation 
Postoperative serum decreases the level of mHLA-DR on cultured PBMCs obtained from healthy 
controls (A). The addition of an Fc blocker to the culture medium was necessary to eliminate nonspecific 
antibody actions (B). All data (A & B) from 2 independent experiments. All data displayed as median 
and interquartile range, HLA-DR quantified as geometric MFI on CD14+ cells. Patient characteristics 





Figure 5.5 - Effects of postoperative serum on healthy control monocyte HLA-DR 
expression following IL-10 neutralisation or recombinant IL-10 incubation 
Postoperative serum decreases the level of mHLA-DR on cultured Fc blocked PBMCs obtained from 
healthy controls, this decrease was reversed with the pre-incubation in IL-10 blocking antibody (A). The 
addition of an Fc blocker to the culture medium was necessary to eliminate nonspecific antibody actions. 
Incubation of recombinant IL-10 with preoperative serum decreased the level of mHLA-DR PBMCs (B). 
(A) Data from 3 independent experiments. (B) Data from 2 independent experiments. All data displayed as 
median and interquartile range, HLA-DR quantified as geometric MFI on CD14+ cells. Patient 
characteristics outlined in Supplementary Tables 14 & 15, respectively. 
5.3.6 Effect Of Postoperative Serum On Healthy Control mHLA-DR Expression 
& Following IL-10 Neutralisation & Recombinant IL-10 Incubation 
 Serum was collected from 12 patients preoperatively and again at 24 hours. Healthy 
control monocyte HLA-DR gMFI fell when incubated with serum collected 24 hours following 
major surgery when compared with gMFI levels following incubation with preoperative serum 
(Figure 5.4A, P=0.005, n=12). Pre-incubation with IL-10 neutralising antibody increased the 
mHLA-DR geometric MFI to preoperative values (Figure 5.4A, p=0.002).  
 Serum from a further 8 patients was collected preoperatively and incubated with 




a similar manner to the postoperative serum. The patient characteristics for both experiments 
are outlined in Supplementary Tables 14 & 15, respectively. 
 
Figure 5.6 - Effects of postoperative serum on healthy control monocyte HLA-DR 
expression following IFN-γ or GM-CSF stimulation 
Postoperative serum decreases the level of mHLA-DR on cultured PBMCs obtained from healthy controls 
comparison (A & B). When postoperative serum was co-cultured with IFN-γ (250 IU), mHLA-DR levels 
were restored to those levels seen with preoperative serum (A). The same is seen with increasing doses of 
GM-CSF (2 - 20ng/mL) (B). All data (A & B) from 2 independent experiments. All data displayed as 
median and interquartile range, HLA-DR quantified as geometric MFI on CD14+ cells. Patient 
characteristics outlined in Supplementary Tables 16 & 17, respectively. 
5.3.7 Effect of Postoperative Serum On Healthy Control mHLA-DR Expression 
Following IFN-γ & GM-CSF Stimulation 
 Again there was a fall in mHLA-DR gMFI following incubation with serum taken at 24 
hours (Figures 5.5 A & B). Co-incubation with IFN-γ resulted in an increase in mHLA-DR 




co-incubation with GM-CSF in a dose dependent manner (p=0.008, figure 5.5B, n=8). The 
patient characteristics for both experiments are outlined in Supplementary Tables 16 & 17, 
respectively. 
 These data were also re-analysed excluding those patients with preoperative 
immunosuppression. A similar fall in mHLA-DR gMFI following incubation with serum taken 
at 24 hours was demonstrated which was prevented by co-incubation with IFN-γ (n=7) or GM-
CSF (n=7).  
5.4 Discussion 
 In this Chapter we have determined plasma levels of IL-6 and IL-10 protein in patients 
over 45 years of age undergoing elective surgery involving the gastrointestinal tract and 
described an independent association between higher postoperative levels of both cytokines and 
later nosocomial infections. We have shown that at 24 and 48 hours postoperatively there is a 
marked reduction in the density of HLA-DR receptors on patient monocytes. In addition to this 
we have also demonstrated that serum collected in the postoperative period contains soluble 
mediators, which reduce the antigen presenting capabilities of healthy monocytes as measured 
by HLA-DR expression. Our data suggests that IL-10, but not IL-6, dependent pathways are 
one of the essential mediators of this immune suppressed phenotype. Treatment with IFN-γ and 
GM-CSF in vitro reverses the induced deficit in the antigen presenting capabilities of 
monocytes exposed to postoperative serum.  
 The association between IL-6 and IL-10 levels and postoperative infections is not 
unexpected and has been previously described (Klava et al., 1997; Mokart et al., 2002; Mokart 
et al., 2005b). Unsurprisingly, we also report that levels of both cytokines are higher in those 
patients undergoing lengthier procedures. These procedures are likely to be more complex with 
a higher probability of postoperative complications. Importantly, however, we have found that 




of the duration of the surgical procedure. It is also well recognised that postoperative patients 
display features of immune suppression (Mokart et al., 2011; Wakefield et al., 1993). However, 
whereas previous investigators have reported alterations in the properties of specific cell 
subtypes or their cell surface markers (Gaudilliere et al., 2014; Wakefield et al., 1993) we 
demonstrate that immune suppression is mediated, at least in part, by soluble compounds that 
remain 24 hours following surgery, as opposed to the direct effect of either tissue damage, 
anaesthesia or endotoxin release on immune cell subtypes. These data may be of crucial 
importance in developing potential treatments to alleviate postoperative immune suppression.  
 The key link between the tissue damage characteristic of major surgery or severe 
polytrauma and the subsequent inflammatory response is the release of alarmins (Oppenheim & 
Yang, 2005). Alarmins are a group of structurally diverse compounds, which include high-
mobility-group box (HMGB) proteins and mitochondrial DNA (mtDNA), which are released 
following tissue damage as cells undergo physiological stress or necrosis (Chan et al., 2012). 
These are then recognised by a wide variety of pattern recognition receptors (PRRs), which 
include the membrane bound Toll-like receptors (TLRs) and the cytoplasmic NOD-like 
receptors (NLRs) (Chan et al., 2012). Activation of PRRs induces an enzymatic cascade, which 
results in down-stream phosphorylation of transcription factors such as nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB), which in turn alters cytokine transcription.  
 IL-6 is a cytokine that is consistently upregulated acutely following activation of this 
cascade (Xiao et al., 2011). Furthermore, following traumatic injury elevated levels of IL-6 are 
seen concurrently with evidence of immune suppression and reduced antigen presentation 
capabilities (Gouel-Cheron et al., 2012). This association, together with the consistent 
observation that higher IL-6 levels and infectious complications are linked following major 
tissue damage raises the possibility that in this scenario IL-6 functions not in its traditional pro-
inflammatory role but rather to promote an immune suppressed phenotype. This hypothesis is 




effects of IL-6 acting through a classical signalling pathway involving the membrane bound IL-
6 receptor and SOCS1 and STAT3 dependent mechanisms which ultimately inhibit IFN-γ 
production (Diehl & Rincon, 2002; Scheller et al., 2011; Sofi et al., 2009). Although IL-6 
antagonists such as tocilizumab are in clinical use, it is imperative that prior to considering their 
potential use following major surgery evidence is available that the increased IL-6 observed in 
this scenario is of significance as a specific mediator of poor clinical outcomes as opposed to 
being a biomarker of a poor clinical outcome (Smolen et al., 2013). In the case of postoperative 
immune suppression our data suggests that although elevated IL-6 levels are associated with 
clinical correlates of immune suppression such as postoperative infectious complications it 
does not play a key role in impairing the antigen presenting capabilities in the postoperative 
period. Interestingly, it has recently been reported that the development of postoperative 
inflammatory complications and infection in particular, is preceded by increased expression of 
TLR4 and TLR5 on an intermediate (CD14++CD16+) monocyte population (Lahiri et al., 2015). 
These same patients displayed higher resting and TLR-stimulated IL-6 levels in the early 
postoperative period in conjunction with enhanced activity in the NF-κB signalling pathway 
(Lahiri et al., 2015). 
 IL-10 plays a pivotal regulatory role in the immune system, classically providing a 
regulatory role, preventing the development of chronic pro-inflammatory states (Saraiva & 
O'Garra, 2010). However in both trauma and major surgery this cytokine is consistently 
upregulated early post-insult (Mokart et al., 2002). These elevations may be induced by 
circulating DAMPS or PAMPS, stimulating IL-10 production either via a TLR (specifically 
TLRs 2, 4 and 9) or TLR-independent pathways in macrophages and myeloid dendritic cells 
(Ng et al., 2013). Following TLR stimulation, activation of adaptor molecules (myeloid 
differentiation primary-response protein 88 (MYD88) and TIR-domain-containing adaptor 
protein inducing IFN-β (TRIF)) occurs (Boonstra et al., 2006) causing triggering of 
extracellular signal-regulated kinases (ERK1 and 2), p38 and NF-κB downstream signalling. 




2006) or ERK inhibitors (Kaiser et al., 2009) affecting IL-10 production. In the in vitro model, 
circulating DAMPS will certainly exist in patient serum and may stimulate IL-10 production 
from healthy monocytes further potentiating the immunosuppressive effects of the IL-10 
already contained in the serum. 
 IFN-γ also plays an important regulatory role in IL-10 production via ERK- and p38-
dependent signalling; with further downstream signalling leading to reduced TLR-induced IL-
10 production via inhibition of the IL-10 promoter (Hu et al., 2006). This pathway may be one 
of the secondary mechanisms observed in vitro.  
 In this cohort elevated IL-10 levels are associated with clinical correlates of immune 
suppression such as postoperative infectious complications as well as a reduction in mHLA-DR 
antigen density. A previous study in a septic cohort of patients described HLA-DR molecules 
being re-endocytosed and retained intracellularly in monocytes, with their data suggesting that 
this phenomenon is partially mediated by IL-10 (Fumeaux & Pugin, 2002). This phenomenon 
may partly explain our findings as IL-10 is known either directly (and indirectly via antigen 
presentation cells) to inhibit T-cell responses (Mittal & Roche, 2015) thus increasing patients’ 
susceptibility to postoperative nosocomial infection.  
 Our results indicate that both IFN-γ and GM-CSF independently restore HLA-DR 
expression in affected monocytes. There are conflicting reports in the surgical literature on the 
effect of postoperative IFN-γ administration. In patients with colonic cancer IFN-γ appears to 
increase HLA-DR expression on PBMCs (Wiesenfeld et al., 1995) whereas in other patients 
undergoing gastrointestinal surgery IFN-γ administered as part of in vitro experiments failed to 
reconstitute defective pro-inflammatory cytokine production (Wiesenfeld et al., 1995). In the 
literature there is limited evidence of GM-CSF administration to perioperative patient cohorts, 
however there is an increasing evidence basis for targeted GM-CSF treatment in sepsis with a 




increases in pro-inflammatory cytokine productions, reductions in ventilator days and ICU stay 
(Mathias et al., 2015; Meisel et al., 2009). 
 Our data demonstrates that the in vitro administration of IFN-γ and GM-CSF can 
reverse features of defective antigen presenting capacity following major surgery in patients 
both with and without cancer. Our use of a well-validated, standardised biomarker of immune 
suppression (mHLA-DR) of particular relevance in the prediction of septic complications 
enhances the potential clinical applicability of these results (Docke et al., 2005; Gouel-Cheron 
et al., 2012; Meisel et al., 2009). Further mechanistic work is required to identify the 
downstream pathways mediated. 
 There are a number of inherent strengths to this Chapter. We have studied a clinically 
relevant at-risk population selected by using age over 45 years old as an inclusion criterion. 
This ensures that the event rate of our primary outcome, infectious complications following 
elective surgery, is sufficiently high at 38% and is in keeping with recent data from similar 
cohorts (Pearse et al., 2014). As all patients were undergoing elective surgery this allows each 
patient in the in vitro analysis to act as their own control. This is important as a significant 
number of these patients had a diagnosis of cancer or were immunocompromised and the use of 
healthy control serum as a comparator would be inappropriate. Finally, we describe a relatively 
novel method of identifying perioperative immune suppression by culturing healthy monocytes 
in postoperative serum in conjunction with the well-validated methodology of defining immune 
suppression by observing a decrease in mHLA-DR expression (Fumeaux & Pugin, 2002; 
Meisel et al., 2009). 
 Limitations of this Chapter include; not assaying circulating IFN-γ protein levels in the 
postoperative period and the wide variability in the surgical procedures performed resulting in a 
heterogeneous patient population. We chose not to assay circulating IFN-γ protein levels due to 
the insensitivity of the IFN-γ assay in clinical conditions where in our experience IFN-γ levels 





 IL-6 and IL-10 levels increase following major surgery and higher levels are associated 
with an increased susceptibility to postoperative infections. Serum obtained from postoperative 
patients induces an immunosuppressive response through IL-10 dependent but IL-6 
independent pathways, which is reversible with IFN-γ or GM-CSF administration. Although, 
increased IL-6 levels may be useful as a biomarker of impending infectious complications our 
data do not support a causal relationship. Further studies will be required to define the 











6.1  The Novel Findings Of This Thesis 
6.11  The Targeted Th cell Transcriptomic Response To Trauma & Major 
Abdominal Surgery 
 Chapters three and four begin by describing the hyper-acute (<two hours) and acute 
(<24 hours) transcriptomic changes that take place following severe polytrauma and major 
abdominal surgery, respectively. Specifically, when comparing whole blood mRNA expression 
of targeted Th cell cytokines and transcription factors from a cohort of healthy controls to those 
suffering severe polytrauma, it is apparent in the latter that there is a well-developed 
inflammatory response that is already present on admission. The hyper-acute elevation of the 
prototypical anti-inflammatory cytokine IL-10 implies that there is a strong immunosuppressive 
component to this. This is compounded by hyper-acute reductions in other classically pro-
inflammatory Th cell related cytokines and transcription factors, interestingly with the 
exception of a hyper-acute rise in IFN-γ mRNA. At 24 hours this immunosuppressive picture 
continues with the IL-10 mRNA levels peaking, and all other assayed cytokines and 
transcription factors falling below the levels assayed in the healthy control cohort. Although 
this upregulation of IL-10 with adaptive immune suppression has been demonstrated on 
analysis of the leukocyte transcriptome in the seminal ‘Genomic Storm’ paper (Xiao et al., 
2011). These data were however assayed at a less homogeneous and significantly a much later 
time point following injury (<12 hours), meaning that large numbers of the patients had 
received extensive resuscitation or emergency surgery prior to their initial blood sample. These 
data discussed in the thesis also reflect a more up to date resuscitation practice, which now 
minimises the use of use of clear fluids. 
 Interestingly, in the cohort of major surgical patients, postoperative whole blood 
mRNA sampling at 24 hours, using the same selection of cytokines and transcription factors, 
showed a similar rise in IL-10 with downregulation of Th1 and Th17 pathways. The similarities 




mediated DAMPS released into the circulation, as there was no evidence of shock or 
ischaemia-reperfusion injury in the major abdominal surgical cohort.  
It is very significant that the magnitude of the early anti-inflammatory response or 
indeed the failure to mount or maintain a pro-inflammatory response was closely associated 
with the acquisition of subsequent infections in both cohorts, and with death in the trauma 
cohort. In both cohorts, patients suffering nosocomial infection had longer durations of hospital 
stay, with higher incidences of multi-organ failure in the trauma cohort.  
6.12  The Influence Of Allogeneic Transfusion On The Th Cell transcriptome In 
Trauma & Major Abdominal Surgery 
The subsequent aspects of Chapters three and four then described the influence that 
allogeneic blood transfusion has on whole blood transcriptome. Allogeneic transfusion, a 
commonly administered treatment in both trauma and elective major abdominal surgery 
cohorts, has long been associated with immunomodulatory effects (Rohde et al., 2014), (Figure 
6.1). However there has been little descriptive in vivo evidence of how transfusion may 
modulate the immune system, particularly in severe polytrauma where patients often receive 
significant volumes of blood products. In the trauma cohort patients were dichotomised into 
two groups based on whether they received a transfusion or not, prior to their admission sample 
(immediate transfusion), or prior to their 24 hour sample (early transfusion). We found that a 
specific pattern of altered gene expression is apparent within two hours of the injury and that 
the immunosuppressive nature of this response is exacerbated by the transfusion of blood. A 
similar picture was seen at the 24 hour sampling point with allogeneic transfusion suppressing 
the pro-inflammatory gene expression profile while simultaneously increasing IL-10 gene 
expression. Although those patients transfused had an increased severity of injury and shock 
state, multivariate models, aimed to account for confounding variables, implied the 




incidence of nosocomial infection, specifically blood stream infections, and an increased risk of 
death in those patients transfused prior to their 24 hour blood sample.  
 The role of allogeneic transfusion was also investigated in the perioperative cohort, 
demonstrating that those patients receiving a perioperative blood transfusion following major 
gastrointestinal surgery displayed patterns of gene expression consistent with greater 
immunosuppression when compared with a cohort not receiving a blood transfusion (Figure 
6.1). Again this observation was independent of variables descriptive of the extent of tissue 
injury. These patients also had an excess of postoperative infectious complications when 
compared with patients who did not receive a blood transfusion.  
 Following on from describing the influence of allogeneic transfusion, the final aspects 
of Chapter three investigated the effects of the duration of storage of PRBCs. There has been 
considerable interest in literature regarding the role that age related storage lesions of stored 
blood play in modulating the immune response. We identified that patterns of altered gene 
expression consistent with greater immunosuppression were associated with the transfusion of 
older PRBCs. These data suggested a reduced activity in the pro-inflammatory Th1 and Th17 
pathways with reductions in the gene expression of the prototypical Th1 polarising cytokine, 
IL-12, the Th17 promoting cytokine, IL-23, and the Th17 specific transcription factor RORγt.  
 In addition, with increasing age of transfused PRBCs there was also increased 
expression of the apoptotic and anti-inflammatory gene, TGF-β. This further points to the 
immunosuppressive nature of the response observed following the transfusion of older PRBCs, 
despite more recent RCTs in sepsis (Lacroix et al., 2015) and cardiac surgery (Steiner et al., 
2015) pointing to equivalence between ‘younger’ and ‘older’ blood transfused. However a 
recent systematic review article (Ng et al., 2015) incorporating trauma patients suggested that 
there may still be an increased risk of nosocomial infection with the transfusion of ‘older’ 






Figure 6.1 - Pathways of immune activation following tissue damage 
Tissue damage leads to the release of Damage Activated Molecular Patterns (DAMPs) into the circulation, in this case illustrated 
by high-mobility-group box (HMGB) 1 and mitochondrial DNA (mtDNA), causing activation of pattern recognition receptors 
(PRRs). DAMPs also independently activate neutrophils, monocytes and dendritic cells. Activation of PRRs causes the triggering 
of signalling pathways and transcription factors such as NF-kB. NF-kB then translocates to the nucleus, promoting cytokine gene 
transcription. Protein translation results in the secretion of cytokines and chemokines.  
Postoperatively, increases in neutrophils, monocytes and natural killer (NK) cells are seen along with later decreases in CD4+ and 
CD8+ T-cells. IL-6 and IL-10 consistently increase during this phase and IL-10 is associated with downregulation of HLA-DR 
expression on the surface of circulating monocytes. Immunosuppressive Treg cells and myeloid derived suppressor cells (MDSCs) 
increase postoperatively. MDSCs cause T-cells suppression via the secretion of reactive oxygen species (ROS), arginine-1 as well 
as the immunosuppressive cytokines, IL-10 and TGF-β, amongst other mechanisms. Treg cells are known producers 
immunosuppressive cytokines; IL-10, TGF-β and IL-4. 
The transfusion of blood and blood products is known to contribute to this immunosuppressive environment, while anaesthetics 
and opioids cause increase T-cell apoptosis, impair neutrophil phagocytosis and suppress NK cells suppression. Anaesthetics 




6.13  HLA-DR Expression On In Vivo Monocytes & Cultured Healthy Control 
In Vitro Monocytes, Strategies For In Vitro Reversal Of Immunoparalysis. 
 In the final results Chapter (five) we determined plasma levels of IL-6 and IL-10 
protein via ELISA in high-risk patients undergoing major abdominal surgery, describing an 
independent association between higher postoperative levels of both cytokines and later 
acquisition of nosocomial infection. Using a standardised international protocol (Docke et al., 
2005) we have shown that at 24 and 48 hours postoperatively there is a marked reduction in the 
density of HLA-DR receptors on patient monocytes. This widely published, internationally 
standardised, measure of immune competence validates the previous statements alluding to the 
immunosuppressive nature of the gene expression patterns in earlier Chapters.  
 Although the previous data described in this Chapter have been described in smaller 
cohorts, the functional aspects of these cytokines on healthy monocyte HLA-DR expression 
have not. Consequently we demonstrated that serum collected in the postoperative period 
contains soluble mediators, which reduce the antigen presenting capabilities of healthy 
monocytes. Our data suggests that IL-10, but not IL-6, dependent pathways are one of the 
essential mediators of this immune suppressed phenotype (Figure 6.1). Treatment with IFN-γ 
and GM-CSF in vitro reverses the induced deficit in the antigen presenting capabilities of 
monocytes exposed to postoperative serum. This opens up the possibility of these licenced 
immune-stimulants being used to treat perioperative patients in a targeted manner.  
6.2  Strengths Of This Thesis 
6.22  Trauma Research Infrastructure At The Royal London Hospital 
 One of the major factors that was central to the success of this thesis was the 
infrastructure that was already in place prior to my commencing this investigation. The Royal 
London Hospital is recognised as one of the UK leaders in terms of polytrauma research. The 




sampling window, has clear advantages in defining early immunological changes secondary to 
the tissue damage and shock, that was previously unavailable in the rest of the world. To 
facilitate this there is a research fellow rota, which operates from 08:00 to 20:00. This allows 
the systematic recruitment of all trauma patients eligible to be included in ACIT2. Although the 
ACIT2 recruitment model has now extended to national as well as international partners, this 
investigation utilised samples recruited solely from the RLH. As a consequence, all trauma 
patients were recruited within a single centre, with standardised pre-hospital care and 
resuscitation protocols. These protocols did not evolve during the recruitment phase discussed 
in this thesis. 
 The use of professional consent allows the systematic inclusion of all patients deemed 
eligible for recruitment by the trauma team leader. Great care is taken to ensure that patients or 
their LAR are approached as soon as appropriate after the acute phase of their admission. When 
professional consent has initially been given, only a small number of patients or relatives refuse 
participation when later approached for written consent, any that did were excluded from 
analysis. One of the most important qualities of the thesis is the strength of the clinical follow 
up conducted by the trauma research team. A daily ward round is performed to ensure that 
outcomes were collected prospectively; at that point patient consent or assents for samples 
obtained under professional consent were obtained and relevant temporal blood testing was 
performed.  
 A common criticism levelled at trauma research is survival bias; this is particularly 
relevant in coagulopathy research where patients receiving the ‘optimal’ ratios of PRBCs to 
FFP may not have been as severely injured as those who required large volumes of PRBCs to 
maintain an adequate MAP. As a result, in this cohort all patients were included in the analysis, 
despite their outcome, meaning that, despite the observational nature of the study design, 




6.23  Perioperative Research Infrastructure At The Royal London Hospital 
 Perioperative research at the Royal London Hospital is also internationally renowned, 
due to the work of Professor Rupert M Pearse. As a result it recruits patients not only for in-
house-designed studies, which often have national and international arms, but it also acts as a 
UK site for large international studies conceived outside the group. The wide diversity of 
surgeries performed at Barts Health NHS trust means that a homogenous population of specific 
surgeries (for instance high-risk, major abdominal surgery) can be recruited in a short period of 
time.  
 Due to funding from the Barts Health Comprehensive Local Research Network 
(CLRN), as well as from other independent funding streams, there is a cohort of highly skilled 
research nurses who screen, consent, take bloods and follow up the patients for the duration of 
their admission. As all surgery is elective, there are not the same consent issues and a timely 
informed consent can be obtained prior to surgery.  
6.24  Experimental Methodologies 
 Due to the symbiotic relationship between Barts Health NHS trust and Bart & the 
London School of Medicine & Dentistry the transfer of clinical samples, technical analysis, as 
well as scientific advice was available by collaboration with core centres or other research 
groups. For the genomic analysis prior to extraction of total RNA conversations took place with 
the Genome Centre, William Harvey Research Centre as well as Professor Julian C Knight’s 
Group at the Wellcome Trust Centre for Human Genomics, Oxford as to best research practice. 
This allowed us to extract total RNA from all samples, permitting mRNA analysis as well as 
later (ongoing) analysis of smaller non-coding RNA for epigenetic analysis. Gene expression 
with the Taqman system is a well-validated and reproducible protocol, as the 384 well plate 
preparation was carried out by robot, which also minimised pipetting error. The analysis of 
protein concentration via ELISA assay was performed in a well-validated, reproducible manner 




international standardised protocol that is widely used in the published literature as a marker of 
immune competence. Due to the study design in the perioperative cohort, with each patient 
acting as their own control, this allowed accurate inferences to be made when incubating pre 
and postoperative serum on pooled healthy donor PBMCs. This then accounted for their 
individual premorbid comorbidities such as the preoperative diagnosis of cancer, diabetes or 
preoperative immunosuppression via paired statistical analysis. In the trauma cohort the use of 
a healthy control population with whole blood total RNA gathered in the same manner 
provided a valid comparator. Although this required the use of a separate set of ethics, this, we 
felt, provided a more robust control than recruiting minor injured patients (ISS<4) who will still 
have a degree of systemic immune activation following injury. 
6.25  Statistical Analysis 
 Statistical analysis was carried out by myself and Dr Michael J O’Dwyer (primary 
Ph.D. supervisor) with consultation from the perioperative medicine group in-house statistician 
Ms Tahania Ahmad and Dr John R Prowle, a renal intensivist with a comprehensive statistical 
background. Missing data is an unfortunate hazard of clinical research, however every effort 
was made by me to minimise this by requesting and reviewing the original patient case notes, 
allowing a more complete data set to be analysed. In the case of the trauma cohort, due to the 
severity of the injuries that these patients suffered a small minority, 9 patients (8%), did not 
survive to the 24 or 72 hour sampling time points. As one of the primary aims of the thesis was 
to examine the acute changes in gene expression on targeted Th cell inflammatory pathways 
following polytrauma it was important that all eligible patients were included. In the case of the 
perioperative cohort the data set and sample bio-bank was much more complete. 
 Variables were analysed preferentially as continuous variables without dichotomising 
them. If variables were dichotomised then these were based on standardised definitions such as 
the presence of shock on admission (Davis et al., 1991; Spahn et al., 2013) or the presence of 




was performed on all variables thought likely to play a clinical role in the process, with those 
recording a P-value of <0.1 being included in the model. All P-values were reported as un-
corrected to allow comparison between the differing models in each Chapter.  
6.3  Weaknesses Of This Thesis 
6.31  Introduction  
 The limitations of each individual Chapter have been discussed in the relevant sections, 
however there are some broad overarching weaknesses that require further clarification. 
6.32  Study Design In The Trauma Cohort 
 ACIT2 is a study that was primarily designed to examine the hyper-acute and acute 
effects of ATC and Trauma Induced Coagulopathy (TAC). As a consequence the sampling 
times, as well as the samples that are collected, are designed primarily address these 
coagulopathy-based research questions. Following the results generated from this thesis and the 
more in depth genomic analysis that is ongoing there is a move to alter the blood draw to 
initially; capture the immunological response more comprehensively with the isolation PBMCs 
for flow cytometry analysis in order to undertake in vitro work on the collection of serum 
(rather than citrated plasma) for cell based models. There is also a move towards the 
implementation of later blood sampling points in order to capture more accurately the changes 
to the adaptive arm of immune system and more closely monitor the immune systems of 
patients when they are suffering from persistent MODS on the critical care unit. 
 As has been demonstrated in the perioperative aspects of this thesis, tissue damage in 
the absence of shock profoundly affects the human immune system. In the introduction of this 
thesis our current understanding of the consequences of general anaesthesia, temperature 
control as well as the influences of the numerous therapeutics that are administered during this 
period as well as on the critical care unit and their affect on the immune response are outlined. 




be dedicated to recording these influences allowing later research to address more holistically 
the inflammatory paradigm. 
6.33  Study Design In The Perioperative Cohort 
 In the perioperative cohort, due to the fact that samples were drawn from patients 
enrolled in a study designed to detect postoperative rises in Troponin T (Vascular Events In 
Noncardiac Surgery Patients Cohort Evaluation Study et al., 2012), these pre-defined sampling 
time points meant that we were unable to examine the hyper-acute response to major abdominal 
surgery. As a consequence, on analysing these limited time points we may have missed hyper-
acute rises in the assayed genes, such as the IFN-γ peak that was seen in the trauma cohort. 
However, following on from these data, a study designed specifically to examine the 
relationship between immunological changes following major abdominal surgery and the 
acquisition of late nosocomial infection began recruiting in May 2015. To date this has 
recruited over 100 patients, with the first 50 patients being sampled at a hyper-acute 2-6 hour 
time period following abdominal closure. We await the analysis of these data. The instigation 
of a study purely designed to address inflammation means that similar concerns that were 
discussed with the ACIT2 study, such as sample types, are addressed in this cohort 
6.33 Data Collection 
 In the context of an observational study a balance has to be met with a level of data that 
can be pragmatically (accurately) collected and the utility of the data. As has already been 
highlighted in this thesis the research discussed here was carried out as two sub-studies of two 
large international observational studies not primarily designed to address the immunological 
consequences of tissue damage or shock. As a result as discussed in the introduction of this 
thesis, the immune system is clearly influenced by a multitude of factors with a number of 
these factors perhaps not adequately represented with the current data collection constraints. 
Some clear aspects that require better clarification and documentation in the future are the 




emergency) trauma surgery) and transfusion triggers for perioperative transfusion as well as 
transfusion on the critical care unit as these are aspects of care that are not protocolled and as a 
result are left to the discretion of the consultant anaesthetist or intensivist. This is in stark 
contrast to the pre-hospital care that trauma patients receive which is heavily standardised and 
protocolled. Other factors that have been added to the clinical research form for the novel study 
include measures of temperature, a preoperative risk score and the use of perioperative 
dexamethasone or catecholamines. In both cohorts the value of neutrophil: lymphocyte ratios 
and neutrophil: monocyte ratio was assessed as this had been suggested as a valuable predictor 
of poor outcome in both perioperative cohorts and trauma cohorts. Unfortunately no signal was 
detected, this may be in part due to the low patient numbers when compared to previously 
published studies (Salciccioli et al., 2015). 
 Outcome scoring is another aspect that can be improved upon. It is now simply not 
enough to report mortality or length of stay in RCTs so more detail is clearly required in 
hypothesis generating observational studies. The recording of organ dysfunction particularly in 
trauma is important but its measurement is complicated by an often-coexisting TBI. In order to 
maximize cerebral perfusion pressure thus aiming to prevent secondary brain injury patients 
often will be placed on large doses of noradrenaline to drive up their MAP. This means that 
when using SOFA as a measure of organ dysfunction this will lead to a skewing of the scores 
as the patient may have no cardiovascular organ failure (as assessed by MAP and noradrenaline 
dose, outlined in Supplementary Table 3) yet will be scored incorrectly as having not only a 
single organ failure (TBI) but also suffering from multi organ failure. The scoring of lung 
injury is again an aspect that can be improved upon in the context of trauma patients. As has 
been previously discussed, with the preponderance of western trauma being blunt, many 
patients will present with pneumothoraces, haemothoraces or lung contusions or a combination 
of all of three of these pathologies. This then makes the interpretation of chest radiographs and 
CTs problematic, as it is not clear if infiltrates are secondary to the initial traumatic injury or 




routinely by the trauma group a decision was made to characterise patients as having the 
presence or absence of ARDS through their respiratory SOFA score, essentially their PaO2 FiO2 
(P/F) ratio with those recording a P/F ratio of ≤26.7 (kPa) for a period of ≥48 hours being 
classified as having ARDS. The limitations of this as an accurate measure of true ARDS in the 
absence of the classification via the Berlin definition is acknowledged. In future studies data 
collection has improved in order to fully classify patients as mild, moderate or severe ARDS 
based on the much more robust Berlin criteria (Force et al., 2012). 
6.34  Experimental Techniques 
 Due to funding constraints at the start of the project concessions were made regarding 
the extent of the initial genomic analysis, which was to be performed on the samples available. 
As a consequence a more frugal targeted approach was selected, examining a series of markers, 
which were felt to represent temporal T-helper cell differentiation. If greater amounts of 
funding had been available initially a more systematic approach would have been favoured 
either utilising a targeted gene array chip to examine a more complete selection of adaptive 
genes, a genome wide array in the same manner as utilised in the genomic storm paper (Xiao et 
al., 2011) or RNA sequencing techniques. Interestingly, following the successful genomic data 
outlined in this thesis, funding was made available to carry out genome wide gene expression 
using an array chip on a number of the mRNA samples isolated from patients included in this 
body of work. Further details regarding this are briefly outlined in the further work aspect of 
this Chapter. With the commencement of a novel study aiming to describe the temporal 
immunological response following major abdominal surgery a more systematic quantification 
of gene expression will also be possible in the perioperative cohort allowing novel analysis of 
the hyper-acute inflammatory changes with the 2-6 hour postoperative sampling point. 
 PAXgene® tubes are a highly reliable product for the collection and storage of whole 
blood total RNA, however they are limited by what they are actually collecting, whole blood 




which are demonstrated to be expressed at stable levels in these patients we were able to correct 
for the effect of relative changes in the total leukocyte population in individual whole blood 
mRNA samples (Vandesompele et al., 2002). However, due to the fact that there are disparities 
in the differential leukocyte count, such as 24 and 72 hour sampling points, a neutrophilia and 
simultaneous lymphopenia, we cannot exclude the possibility that the observed changes in 
mRNA levels are explained, at least in part, by alterations in the relative abundance of specific 
leucocyte subpopulations collected in the whole blood samples from which the RNA was 
extracted for this study (Laudanski et al., 2006). A paired full blood counts sample is sent to 
the clinical laboratory with each blood draw, which gives data on the differential leukocyte 
count. In an attempt to account for the potential lymphopenia it was discussed as to whether 
there was validity in dividing the gene expression values by the paired lymphocyte count, of 
those lymphocyte specific cytokines and transcription factors, in an attempt to obtain a gene 
expression value independent of any co-existing lymphopenia. Despite extensive discussions 
with colleagues and literature searches we have been unable to find a study that utilises this 
methodology and validates this potential methodology. In the case of the ongoing analysis of 
whole blood mRNA genome wide gene expression array in order to account for the variability 
of the leukocyte subpopulations a novel algorithm is employed (Abbas et al., 2005; Zhong et 
al., 2013). This algorithm aims to extract cell-specific gene expression signatures allowing 
whole blood mRNA or mixed tissue samples to be analysed as though they had been FACS 
sorted. This is an exciting and novel experimental technique. 
6.4  Further Work 
 In order to continue this research stream data generated from this thesis and from 
ongoing postdoctoral work has been used in the application for grants to further both the 




6.4.1  Trauma Research 
6.4.1.1 Genomics 
 As has been previously alluded to there have been expansions in the genomic research 
streams due to the promising pilot data generated as part of this thesis. A more homogenous 
cohort of patients with or without multi-organ dysfunction, all suffering blunt polytrauma in the 
absence of TBI, have undergone genome wide gene expression array (Illumina HumanHT-12 
v4 Expression BeadChip) analysis in order to examine more completely the temporal peripheral 
immunological response. These data describe a focused leukocyte response involving only 4% 
of the transcriptome within the hyper-acute time window, rapidly blossoming to a full 20% of 
the whole leukocyte genome at 24 hours, when compared to controls with minor injuries 
(ISS<4). On further analysis, utilising the IRIS system (Abbas et al., 2005), demonstrated 
changes in innate lymphoid cell populations, specifically NK cells. As a result ongoing 
collaborative work led by Dr Joanne Shepherd will focus on the mechanistic role that NK cells 
play in the pathology of protracted multi-organ dysfunction. 
6.4.1.2 Epigenomics 
 As total RNA was extracted from the PAXgene® tube, this permitted not only the 
analysis of mRNA but also non-coding RNAs such as miRNAs. In order systematically to 
characterise the expression levels of both circulating and intracellular miRNAs following 
severe polytrauma miRNA 100 patients were selected at two time points (0 and 24 hours), 50 
suffering a pneumonia and 50 not. miRNA sequencing was performed using the Illumina 
HiSeq2500. Following this the sequences were aligned to the human GRCh37 reference 
genome with functional enrichment analysis performed using Ingenuity Pathway Analysis on 
all miRs reaching an adjusted p value of <0.1. The complementary mRNA targets of interest 
were identified using miRBase and TargetScan (www.mirbase.org, www.targetscan.org). 
Ingenuity Pathway Analysis highlighted Cancer, Haematological Disease, Immunological and 




altered between infected and non-infected patients. A more in-depth bioinformatics analysis as 
ongoing directed by Dr Michael Barnes and Dr Timothy F Jones. 
In addition to this there is ongoing work examining the role of genome wide methylation 
of peripheral leukocytes and the influence that this has in enhancing the susceptibility to 
nosocomial infection. 
6.4.1.3 Flow Cytometry 
 Following the description of the acute changes in mHLA-DR expression resulting from 
major abdominal surgery a cohort of 12 consecutive patients requiring ICU admission were 
recruited to identify if similar changes occurred following severe polytrauma.  
 In addition to the characterisation of mHLA-DR expression on a larger cohort of 
trauma patients a systematic approach to the immunophenotyping and sorting of peripheral 
leukocytes has commenced. The panels are based on proposed methodologies to standarise the 
markers used for the identification of human leukocytes (Maecker et al., 2012). This Work is 
being continued by Dr Joanne Shepherd. 
6.4.1.4 In Vitro Work 
Work is on going to replicate the findings outlined in Chapter five, but in a severe 
polytrauma cohort. Healthy CD14+ cultured cells are additionally being sorted following flow 
cytometry (mHLA-DR) interrogation to allow later downstream targeted gene expression analysis 
after culture in the differing environments described in Chapter five. There is also the potential to 
assess the influence of trauma or perioperative PBMCs, their response to either healthy control 
serum to see if they spontaneously re-express HLA-DR molecules after removal from the 
proposed immunosuppressive environment as well as culture with immune stimulants to assess 




6.4.2 Perioperative Research 
6.4.2.1  Biomarker Based Identification of Nosocomial Infectious Complications (BIONIC) 
 As had been alluded to earlier in this Chapter a novel observational study has 
commenced recruiting elective major abdominal surgical patients at the RLH since May 2015. 
The inclusion criteria is similar to the cohort of patients analysed in Chapters four and five of 
this thesis, with the first 50 patients recruited undergoing sampling at 2-6 hour point, following 
abdominal closure. This will allow capture of the hyper-acute inflammatory response that was 
lacking in the previous investigations described in this thesis. In addition to the routinely 
collected citrated plasma, buffy coats, serum and PAXgene® tubes, EDTA anticoagulated 
blood was drawn and stained <one hour from blood draw for the immediate quantification of 
mHLA-DR expression pre and postoperatively. The interim data analysis of the first 80 patients 
recruited demonstrated that initially there were marked changes in the mHLA-DR expression 
levels as early as 2-6 hours postoperatively. At 24 hours there was a difference between those 
who went on to acquire a postoperative nosocomial infection and those who remained infection 
free. This phenomenon became more profound at the 48 hour sampling time point.  
 
6.5  Conclusions 
 This thesis has completed all the previously defined aims. It has provided novel 
experimental data; with large amounts already being published in leading speciality peer 
reviewed journals. It describes a significant host immune response, which occurs immediately 
following significant tissue damage that is dominated by features of immune suppression. 
Allogeneic blood transfusion appears to have a distinct, additive effect in both severe 
polytrauma and perioperative care. Finally the thesis finally identifies a potential role for 
targeted treatment with currently licenced immune stimulants (IFN-γ and GM-CSF) as well as 




nosocomial infections. Work is continuing in both the fields of trauma and perioperative 
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Supplementary Figure 1 - 
The relationship between 
IL-10 expression and injury 
severity (ISS) 
All results are expressed as a relative 
quantification ratio between candidate 
and reference genes. 
 
Supplementary Figure 2  - 
Efficacy of IL-6 blocking 
antibody 
Changes in IL-6 protein 
concentration when postoperative 
serum was cultured in the presence 
or absence of an IL-6 blocking 
antibody. All data displayed as 





Supplementary Tables  
 
Supplementary Table 1 - Screening protocols for ACIT2 
Exclusion criteria 
 
E1 The patient is <16 years old 
 
E2 The patient has been transferred from another hospital 
 
E3 More than 2 hours has elapsed from the time of injury 
 
E4 Received more than 2000ml fluids 
 
E5 Patient has suffered >5% burns BSA 
 
E6 Known severe liver disease 
 
E7 Known bleeding abnormality/coagulation drugs 
 
E8 The trauma team leader deems the patient inappropriate for the trial 
 
Other reason(s) why the patient was not recruited 
 
R1 Unable to attend call 
 




R4 Unable to gain access for blood sample 
 






Supplementary Table 2 - Calculation of the Injury Severity Score (ISS) 
 
 





Anatomical Regions Abbreviated Injury Score (AIS) 




Head & Neck 
 
1 – Minor 
Taking the top 
three AIS scores, 
square each one 
and add them 
together to obtain 
a score out of 75 
Face 2 – Moderate 
Chest 3 – Severe (Non life-threatening) 
Abdominal or pelvis 
contents 4 – Severe (Life-threatening) 
Extremities or pelvic 
girdle 5 – Critical (Survival uncertain) 
External   
SOFA Score 0 1 2 3 4 
PaO2 / FiO2 (kPa) >53.3 ≤53.3 ≤40 ≤26.7 ≤13.3 
Platelets ≥150 <150 <100 <50 <20 
Bilirubin µmol/L <20 20-32 33-101 102-204 >204 
CVS MAP≥70 MAP<70 Dopamine ≤5 














GCS 15 13-14 10-12 6-9 <6 






















Infection site Definition 
  










Laboratory-Confirmed Bloodstream Infection (LCBI) must meet at least 1 of 
the following criteria: 
1. Patient has a recognized pathogen cultured from 1 or more blood cultures. 
AND organism cultured from blood is not related to an infection at another site. 
2. Patient has at least 1 of the following signs or symptoms: fever (>38°C), chills, or 
hypotension. 
AND signs and symptoms and positive laboratory results are not related to an infection 
at another site. 
AND common skin contaminant is cultured from 2 or more blood cultures drawn on 
separate occasions. 
 
Secondary Bloodstream Infection (BSI) 
In a patient suspected of having an infection, blood and a site-specific specimen are 
collected for culture and both are positive for at least one matching organism. If the site-
specific culture is an element used to meet the infection site criterion, then the BSI is 




Pneumonia requires any 1 of the following:  
1. Rales or dullness to percussion on physical examinations of chest 
AND any of the following: 
A. New onset of purulent sputum or change in character of sputum. 
B. Isolation of organism from blood culture. 
C. Isolation of pathogen from specimen obtained by trans-tracheal aspirate, bronchial 
brushing, or biopsy. 
2. Chest radiography showing new or progressive infiltrate, consolidation, cavitation, or 
pleural effusion. 
AND any of the following: 
A. New onset of purulent sputum or change in character of sputum. 
B. Isolation of organism from blood culture. 
C. Isolation of pathogen from specimen obtained by trans-tracheal aspirate, bronchial 
brushing, or biopsy. 
D. Isolation of virus or detection of viral antigen in respiratory secretions. 
E. Diagnostic single antibody titre (IgM) or fourfold increase in paired serum samples 
(IgG) for pathogen. 
















A superficial incisional SSI must meet the following criterion:  
Infection occurs within 30 days after the operative procedure. 
AND involves only skin and subcutaneous tissue of the incision. 
AND patient has at least 1 of the following: 
A. Purulent drainage from the superficial incision. 
B. Organisms isolated from an aseptically obtained culture of fluid or tissue from the 
superficial incision. 
C. At least 1 of the following signs or symptoms of infection: pain or tenderness, 
localized swelling, redness, or heat, and superficial incision is deliberately opened by 
surgeon and is culture positive or not cultured. A culture-negative finding does not 
meet this criterion. 
D. Diagnosis of superficial incisional SSI by the surgeon or attending physician. 
 
A deep incisional SSI must meet the following criterion: 
Infection occurs within 30 days after the operative procedure if no implant is left in 
place. 
AND involves deep soft tissues (eg, fascial and muscle layers) of the incision. 
AND patient has at least 1 of the following: 
A. Purulent drainage from the deep incision but not from the organ/space component 
of the surgical site. 
B. A deep incision spontaneously dehisces or is deliberately opened by a surgeon and 
is culture-positive or not cultured when the patient has at least 1 of the following signs 
or symptoms: fever (>38°C), or localized pain or tenderness. A culture-negative 
finding does not meet this criterion. 
C. An abscess or other evidence of infection involving the deep incision is found on 
direct examination, during reoperation, or by histopathologic or radiologic 
examination. 






A symptomatic urinary tract infection must meet at least 1 of the following 
criteria: 
1. Patient has at least 1 of the following signs or symptoms with no other recognized 
cause: fever (>38°C), urgency, frequency, dysuria, or suprapubic tenderness. 
AND patient has a positive urine culture, that is, ≥105 microorganisms per cc of urine 
with no more than 2 species of microorganisms. 
2. Patient has at least 2 of the following signs or symptoms with no other recognized 
cause: fever (>38°C), urgency, frequency, dysuria, or suprapubic tenderness. 
AND at least 1 of the following: 
A. Positive dipstick for leukocyte esterase and/or nitrate. 
B. Pyuria (urine specimen with ≥10 white blood cell [WBC]/mm3 or ≥3 WBC/high-
power field of unspun urine). 
C. Organisms seen on Gram's stain of unspun urine.  
D. At least 2 urine cultures with repeated isolation of the same uropathogen (gram-
negative bacteria or Staphylococcus saprophyticus) with ≥102 colonies/mL in 
nonvoided specimens. 
E. ≤105 colonies/mL of a single uropathogen (gram-negative bacteria or S 
saprophyticus) in a patient being treated with an effective antimicrobial agent for a 
urinary tract infection. 
F. Physician diagnosis of a urinary tract infection. 















Organ/space-Organ/space surgical site infection must meet the following 
criterion: 
Infection occurs within 30 days after the operative procedure if no implant is left in place 
or within 1 year if implant is in place and the infection appears to be related to the 
operative procedure. 
AND infection involves any part of the body, excluding the skin incision, fascia, or 
muscle layers, that is opened or manipulated during the operative procedure. 
AND patient has at least 1 of the following: 
A. Purulent drainage from a drain that is placed through a stab wound into the 
organ/space. 
B. Organisms isolated from an aseptically obtained culture of fluid or tissue in the 
organ/space. 
C. An abscess or other evidence of infection involving the organ/space that is found on 
direct examination, during reoperation, or by histopathologic or radiologic examination. 
D. Diagnosis of an organ/space SSI by a surgeon or attending physician. 
IAB-Intra-abdominal, not specified elsewhere including gallbladder, bile ducts, 
liver (excluding viral hepatitis), spleen, pancreas, peritoneum, subphrenic or 
subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere 
must meet at least 1 of the following criteria: 
1. Patient has organisms cultured from purulent material from intraabdominal space 
obtained during a surgical operation or needle aspiration. 
2. Patient has abscess or other evidence of intra-abdominal infection seen during a 
surgical operation or histopathologic examination. 
3. Patient has at least 2 of the following signs or symptoms with no other recognized 
cause: fever (>38°C), nausea, vomiting, abdominal pain, or jaundice. 
AND at least 1 of the following: 
A. Organisms cultured from drainage from surgically placed drain (eg, closed suction 
drainage system, open drain, T-tube drain). 
B. Organisms seen on Gram's stain of drainage or tissue obtained during surgical 
operation or needle aspiration. 
C. Organisms cultured from blood & radiographic evidence of infection (eg, abnormal 
findings on ultrasound, CT scan, MRI, or radiolabel scans [gallium, technetium, etc] or 








Arterial or venous infection must meet at least 1 of the following criteria: 
1. Patient has organisms cultured from arteries or veins removed during a surgical 
operation. 
AND blood culture not done or no organisms cultured from blood. 
2. Patient has evidence of arterial or venous infection seen during a surgical operation or 
histopathologic examination. 
3. Patient has at least 1 of the following signs or symptoms with no other recognized 
cause: fever (>38°C), pain, erythema, or heat at involved vascular site. 
AND more than 15 colonies cultured from intravascular cannula tip using 
semiquantitative culture method. 
AND blood culture not done or no organisms cultured from blood. 
4. Patient has purulent drainage at involved vascular site. 






















Skin infection (SKIN) 
 
Skin infections must meet at least 1 of the following criteria: 
1. Patient has purulent drainage, pustules, vesicles, or boils. 
2. Patient has at least 2 of the following signs or symptoms with no other recognized 
cause: pain or tenderness, localized swelling, redness, or heat. 
AND at least 1 of the following: 
A. Organisms cultured from aspirate or drainage from affected site; if organisms are 
normal skin flora they must be a pure culture. 
B. Organisms cultured from blood. 
C. Positive antigen test performed on infected tissue or blood (eg, herpes simplex, 
varicella zoster, H influenzae, N meningitidis). 
D. Multinucleated giant cells seen on microscopic examination of affected tissue. 




























0.004 0.02 0.2 0.47 
IL-10 
24HR 
0.014 0.0001 0.0001 .0.4 0.0001 0.0001 0.14 0.03 0.97 
RORγt 
24HR 
0.17 0.05 0.016 0.25 0.08 0.1 0.66 0.1 0.22 
Δ TNF-α 
0-24HR 
0.0197 0.015 0.05 0.043 0.61 0.6 0.61 0.02 0.006 
Δ INFγ 
0-24HR 
0.0062 0.035 0.0002 0.14 0.0001 0.0001 0.13 0.008 0.9 
Δ T-bet 
0-24HR 
0.15 0.03 0.0008 0.037 0.0001 0.0001 0.23 0.057 0.67 
Δ , Signifies dynamic variables, as change in cytokine expression over time period shown. BE, time 0HR base excess. Early Transfusion, transfusion within the first 24HR of 
injury. Immediate Transfusion, transfusion of PRBC prior to 0HR blood draw. ISS, Injury Severity Score. Lactate, time 0HR Lactate. N/A, not applicable. Number of Units, 





Supplementary Table 6 - Multivariate regression analysis for prediction of gene expression following polytrauma 
 
   
Response 
Variable 
Predictor Variables Included in the model Whole  
Model 
R2 














sSBP Lactate BE ISS TBI Age 
 
                   
IL-10  
0HR 
x     x x   0.16 0.04      0.005   
IL-10 
24HR 
x x x  x x  x  0.44 .09  <0.0001*   
 
0.04 
   
RORγt 
24HR 
 x x  x x    0.09   0.01*       
Δ TNF-α  
0-24HR 
x x x x    x x 0.39 0.08 0.05  0.01     0.0008 
Δ INFγ  
0-24HR 
x x x  x x  x  0.004  0.006*        
Δ T-bet  
0-24HR 
 x x x x x  x  0.07  0.7*   0.06     
Multivariate regression analysis of gene expression using transfusion requirements, early blood pressure measurements and selected markers of tissue ischaemia and tissue perfusion. Each x represents an 
individual variable included in the model. These univariate analyses are presented in a Table 4. Selection of variables is described in the methods section. The numbers under ‘Predictors Independently Associated 
With Response Variable’ represent the p-values obtained when the model was run and are indicative of an independent association with the response variable. An empty cell implies that no independent 
association was detected. *, Indicates p-value obtained following backwards elimination. Δ , Signifies dynamic variables, as change in cytokine expression over time period displayed. BE, time 0HR base excess. 
Early Transfusion, transfusion within the first 24HR of injury. Immediate Transfusion, transfusion of PRBC prior to 0HR blood draw. ISS, Injury Severity Score. Lactate, time 0HR Lactate. Number of Units, 














Bacillus cereus 1  
Bacteroides fragilis 1  
Candida albicans 2  
Enterobacter cloacae 2  
Escherichia coli 3  
Klebsiella pneumonia 1  
Moraxella catarrhalis 1  
Pseudomonas aeruginosa 2  
Staphylococcus aureus 3  
All positive blood cultures were reviewed in conjunction with the microbiology department and likely 
contaminants were excluded from the subsequent analysis. BSI, blood stream infection encompassing 
bacteraemias and fungaemias. Patients recorded multiple BSIs as a result all infective organisms 
cultured have been recorded. 
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Predictor Variables on Univariate Analysis for the Model 
Whole 
Model  

















Δ  RORγt 
24 / 0 HR 
r2 = 0.19 
P = 0.003 
 
r2 = 0.09  
P = 0.05 
 
r2 = 0.07  
P = 0.09 
 
r2 = 0.009  
P = 0.58 
 
r2 = 0.02  
P = 0.37 
 
r2 = 0.07  
P = 0.06 
 
r2 = 0.28  
P = 0.01 
P = 0.01 P = 0.36 P = 0.46 x x P = 0.40 
Δ  IL-12  
24 / 0 HR 
r2 = 0.10    
P = 0.03 
 
r2 = 0.03 
 P = 0.26 
 
r2 = 0.05  
P = 0.16 
 
r2 = 0.03  
P = 0.33 
 
r2 = 0.009  
P = 0.52 
 
r2 = 0.09  
P = 0.04 
 
r2 = 0.15  
P = 0.04 
P = 0.05* x P = 0.23* x x P = 0.25†  
Δ  IL-23  
24 / 0 HR 
r2 = 0.10  
P = 0.03 
 
r2 = 0.04  
P = 0.19 
 
r2 = 0.03  
P = 0.30 
 
r2 = 0.003  
P = 0.74 
 
r2 = 0.007  
P = 0.74 
 
r2 = 0.17  
P = 0.005 
 
r2 = 0.22  
P = 0.01 
P = 0.29 P = 0.16 x x x P = 0.11 
Δ  FOXP3  
24 / 0 HR 
r2 = 0.09  
P = 0.04 
 
r2 = 0.0002  
P = 0.93 
 
r2 = 0.0003 
P = 0.91 
 
r2 = 0.03  
P = 0.36 
 
r2 = 0.002  
P = 0.78 
 
r2 = 0.14  
P = 0.01 
 
r2 = 0.16  
P = 0.02 
P = 0.24 x x x x P = 0.06 
Δ  GATA-3 
24 / 0 HR 
r2 = 0.16  
P = 0.007 
 
r2 = 0.02  
P = 0.39 
 
r2 = 0.01 
 P = 0.47 
 
r2 = 0.008 
 P = 0.60 
 
r2 = 0.00003 
P = 0.97 
 
r2 = 0.21  
P = 0.002 
 
r2 = 0.26  
P = 0.002 
P = 0.08 x x x x P = 0.02 
Δ  IL-12  
72 / 0 HR 
r2 = 0.21 
 P = 0.01 
 
r2 = 0.04  
P = 0.27 
 
r2 = 0.004  
P = 0.75 
 
r2 = 0.007  
P = 0.70 
 
r2 = 0.02  
P = 0.48 
 
r2 = 0.12 
 P = 0.07 
 
r2 = 0.24  
P = 0.03 
P = 0.05 x x x x P = 0.31 
Δ  TGF-β 
72 / 0 HR 
r2 = 0.16  
P = 0.03 
 
r2 = 0.006  
P = 0.69 
 
r2 = 0.008  
P = 0.65 
 
r2 = 0.01  
P = 0.58 
 
r2 = 0.006  
P = 0.90 
 
r2 = 0.04  
P = 0.27 
 
r2 = 0.16  
P = 0.03 
P = 0.03 x x x x x 
 
Multivariate regression analysis of gene expression using median age of blood transfused, transfusion requirement, selected markers of tissue injury, tissue ischaemia and age. Each univariate P-value and r2 value is displayed.  
*, Indicates P-value obtained following backwards elimination. †, Indicates P-value obtained prior to exclusion via backward elimination. Δ , Indicates dynamic variables, as change in cytokine expression over time period 
displayed. BD, base deficit (at baseline (admission) and 24HR (24HR after injury). ISS, Injury Severity Score. Quantity of PRBCs transfused, number of units of packed red blood cells (PRBCs) transfused in first 24HR post-






























Δ  RORγt 
24 / 0 HR 
r2 = 0.19  
P = 0.003 
 
r2 = 0.09  
P = 0.05 
 
r2 = 0.07  
P = 0.09 
 
r2 = 0.009 
P = 0.58 
 
r2 = 0.02  
P = 0.37 
 
r2 = 0.07 
P = 0.06 
 
r2 = 0.31 
P = 0.07 
P = 0.06 P = 0.23 P = 0.79 P = 0.97 P = 0.48 P = 0.63 
Δ  IL-12  
24 / 0 HR 
r2 = 0.10 
 P = 0.03 
 
r2 = 0.03  
P = 0.26 
 
r2 = 0.05  
P = 0.16 
 
r2 = 0.03 
P = 0.33 
 
r2 = 0.009  
P = 0.52 
 
r2 = 0.09 
P = 0.04 
 
r2 = 0.20 
P = 0.33 
P = 0.37 P = 0.76 P = 0.13 P = 0.45 P = 0.30 P = 0.13  
Δ  IL-23  
24 / 0 HR 
r2 = 0.10  
P = 0.03 
 
r2 = 0.04  
P = 0.19 
 
r2 = 0.03 
 P = 0.30 
 
r2 = 0.003 
P = 0.74 
 
r2 = 0.007  
P = 0.74 
 
r2 = 0.17 
P = 0.005 
 
r2 = 0.26 
P = 0.16 
P = 0.42 P = 0.31 P = 0.93 P = 0.91 P = 0.47 P = 0.12 
Δ  FOXP3  
24 / 0 HR 
r2 = 0.09  
P = 0.04 
 
r2 = 0.0002  
P = 0.93 
 
r2 = 0.0003 
P = 0.91 
 
r2 = 0.03 
P = 0.36 
 
r2 = 0.002  
P = 0.78 
 
r2 = 0.14 
P = 0.01 
 
r2 = 0.20 
P = 0.02 
P = 0.40 P = 0.38 P = 0.67 P = 0.66 P = 0.86 P = 0.20 
Δ  GATA-3 
24 / 0 HR 
r2 = 0.16  
P = 0.007 
 
r2 = 0.02  
P = 0.39 
 
r2 = 0.01 
 P = 0.47 
 
r2 = 0.008 
P = 0.60 
 
r2 = 0.00003 
P = 0.97 
 
r2 = 0.21 
P = 0.002 
 
r2 = 0.32 
P = 0.06 
P = 0.15 P = 0.27 P = 0.85 P = 0.90 P = 0.81 P = 0.12 
Δ  IL-12  
72 / 0 HR 
r2 = 0.21  
P = 0.01 
 
r2 = 0.04  
P = 0.27 
 
r2 = 0.004 
 P = 0.75 
 
r2 = 0.007 
P = 0.70 
 
r2 = 0.02  
P = 0.48 
 
r2 = 0.12 
P = 0.07 
 
r2 = 0.28 
P = 0.43 
P = 0.17 P = 0.41 P = 0.72 P = 0.81 P = 0.81 P = 0.61 
Δ  TGF-β 
72 / 0 HR 
r2 = 0.16  
P = 0.03 
 
r2 = 0.006 
 P = 0.69 
 
r2 = 0.008  
P = 0.65 
 
r2 = 0.01 
P = 0.58 
 
r2 = 0.006  
P = 0.90 
 
r2 = 0.04 
P = 0.27 
 
r2 = 0.27 
P = 0.45 
P = 0.17 P = 0.45 P = 0.36 P = 0.22 P = 0.85 P = 0.39 
 
Multivariate regression analysis of gene expression using median age of blood transfused, transfusion requirement, selected markers of tissue injury, tissue ischaemia and age. Each univariate P-value and r2 value is 
displayed. Δ , Indicates dynamic variables, as change in cytokine expression over time period displayed. BD, base deficit (at baseline (admission) and 24HR (24HR after injury). ISS, Injury Severity Score. Quantity of PRBCs 











Supplementary Table 10 - Changes in mRNA levels from baseline to 24 hours 
following major abdominal surgery 
  
Gene Median baseline 
mRNA level 




    
IL-10 0.0000859 0.00034 3.96 (+) 
FOXP3 0.00308 0.00136 2.26 (-) 
GATA-3 0.0105 0.00375 2.8 (-) 
IFN-γ 0.00021 0.0000866 2.42 (-) 
IL-12 0.00036 0.00022 1.64 (-) 
T-bet 0.0157 0.00661 2.38 (-) 
TNF-α 0.00737 0.00495 1.49 (-) 
IL-23 0.00093 0.00039 2.38 (-) 
IL-27 0.01 0.0089 1.12 (-) 
RORγT 0.00065 0.00025 2.6 (-) 
TNF-α / IL-10  82.68 14.32 7.3 (-) 
A comparison of the median mRNA levels at baseline and at 24 hours. mRNA levels are a 
relative quantification ratio between the candidate and the reference genes. (+), increasing 




Supplementary Table 11 - Multivariate linear regression analysis for prediction of gene expression following major abdominal surgery 
Response  
Variable 
Predictor Variables Included in the model Whole 
Model  
R2 






























FOXP3 24HR x   x x   0.16 0.03   0.03 0.37   
FOXP3 48HR x x x x    0.16 0.051 0.45 0.15 0.15   
 
 
GATA-3 24HR x   x  x x 0.13 0.23   0.03  0.23 0.03 
IL-12 24HR x   x    0.10 0.04   0.04    
TNF-α 48HR x   x    0.06 0.39   0.04    
IL-23 24HR x  x x x   0.23 0.25  0.0008 0.002 0.46   
IL-23 48 HR x x x x    0.17 0.37 0.28 0.01 0.05    
RORγT 24 HR x   x    0.15 0.04   0.003    
RORγT 48 HR x x  x    0.19 0.051 0.34  0.002    
TNF-α / IL-10 24HR x  x x    0.15 0.03  0.005 0.2    
TNF-α / IL-10 48HR x x x x    0.13 0.041 0.39 0.03 0.27    
Multivariate linear regression analysis of gene expression using requirement for blood transfusion, diagnosis of cancer, duration of the surgical procedure, age, ASA class and the presence of preoperative immunosuppression 
transfusion as potential independent variables. Each x represents an individual variable included in the model (when the univariate p value <0.1). Selection of variables is described in the methods section. The numbers under 
‘Predictors Independently Associated With Response Variable’ represent the p-values obtained when the model was run and are indicative of an independent association with the response variable. 1Indicates p-value obtained 
























Predictor Variables Included in the model Whole  
Model 
 R2 (U) 

















x x x 0.10 0.006 0.08 0.007 
Multivariate logistical regression analysis of postoperative infections using cancer diagnosis, duration of surgery and transfusion with the first 24 hours postoperatively as 
independent variables. Each x represents an individual variable included in the model (when the univariate p value <0.1) (Table 2). Selection of variables is described in the 
methods section. The numbers under ‘Predictors Independently Associated With Response Variable’ represent the p-values obtained when the model was run and are 








Supplementary Table 13 - Anti IL-6 cell culture patient sample demographics 
 
   Male  8 (100%) 
Age (years) 64 (58 – 74) 
ASA grade 3 or 4 1 (12.5%) 
Operation details  
Elective  8 (100%) 
Planned postoperative ICU admission 8 (100%) 
Operation length (minutes) 296 (255 – 326) 
Colorectal 2 (25%) 
Upper GI 2 (25%) 
HPB 4 (50%) 
Laparoscopic 2 (25%) 
Cancer 5 (62.5%) 
Preoperatively immunosuppressed  2 (25%) 
Nosocomial Infection 3 (37.5%) 
Wound 2 (25%) 
UTI 1 (12.5%) 
Days post op infection (days) 11 (2-14)  
Plasma IL-6 (ELISA) (pg/ml)  
Pre-Op 2.47 (2.25 – 3.08)  
24hrs 64.91 (41.17 – 93.36)  
48hrs 79.96 (30.33 – 86.11)  
Data are described as medians with interquartile range or numbers with percentages in 











Supplementary Table 14 - Anti IL-10 cell culture patient sample demographics 
Male  11 (92%) 
Age (years) 61 (58 – 72) 
ASA grade 3 or 4 1 (12.5%) 
Operation details  
Elective 12 (100) 
Planned postoperative ICU admission 12 (100) 
Operation length (minutes) 307 (240 – 319) 
Colorectal 4 (33%) 
Upper GI 4 (33%) 
HPB 4 (33%) 
Laparoscopic 2 (17%) 
Cancer 9 (75%) 
Preoperatively immunosuppressed  5 (42%) 
Nosocomial Infection 4 (33%) 
Wound 3 (25%) 
UTI 1 (8%) 
Days post op infection (days) 13 (4-16)  
Plasma IL-10 (ELISA) (pg/ml)  
Pre-Op 1.0 (0.5 – 1.3)  
24hrs 3.7 (2.5 – 5.2)  
48hrs 2.2 (1.6 – 3.0)  
Data are described as medians with interquartile range or numbers with percentages in 










Supplementary Table 15 - Recombinant IL-10 cell culture patient demographics 
Male  6 (75%) 
Age (years) 58 (52 – 69) 
ASA grade 3 or 4 2 (25%) 
Operation details  
Elective  8 (100%) 
Planned postoperative ICU admission 7 (87.5%) 
Operation length (minutes) 275 (255 – 302) 
Colorectal 2 (25%) 
Upper GI 2 (25%) 
HPB 4 (50%) 
Laparoscopic 2 (25%) 
Cancer 5 (62.5%) 
Preoperatively immunosuppressed  1 (12.5%) 
Nosocomial Infection 3 (37.5%) 
Wound 1 (12.5%) 
UTI 3 (37.5%) 
Days post op infection (days) 22 (18-22)  
Plasma IL-10 (ELISA) (pg/ml)  
Pre-Op 0.73 (0.61 – 1.1)  
24hrs 11.0 (4.0 – 17.3)  
48hrs 2.6 (2.1 – 4.1)  
Data are described as medians with interquartile range or numbers with percentages in 













Supplementary Table 16 - IFN-γ cell culture patient sample demographics 
Male  5 (62.25%) 
Age (years) 60 (52 – 69) 
ASA grade 3 or 4 1 (12.5%)  
Operation details  
Elective 8 (100%) 
Planned postoperative ICU admission 8 (100%) 
Operation length (minutes) 286 (225 – 362) 
Colorectal 3 (37.5%) 
Upper GI 2 (25%) 
HPB 3 (37.5%) 
Laparoscopic 3 (37.5%) 
Cancer 6 (75%) 
Preoperatively immunosuppressed  1 (12.5%) 
Nosocomial Infection 2 (25%) 
Wound 1 (12.5%) 
UTI 2 (25%) 
Pneumonia 1 (12.5%) 
Intra abdominal 1 (12.5%) 
Days post op infection (days) 15.5 (8 – 24)  
Plasma IL-6 (ELISA) (pg/ml)   
Pre-Op 2.74 (2.08 – 3.33)  
24hrs 47.31(27.02 – 176.90)  
48hrs 25.88 (16.68 – 58.63)  
Data are described as medians with interquartile range or numbers with percentages in 














Supplementary Table 17 - GM-CSF cell culture patient sample demographics 
Male  1 (12.5%) 
Age (years) 62 (57.5 – 72.5) 
ASA grade 3 or 4 2 (25%) 
Operation details  
Elective 8 (100%) 
Planned postoperative ICU admission 5 (62.5%) 
Operation length (minutes) 163 (93 – 369) 
Colorectal 3 (37.5%) 
Upper GI 2 (25%) 
HPB 3 (37.5%) 
Laparoscopic 2 (25%) 
Cancer 6 (75%) 
Preoperatively immunosuppressed  1 (12.5%) 
Nosocomial Infection 2 (25%) 
Wound 0 (0%) 
UTI 1 (12.5%) 
Days post op infection (days) 10.5 (10-11)  
Plasma IL-6 (ELISA) (pg/ml)  
Pre-Op 3.6 (2.7 – 5.1)  
24hrs 47.2 (18.0 – 150.1)  
48hrs 41.5 (22.0 – 161.3)  
Plasma IL-10 (ELISA) (pg/ml)  
Pre-Op 0.9 (0.8 – 1.1) 
24hrs 3.6 (2.2 – 4.3)  
48hrs 2.6 (1.9 – 9.0)  
Data are described as medians with interquartile range or numbers with percentages in 
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To provide pre-hospital blood transfusion to trauma patients whilst complying with local 




• Describe the arrangements for the availability of emergency blood for pre-hospital teams. 
• Describe the indications for pre-hospital blood transfusion. 




Approximately 10% of London HEMS patients will trigger the Code RED protocol. These 
patients require early administration of blood products and rapid vascular control if they are to 
survive. In addition, patients in traumatic cardiac arrest may benefit from blood transfusion if 




• Emergency blood is a precious and limited resource. 
• Blood transfusion is not a replacement for careful packaging and splintage. 
• LAA teams will ensure all efforts to preserve blood volume are maximised prior to and 
during emergency blood transfusion.  
• LAA carries blood in accordance with NHSBT policies and guidance. 
• The duty PHC Consultant on-call should be contacted prior to pre-hospital transfusion in 
all cases. 
• All units of blood must be fully traceable via documentation and database records. 
• All Code RED patients should be given warmed blood. 
• Tranexamic Acid 1g bolus should be given as per Code RED protocol. 









Indications to transfuse pre-hospital emergency blood 
 
• Traumatic cardiac arrest where hypovolaemia is judged to be a contributing factor. 
• Code RED patients (see SOP Code RED) where volume resuscitation is deemed 
necessary prior to arrival at hospital. 
 
Storage of pre-hospital emergency blood: 
 
• Emergency blood is packed into the Golden Hour box™ and sealed with a tag by Barts 
Health transfusion staff.  
• Each box contains 4 units of O negative emergency blood and a data logger. 
• The outer carry bag contains transfusion paperwork and a pre-labelled blood bag from the 
pre-transfusion sample. 
• The outer carry bag should be sealed by the transfusion staff with a tag to indicate that the 
contents are complete and unused. 
• Golden hour boxes™ can maintain a steady state temperature of 2-4C for 48-72 hrs. 
• Golden hour boxes™ should be returned to the transfusion lab every 24 hours for 
repacking. 
• All boxes must remain sealed until the LAA doctor declares “Code RED and intention to 
transfuse”. 
 
Location of Golden Hour boxes: 
 
• Pre-packed Golden hour boxes™ are available to all operational teams. Boxes are kept in 
the aircraft and in the boot of operational trauma response vehicles. 




• The medical team should make a decision based on information available whether to take 
the blood to scene as a primary action. They should consider the information from EOC, 












• If blood transfusion is deemed necessary and the blood box is in the aircraft, the team 
should either ask the pilots to bring the blood box to scene or a member of the emergency 
services may be dispatched to retrieve the blood box from the aircraft. 
 
• Obtain pre-transfusion blood sample in a Group & Screen (cross match) bottle (BD 
purple long tube) and a clotting sample (blue bottle) for ROTEM analysis at RLH. 
Paediatric bottles (red top) are available for infants. These bottles are acceptable to all 
London MTC transfusion laboratories. 
 
• The pre-transfusion blood sample should be drawn from an unflushed cannula or a 
femoral stab sample if IV access has already been obtained and flushed with saline.  
 
• The doctor must sign, date and time the sample immediately. This blood sample should 
be kept in a safe place (doctor’s pocket) to be handed over at the MTC.  
 
The Golden Hour box™ must only be opened when the decision has been made to transfuse 
blood.  
 
• Break the seal and open the Golden Hour™ box. 
• Keep the enclosed paperwork safe. 
 
• Remove required no of units and close box immediately. This will avoid wastage of 
unused units. Unused units can be returned to the lab and reallocated for use within Barts 
Health NHS trust. 
 
• Check units of blood using challenge and response: perform visual inspection of unit 
(look for discolouration, haemolysis, large clots), confirm blood type (O neg) and expiry 
date. At least one member of the LAA team must perform the visual blood inspection 
 
• Transfuse emergency blood via Belmont buddy lite™ warming system at an appropriate 
rate based on patient physiology and to allow blood to be heated. 
 
• Contact MTC and place pre-alert call stating HEMS team call sign, CAD no, gender, and 
mechanism of injury. State that patient meets Code RED criteria and pre-hospital blood 






• A “pre-hospital blood transfusion” patient wristband must be placed on the patient at the 
time of transfusion. 
 
• Each wristband has a unique number, which can be recorded on the transfusion record 
sheet along with the LAS CAD number and patient details. 
 
Blood unit labelling: 
 
• Each unit of blood has two labels to identify the unit 
 
o Paper tear off tag  
o Main label on front of unit 
 
• The “tear off tag” must be completed, signed and placed in the Golden Hour box™ when 
the unit is transfused and returned to the Royal London Hospital transfusion laboratory 
with the original transfusion record sheet.  
 
• The main label remains on the unit of blood and the empty blood bag can be disposed of 
in a yellow incineration bin by hospital staff when transfusion has finished. 
 
Transfusion record sheet: 
 
• The transfusion record sheet is an A4 form, which is found inside a plastic pouch inside 
the blood box carry bag. 
• The completion of this form is mandatory to ensure 100% traceability for every unit of 
blood. 
• Transfusion staff will complete part of the form with the unique ID for each unit of blood 
when the box is packed. 
• LAA staff must complete the remaining fields after transfusion has occurred. 
• Please check carefully that the unit number on the label and stickers matches the 
unit number on the blood bag and also correlates with the paperwork – there is 
potential for human error at every step of the labelling process. 
• This form must be photocopied at the MTC and handed over directly to the Trauma Team 
Leader along with the photocopied mission record sheet and observations. 
• The original transfusion record form must be returned in the Golden Hour box to Barts 
Health transfusion lab with the tear off labels. 
• The date, time, CAD number and patient destination (e.g. St Mary’s MTC, King’s MTC, 





Handover at MTC: 
 
• The verbal handover must explicitly state that pre-hospital transfusion has occurred. 
• Ensure the patient wristband is still attached to the patient. 
 
• The doctor must complete and sign the cross match form at the MTC and transcribe the 
MTC patient details on to the blood bottle.  
 
• The cross match request form sent to the MTC laboratory should be annotated to indicate 
that this sample has been taken prior to pre-hospital transfusion. 
 
• The LAA transfusion record sheet, cross match bottle and request form must be handed to 
the Trauma Team Leader in the pre-labelled bag. It is their responsibility to check the 
details and take responsibility to send the sample to the lab. 
 
• The MTC should repeat the Group & Screen on arrival as per MTC protocol. 
 
• Unused units of blood must not be left with the MTC but must be returned in the blood 




• The HEMS database must be completed using the drop down intervention menu.  
Include as many of the following as are relevant: 
  
o Code Red 
o Blood (state no of units given) 
o Tranexamic Acid 1g 
o Buddy lite fluid warmer 
 
• The free text section should include the unique unit numbers of the units transfused. 
 










• Any incidents arising from Pre-hospital emergency blood transfusion must be reported 
via the Barts Health Datix system in addition to the local helipad reporting system. 
 
How to arrange resupply of pre-hospital emergency blood: 
 
When a Golden Hour box™ has been opened it must be returned to Barts Health transfusion 
laboratory as soon as possible. The transfusion record sheet and tear off tags must be returned in 
the same box. 
 
• The transfusion lab should be informed when the mission is complete via ext 61117 or 
bleep 1422 out of hours. 
 
• State which number box has been opened and request a replacement. 
 
• A spare Golden Hour box™ may be available on the helipad.  
 
• RLH porters will return and collect Golden Hour boxes™. Porters can be contacted on 
ext 40839 or bleep no 1213 / 1316 / 1613. You should state the number and location of 
the used box, which needs to be returned to the lab. You should also state where the 





1. The Blood Safety and Quality Regulations 2005 no .50 (MHRA) 
http://www.legislation/gov/uk/uksi/2005/50/contents/made 
 











1. Validation graph for Golden Hour box 
2. LAA Transfusion record sheet 
3. Blood box changeover record sheet 














CODE RED TRAUMA – guidance notes July 2011 
Only a senior member of the Trauma Team who has undergone induction training can trigger 
CODE RED TRAUMA 
 
Tranexamic acid: 
Tranexamic acid is an antifibrinolytic agent that inhibits activation of plasminogen to plasmin; the 
latter is responsible for fibrin degradation 
In trauma-induced massive haemorrhage a bolus of Tranexamic acid (1g, iv over 10 min) 
should be started within 3 hours of injury followed by continuous infusion (1g, iv) over 8 hours 
 
Blood Transfusion – Emergency Group O Stock: 
Group O Neg (use in females) and O Pos (use in males) blood available in blood track fridge for 
CODE RED use 
MUST INFORM Blood Bank when units used so that stocks can be replaced 
Switch from Group O to patient’s group as soon as possible to minimize use of Gp O 
 
 
CODE RED PACK A contains:  
6 units Red Cells 





CODE RED PACK B contains:  
6 units RBC 
4units FFP 
1 unit Platelets 
2 pool cryoprecipitate. 
 
Fresh Frozen Plasma: 
FFP needs defrosting before issue – this takes around 30mins (allow time for transit) 
Each dose should contain ~15ml/kg of FFP – around 4units for average adult 
 
Cryoprecipitate: 
Cryoprecipitate needs defrosting before issue – this takes around 30mins (plus allow for time 
transit) Do not put cryo in fridge after defrosting since can precipitate 
Each dose should contain 2 pools cryoprecipitate for average adult 
 
Platelets: 
Stored at ambient temperature DO NOT REFRIGERATE 
Since platelets have short shelf life of 5 days only the blood bank has limited supplies of platelets 
and has to order additional units from the Blood centre as needed. 
 
Laboratory testing: 
Must request fibrinogen as well as coagulation screen and Full Blood count for all patients with 
massive haemorrhage 
Repeat testing of Coagulation screen including fibrinogen and platelet count needed after 





Near Patient Testing 
Any near patient testing device used MUST comply with the Trust Point of Care Testing policy. 
 
Recombinant FVIIa: 
Discuss with Haemophilia Registrar (Bleep 1155 or via switchboard on call) regarding use of 
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To provide an explanation of how the assessment, care and initial treatment of Code Red 
trauma patients should be delivered in order to optimise outcome.  
 
NB. All team members must be familiar with the Trauma Team Response SOP prior to reading 
this document.  
 
Trauma Service Standard Operating Procedure 
 
Code Red Trauma Team response 







• To achieve consistent Code Red trauma team performance. 
• To describe the expected preparation for Code Red trauma patients after pre-alert. 





”Code Red” is the term used to alert the Major Trauma Centre that a trauma patient is at risk of 
death from serious haemorrhage. In many cases this is due to non-compressible haemorrhage and 
damage control surgery or interventional radiology techniques will be required to achieve 
vascular control. 
 
The Royal London Emergency Department activates the Code Red protocol around 150 times per 
year. Activation will mobilise Consultant level attendance for Trauma Surgery and Anaesthesia. 
Specific departments (transfusion, theatre, Interventional Radiology) will take action to ensure the 




• Code Red patients have a high mortality (up to 50%).  
• Code Red patients require additional expertise and resources to be immediately available.  
• Code Red patients are likely to require rapid transfer to another department eg theatre / IR 
within minutes of arrival. Transfer equipment must be prepared in advance of the 
patient’s arrival with this in mind.  
• Code Red trauma calls must be led by an ED Consultant or by a suitably trained registrar 
/ fellow under direct supervision of the ED consultant. Inexperienced team leaders must 
not be left unsupervised as Team Leader for Code red patients. 
• Code Red trauma calls will attract additional staff and interest. Crowd control is the 
responsibility of the TTL and is essential to optimise team performance and patient 
outcome. 
• An in-bound pre-hospital team may declare Code Red or the TTL may decide to declare 




hospital team. Code Red may also be activated if a patient deteriorates after arrival in 
order to provide an escalated response from the “Advanced” trauma call. 




1.0 Code Red Pre-alert and Blue call  
 
• A pre-hospital doctor (usually from an Air Ambulance team) will pass a pre-alert 
message via the dedicated phone in resus to warn of a Code Red patient.  
• The initial pre-alert will only contain brief details ie age, gender, mechanism, code red 
request. This limited information allows additional preparation time prior to the more 
detailed blue call. 
• Details should be recorded on the paper forms provided next to the phone. 
• The senior nurse in resus and the allocated senior doctor must be informed immediately. 
• The Code Red Trauma Team should be activated via switchboard (ext 2222) 15 minutes 
before the estimated time of arrival (ETA). 
• Switchboard will state “Code Red trauma team to A&E resus” over the bleep system. 
• All team members should make their way immediately to the resus room. 
 
2.0 Trauma Team arrival and etiquette 
 
On receipt of the initial pre-alert or the full blue call (whichever is earliest) the following 
actions should be carried out: 
• Request trauma pack from reception – a unique identifier is required to order blood 
products, blood tests and imaging.  
• The TTL role is to provide oversight of the preparation phase and to ensure that all team 
members have a clear understanding of their role. The TTL must pay attention to detail 
and try to anticipate events. 
• The TTL must use the Code Red checklist to ensure all actions are completed in good 
time. 
• All attending members of the Trauma Team must “sign-in” the trauma booklet and don 
lead aprons, plastic over-aprons and gloves. Eye protection is available.  
• Every team member must read their allocated action card and check they have necessary 
equipment to perform their role. 
 
 





• Nurse 1, Nurse 2 and the Operating Department Practitioner play a vital role at this stage 
and as a team must ensure that the designated bay is fully prepared for the reception of 
the patient.  
• Preparation must include anticipation of immediate needs, urgent procedures and rapid 
transfer to other departments eg theatre / IR . 
• Pre-arrival information typed on word document on computer screen in large font. 
• Trauma booklet with sticker on every page and front sheet attached securely. Scribe 
allocated. 
• Resus trolley in central position in bay, positioned at appropriate height with sides in 
“down” position and sheet laid out. 
• Theatre lights x 2 switched on and positioned over trolley. 
• Patient gown, sheet and blanket available. 
• 2 name bands with unique identifier details. 
• Tympanic thermometer and Bair Hugger (machine and sheet) available. 
• Monitoring ready – ECG dots attached to leads, variety of BP cuffs, oxygen saturation 
probe, oesophageal temperature probe, EtCO2 etc. 
• Belmont fluid warmer primed and loaded with blood products (TTL discretion as to 
PRBC or plasma initially, depending on pre-hospital treatment). IV long extension set 
available. 
• Ultrasound machine in position switched on and gel available. Operator allocated 
(radiologist). 
• Anaesthetic equipment – anaesthetic machine checked, 2 oxygen sources, airway kit laid 
out (including airway adjuncts and BVM) if not already intubated, suction working, 
emergency drug tray, propofol infusion and pump, RSI checklist available. 
• Trolley with IV access and venepuncture equipment, blood bottles including research 
samples. If the patient is ventilated, an femoral arterial stab should be performed to obtain 
an arterial blood sample. 
• Sterile procedures preparation – an appropriately trained and competent doctor should be 
scrubbed up and in a surgical gown if it is anticipated that an invasive or surgical 
procedure eg. central line, thoracostomy, thoracotomy or REBOA may be required 
urgently. 
• Transfer kit available – portable monitor, ventilator, full oxygen cylinder, suction, 
transfer bag, bridge for trolley, P1 card. 
 
In addition, for patients arriving by helicopter –  
 
• 2 units PRBC (from resus fridge) and name bands sent to helipad with porter. 
• Resus room and corridor doors should be held open by spare personnel to assist teams in 
progressing rapidly from lift core 4 to the resus room. 
• Trolley should be removed from bay for patients arriving by air. The helicopter team will 









4.0 Pre-arrival briefing 
 
Prior to arrival of the patient, the TTL should brief the team. This is essential to check that 
everyone has the required equipment and is clear about their role. Briefing should be concise but 
should cover the following points: 
 
• Introduction of all team members (first names) and roles. 
• Confirmation of pre-alert info eg mechanism of injury, expected injuries and condition. 
• Confirmation of mode of transport eg by land or air. 
• Ensure all team members are dressed in PPE / sterile gown and gloves. 
• Ensure all team members have required equipment. 
• Ensure any specific actions or roles are allocated eg chest drain insertion. 





• The Pre-hospital team will deliver a verbal handover to the trauma team. This usually 
takes place after the patient has been transferred onto the resus trolley but in certain 
circumstances may be preceded by a request for immediate action eg. start blood 
transfusion or to perform a procedure eg. thoracotomy. 
• All pre-hospital documentation (patient report form, mission record and observations) 
must be secured in the front of the trauma booklet. 
 
 
6.0 Code Red drugs 
 
Code Red patients may require the delivery of rapid anaesthesia in order to deliver invasive 
intervention. 
 
• The ODP / anaesthetist will collect the emergency anaesthetic drug tray from the resus 
drug fridge (mounted on wall).  
• Prepare anaesthetic drugs (usually ketamine and rocuronium), sedation (propofol) and 
analgesia (morphine / fentanyl). 





1. Tranexamic acid 1g bolus and 1g infusion dose (to prevent hyperfibrinolysis) 
2. Calcium chloride 10ml 10% (to treat hypocalcaemia and hyperkalaemia, also acts a 
positive inotrope) 
3. Insulin (Actrapid vial) and 50ml 50% dextrose (to treat hyperkalaemia) 
 
 
7.0 Acute Traumatic Coagulopathy (ATC) 
 
Code red patients are at risk of Acute Traumatic Coagulopathy. This coagulopathy is triggered by 
tissue damage and hypoperfusion (shock). High injury load and / or profound hypotension should 
lead to suspicion that ATC may be present. Blood gas analysis is useful to predict the need for 
massive transfusion eg BE > - 6 and raised lactate suggest that ATC is likely.  
 
ROTEM analysis can confirm or exclude the diagnosis of ATC in under 5 minutes. ROTEM 
analysis is available at RLH. The analyser is kept in theatres but is mobile and can be moved to 
resus or IR if required. Trained operators include ODPs, Trauma Service research team and 
selected anaesthetists / intensivists. 
 
ATC will be exacerbated by other causes of coagulopathy eg hypothermia, acidosis and dilution 
of clotting factors. Steps must be taken to prevent worsening of the patient’s condition: 
 
• Do not give crystalloid or colloid unless explicitly instructed to do so by TTL. 
• Measure core temperature in ventilated patients using an oesophageal 
temperature probe. 
• Maintain normothermia – keep the patient covered up, use Bair Hugger if temp 
<36C, ensure all blood products are given via fluid warmer eg Belmont.  
• Check ionised calcium levels (ABG) and correct as required. Calcium levels may 
be low in severely injured patients and those receiving blood transfusions. 
• Confirm whether pre-hospital team has given Tranexamic Acid (TXA) 1g bolus. 
If not, 1g should be administered, provided it is still within 3 hours of injury.  




• If ROTEM is available use result to guide blood product therapy. 
 
 




• A radiologist should attend Code Red trauma calls. They can be contacted via DECT 
45709 or bleep xxxx.  
• This role will allow face-to-face communication regarding initial diagnostic findings and 
ensure accurate protocols for further imaging.  
• The radiologist should be present in the CT suite at the time of scanning to assist in rapid 
decision-making and to provide a verbal “ABCD – primary survey report”.  
• A more detailed, structured electronic report will be provided within 60 minutes. Any 
updates to reports should be communicated to the Duty ED Consultant on DECT 45722 
or via bleep 1115. 
 
 
8.2 Interventional Radiology 
 
• Interventional Radiology (IR) is provided at the Royal London by a group of 6 
Consultants and a pool of nursing staff.  
• IR has an increasing role in the management of Code Red patients and should be 
available within 30 minutes at a Major Trauma Centre.  
• The Duty IR Consultant should be informed immediately if pre-alert information suggests 
that IR may be required eg serious pelvic injury    
 - Mon-Fri 9-5 ext 40105 
 - Out of hours and weekends via switchboard. 
• All REBOA activations require IR presence in resus. This is to ensure rapid senior 
decision making between TTL, Trauma Surgery and IR Consultants. TTL should inform 
Duty IR Consultant as soon as REBOA pre-alert is received. 
• Anticipation and early activation will allow the IR suite to be prepared, on-call staff to 




• TTL will decide with assistance from colleagues whether transfer to IR is required. The 
whole team should accompany the patient to the IR suite and should anticipate and be 
prepared for deterioration in the patient’s condition.  
 
 
8.3 Imaging requests on CRS 
 
• Detailed imaging may not be prudent in Code Red patients and critical decision-making is 
often made based on physiology and suspected injuries.  
 
• Initial imaging requests should be placed on CRS as soon as the trauma pack is received. 
As much detail as possible should be provided in the clinical details section. Requests 
will be based on mechanism. 
 
• A polytrauma patient may require: 
 
 - CXR 
 - PXR 
 - CT head 
 - CT cervical spine 
 - CT chest, abdomen, pelvis 
 
8.4 Imaging during Code Red trauma calls 
 
• Plain film imaging is useful in unstable patients to exclude unexpected diagnoses eg 
haemothorax, open book pelvis. Remember the reported mechanism may not represent 
the whole story eg; stab to chest may also have fallen from height. 
 
• E-FAST in the hands of an experienced operator can be useful to ascertain which cavity 
presents the greatest threat to life eg intra-abdominal FAST positive may expedite 
transfer to theatre, pericardial tamponade may expedite ED resuscitative thoracotomy. A 





• E-FAST is helpful to identify pneumothorax in supine patients. This modality is more 
sensitive than plain CXR to detect this pathology. 
 
• TTL will decide with assistance from colleagues whether CT is appropriate in an unstable 
patient. In the absence of an obvious indication to perform an immediate procedure, 
transfer to theatre or IR, it may be prudent to undertake CT imaging. The whole team 
should accompany the patient to the CT suite and should anticipate and be prepared for 





• Nurse One is responsible for informing the Transfusion lab of a Code Red trauma call. A 
dedicated telephone in resus provides a direct line to the laboratory. 
• TTL must indicate to Nurse One which blood products are required. The initial request is 
usually for Pack A only (PRBC and plasma). Pack B (PRBC, plasma, platelets and 
cryoprecipitate) can be requested at the same time if required. 
• Packed Red Blood Cells are available in the resus blood fridge (12 units O Neg, 12 units 
O positive). 
• Plasma must be collected from the lab – a minimum time of 20 minutes is required to 
thaw this product. 
• A porter should be sent directly to the Transfusion lab (4th floor pathology building) to 
wait for the thawed plasma to be made available. The porter will then bring the plasma to 
the resus room. 
• All blood products must be prescribed and timed on the Blood Product prescription page 
in the trauma booklet. 
• All blood products must be checked by 2 members of staff prior to infusion. 
• Nurse One must inform the lab if the patient moves to theatre or IR. 
• Any Code Red patient being transferred to theatre or IR should have Pack B requested 
prior to leaving ED. 
• An allocated nurse must complete the Code Red blood product tally document in real-
time. 





See appendix for Code Red guideline. 
 
10.0 Blood test requests 
 
10.1 Trauma panel and near patient testing 
 
• “Trauma panel” blood requests should be placed on CRS as soon as the trauma pack is 
received.  
• Request immediate cross-match 6 units and generate 2 paper forms (one for HEMS 
sample and one for ED sample). 
• Near patient testing machines should be used for blood gas and FBC analysis. 
• A blood gas sample should be analysed as soon as possible – check base deficit and 
lactate. Take an arterial sample in intubated patients to correlate EtCO2 and PaCO2. 
• If the ROTEM machine is available, run EXTEM and FIBTEM channels. 
 
10.2 Pre-transfusion samples 
 
Once several units of blood have been transfused it may be impossible to determine the native 
blood group due to a mixed field sample. Every effort must be made to obtain a pre-transfusion 
sample. 
 
• The HEMS team may provide a pre-transfusion sample. This must be clearly labelled as 
“HEMS sample” on the paper form. The HEMS doctor must complete patient details on 
the sample and sign the bottle and the paper form.  
• The trauma team should provide a second sample as confirmation at the time of 
venepuncture. This should be labelled as the “ED sample” on the second paper form. 
• Occasionally it is not possible to obtain a sample prior to transfusion. The lab should be 
informed and a sample should be sent as soon as it is available. 
 
 





• Near-patient testing (Coaguchek) is available to check INR. This is useful if a patient is 
suspected / or confirmed to be on warfarin. A result will be available within 20 seconds. 
• The Coaguchek machine is kept in the Near Patient testing room near resus. 
• Prothrombin Complex Concentrate (PCC) - Octaplex is kept in the Code Red cupboard in 
resus for the emergency reversal of warfarinised patients.  
• PCC may also be useful for patients on NOACs with severe bleeding. Discussion with the 
Duty Haematology Consultant is advised for this group of patients. 
 
 
12.0 Transfer to CT / interventional radiology / theatre. 
 
• Communication - prior to any transfer, the destination receiving team eg CT / theatre / 
Interventional radiology, must be made aware of the patient’s imminent arrival. 
 
• Priority 1 lift pass is kept in the Code Red cupboard (near bay 8) to facilitate rapid 
transfer to theatre / IR. 
13.0 Documentation and verbal handover 
 
TTL must ensure that the medical notes are an accurate reflection of the events to date. 
An explicit verbal handover to an appropriately senior colleague should take place at an 
appropriate time. This handover must be recorded in the notes.  
 
14.0 Code Red debrief 
 
In order to identify good practice and opportunities for improvement, it is useful to offer a 
debriefing process following Code Red trauma calls. This will usually occur several hours after 
the event due to key personnel being engaged in procedures. A recommended template and 
guidance is provided on the Q drive. Any issues arising can be forwarded to the relevant specialty 





Supplementary Protocol 5: Royal London Hospital Prophylactic 
Antibiotics Guidelines 
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